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Chronic diseases such as rheumatism, spasticity and asthma are irreversible: clinicians
and other health professionals can only minimise their patients’ symptoms and
improve their ability to function in day-to-day life. Physiologic measures are used to
assess the severity of the disease. These objectives or laboratory tests can also be
used as indicators of the course of the disease in the context of the treatment. In
cardiology, for example, clinical measures such as left ventricular ejection fraction
(LVEF), rate pressure product (i.e. heart rate × blood pressure), VO2 Max. and so
on provide tools for classifying the severity of heart disease, and are also used in the
assessment of improvement or deterioration in what these tools measure. A major
disadvantage of these cardiac measures is that they do not necessarily reflect the
patient’s well being, health-related quality of life, or the ability to carry out his or her
normal activities1.
Although extending survival with minimal impairment is the primary goal of
treatment, there is a growing recognition that the treatment should address other
important goals as well, since for some chronic diseases, improvement of health-
related quality of life (HRQL) or health-related functional status (HRFS) may be
more important. In clinical studies, however, quality of life outcomes have turned out
to be a ‘kaleidoscopic’ concept since no consensus exists with regard to the meaning
of the concept in either the research community or the clinical community.
Furthermore, the operationalization of the concept of (health-related) quality of life
is heavily dependent on the disciplinary perspective in outcome assessment. This lack
of consensus has given rise to the development of a myriad of measures involving
different components whose conceptual dimensions vary. 2 .Therefore, instruments
labelled as quality of life measures “may appear as health status, physical functioning,
emotional functioning, perceived health status, symptoms, mood, need satisfaction,
well being, and, often, several of these at the same time”. 3 During the last 10 to 15
years, there has been an exponential increase in the development and use of
instruments to measure the outcomes of medical interventions from the patient’s
perspective. A family of more than 150 instruments were identified in 75 studies; 4
in 1996, Spilker et al. catalogued nearly 215 measures in their second edition of
“Quality of Life and Pharmacoeconomics in Clinical Trials” 5. Since there is no
consensus on the theoretical construct of quality of life, 3,6- 9 the universe of domains
belonging to this concept (and therefore the ongoing discussion on the selection of
items by which it is operationalized), we prefer concepts such as health-related
functional status. Functional status reflects the ability to perform the tasks of daily
life in physical, emotional and social domains. There is also a growing agreement on
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the components of these constructs and the validity of their measurement; for
example, by validating these self-report measures with evidence-based measures. 10-12
By using the term health-related functional status (HRFS) in this thesis, we implicitly
assume that a change in health status or functioning is indirectly related to the
patient’s subjective experience of quality of life.
For clinicians or other health professionals who feel the need to measure HRFS as
an outcome in clinical trials, it is essential to know that the choice of available health
status instruments is related to the methodological debate on the psychometric
properties of instruments (in contrast to clinical outcomes such as physiologic
measures). Consequently, this choice is also associated with methodological issues
relating to the interpretation of outcome in terms of treatment-related change over
time or differences between treated and control groups. Because improving patients’
functional status has become a central therapeutic goal for many diseases, it is
important that both clinicians and researchers develop a common understanding of
1) what HRFS concepts mean; 2) which measure is likely to be the most appropriate
one in the context of the disease and aim of the study; 3) the methods to assess
treatment-related change, and 4) the methods by which a valid interpretation of the
magnitude of that change in terms of clinical relevance or clinical importance can be
achieved.
1.2 OBJECTIVES AND MAIN RESEARCH QUESTIONS OF THIS THESIS
Health status measures have become an important part of clinical research in the
evaluation of treatment efficacy. Furthermore, there is a need to assess treatment
efficacy with evidence-based HRFS measures. When new instruments (e.g. the
‘Minnesota Living with Heart Failure Questionnaire’) are presented to the clinical and
scientific community, 13 reliability and validity are traditionally the most important
features of the instruments that are evaluated. An instrument is reliable if it gives the
same result on repeated assessments of stable subjects whose circumstances have not
changed (test-retest reliabilty), and when the test yields more or less the same results
when administered by different observers (interobserver reliability). The validity of
a measure refers to whether that measure does indeed measure the conceptually
defined property (for example, perceived physical health). In testing the validity of
a new physiological measure, there is often a golden standard or criterion measure
available for comparison. In contrast with physiological measures, there is no gold
standard for a functional status instrument against which to measure its validity.
Therefore, the validity of physical health status can be investigated by a number of
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different procedures by which the same construct is assessed (for example: self-
report vs. performance-based tests); when a similar result occurs, this is called
concurrent or convergent validity. When the reliability and validity of health-related
functioning measures have been established, these psychometric properties of new
and more appropriate tests are generally accepted conditions for use of these
measures in clinical settings and research. However, the appropriateness of the
instrument designed to measure change in persons over time is not only determined
by its reliability and validity. Measuring change in order to evaluate treatment efficacy
requires the instrument to be sensitive to detecting change when patients improve
in physical function after (for example) a coronary artery bypass surgery (CABS).
Over the last 15 years, this property has become well known through the widely used
concept of responsiveness. Responsiveness of health status measures has become one
of the ‘holy trinity’ of necessary psychometric properties of health status instruments.
To quantify responsiveness, several effect sizes are used as estimates of the amount
of change detected with an instrument. In this respect, the most accurate approach
is to ask the patient if the researcher is interested in understanding the patient’s
perception of the direction and amount of change in a domain of health-related
functional status. This is common daily practice for clinicians.  One of the aims of
this thesis is to address some methodological issues relating to the assessment of
change in health-related functional status and the meaning of the magnitude of
assessed change in scores. Traditionally, the many generations of researchers who
have evaluated the efficacy of medical interventions, base their decisions on the
statistical significance of the within-group treatment-related change over time or any
statistically significant difference in change from repeated measurements between
experimental and control groups. In some cases, investigators eager for results are
likely to detect a statistically significant (but very small) change in scores related to
the intervention, simply due to large sample size. Consequently, even if change which
is statistically significant, though trivial in magnitude, is detected, the p < 0.05
doctrine unwittingly pushes the question of how meaningful, important, relevant, or
substantial the changer is into the background. Significance tests support the decision
as to whether the change is due to chance fluctuation or can be functionally related
to treatment. The observed statistical significance does not indicate the magnitude
of change. In spite of this, some researchers implicitly suggest that smaller p-values
represent larger, and thus more ‘relevant’, effects. 14
Against this background, the objectives of this thesis can be formulated in terms of
the following research questions:
How to determine the main psychometric properties of a new, disease-specific,
health status measure?
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How comparable are different operationalizations of effect sizes (ES) when outcome
is interpreted as ‘trivial’ (ES < .20), ‘small’ (ES ≥ .20 < .50), ‘moderate’ (ES ≥ .50 <
.80), or ‘large’ (ES ≥ .80) according to the well-known thresholds of Cohen 15?
How concordant are the effect sizes, labelled by the researcher as ‘trivial’, ‘small’,
‘moderate’, or ‘large’ change in a domain of health-related function with the patient’s
perception of change in the same domain signified with the same qualitative terms?
How reliable and valid are multi-item scales of perceived change after treatment at
follow-up as compared to longitudinal (before-after) assessments with scales
comprised of identical items?
Besides this first chapter, this thesis consists of six other chapters. The main theme
of this thesis deals with methodological problems in the assessment of treatment-
related change in health-related functional status (HRFS). There is a large number of
factors that potentially affect the interpretation of change in HRFS by the researcher
and the perception of the direction and magnitude of change by patients who have
undergone a particular medical intervention. Change over time in HRFS measures
was assessed in patients with severe spinal spasticity and in patients whose symptoms
were considered to belong to what is labelled ‘heart failure’. Both groups underwent
a treatment with known efficacy in order to detect treatment-related change. This
thesis addresses the research questions stated above as follows:
in Chapter 2, the efficacy of a new treatment in health status is evaluated in a
randomised clinical trial design. The analysis is representative of the ‘classical’ model
of testing the null-hypothesis ‘that differences are due to chance fluctuations’.
Besides statistically significant p values, supplementary effect size indices are reported
in order to indicate the relevance of change but no external criterion was used to
decide what constitutes this relevance.
To assess change, an HRFS-instrument as a baseline measure must meet the criteria
of reliability (in stable groups, it yields the same score each time) and content or construct
validity (it reflects what it is supposed to measure), but when applied as a repeatedly
assessed baseline measure, the additional most important and necessary property is
the instrument’s responsiveness (sensitivity to detect change over time). In Chapter 3,
these psychometric properties (research question 1) are evaluated with the
‘Minnesota Living with Heart Failure Questionnaire’ (MLHF-Q) in a sample of
patients who underwent treatment with  known efficacy (DC electrical
cardioversion).
In the evaluation of treatment efficacy, one of the most important properties of
HRFS measures is its ability to detect change that is related to the treatment (and not
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to regression to the mean, due to errors of measurement). This ability is well known
as responsiveness, and is quantified by a variety of measures of effect magnitude. Cohen
provided guidelines for interpreting the magnitude of his first effect size d’ that was
explicitly labelled as such, and expressed the size of treatment effect in units of the
common population standard deviation estimated with the sample’s pooled standard
deviation. These guidelines are used for several indices called effect size, but the size
of treatment effect is expressed in units of the sample standard deviation of either
the baseline score or the change score. In Chapter 4, the risk of overestimation or
underestimation of effect magnitude is evaluated for two comparable effect size
indices (research question 2).
Change can be assessed prospectively with longitudinal assessments and
retrospectively with global questions relating to perceived change. To validate the
prospectively assessed change in HRFS, single global questions are used as an
external criterion for interpreting those change scores valued as being ‘important’ by
the patient (research question 3). In Chapter 5, a comparison is made between the
intervals relating to the thresholds of Cohen of what constitutes small, moderate, or
large longitudinal effects and the patients’ judgement of what is perceived as small,
moderate, or large improvement after treatment.
Patients’ perception of the direction and magnitude of change in domains of health
was assessed with single-item (global) scales, as well as with multiple items scales on
perceived change derived from the original items from the Minnesota Living with
Heart Failure Questionnaire. In Chapter 6, the concurrent or convergent validity is
evaluated by comparison of the dimensions of HRFS in the repeatedly assessed
baseline measure and the global, retrospective measure (research question 4). The
‘known groups validity’ is evaluated by comparison of both instruments between
groups who improved or remained the same in angina pectoris.
The last chapter (Chapter 7) summarizes the results, conclusions, and implications
for further research and development of the methodology for measuring change in
health-related functional status.
Summarising, in addition to reliability and validity, assessment of treatment-related
change in HRFS is highly determined by the so-called ‘third measurement property’
of responsiveness. There is neither consensus on its ‘theoretical’ definition nor on its
operationalization, i.e. the operations needed to quantify this property. The
remainder of this chapter relates to terms and definitions of responsiveness, and
consequently, to the corresponding methods of assessing it. Since no golden standard
or reference range is available for indices of responsiveness, we address the patient’s
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perspective of the HRFS measures to get a better understanding of what a change
in specific patient groups means.
1.3 TERMS AND DEFINITIONS
1.3.1    Responsiveness, a problematic construct
To give greater meaning to the interpretation of the amount of change in scores on
health-related functional status instruments, the concept of responsiveness was
introduced in publications. For clinical purposes, the usefulness of a HRFS-
instrument depends on its ability to detect a change that is clinically meaningful.
Clinically meaningful refers to a change that justifies alteration in management of the
disease or to a change that indicates the efficacy of an innovative type of treatment
in domains of health status. Responsive measures discriminate between trivial and
substantial changes within clinical trial groups and consequently show the difference
in change between those groups. Thus, the term responsiveness is used as an indicator
of the instrument’s sensitivity to change, as well as an indicator of the magnitude of
treatment-related change over time. The term responsiveness is however, a confusing
one for the beginner who encounters it in the literature, since papers addressing
treatment-related change in health-related functional status may refer to a varying
composite of aspects. As appears from a selection of scientific papers, the term
responsiveness is used as an operational definition of: 1) an indicator of the sensitivity
of an instrument to detect change over time 16-21 or even refer to the extent to which
a measure is sensitive to real change 22; 2) ‘statistically significant change in an
experimental group in which change should be present’ 23; 3)  an indicator of the
magnitude of treatment-related change 19-21,24-28; and 4) a measure of clinically
relevant change in health 29,30, although some investigators prefer the term ‘clinically
significant change’ 31,32. Qualitative terms such as ‘clinically important’ need at least a
golden standard. As mentioned before, such a standard is not available for health-
related functional status. The blinded observation of a clinician can be used as an
external criterion for justifying the interpretation in terms of clinically relevant or
important change in HRFS. Another external criterion or yardstick for the
interpretation of changes in HRFS is the patient’s perception of the importance of
change after (for example) a specific treatment.
Husted et al. 33 distinguished internal responsiveness from external responsiveness by
defining internal responsiveness as the ability of a measure to detect change over
time, whereas external responsiveness was defined as the extent to which change in
a measure relates to corresponding change in a reference measure. 12,34,35 Despite this
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clarification of the concept of responsiveness by this recently published classification,
the assessment of change in HRFS over time in clinical research is quantified using
a variety of approaches. For the sake of clarity, we will therefore, in this thesis use the
concepts in the following meaning:
- responsiveness: the psychometric property of a measurement instrument, namely
its sensitivity to detect difference between two points in time (change over time)
within groups;
- meaningful or relevant difference: the amount of change in scores or the magnitude
of change within and between groups, according to statistical or other
quantitative criteria (e.g. effect size indices);
- clinically relevant or clinically important change in scores on a health-related
functional status measure (always linked to an external criterion of relevance).
The purpose of a study and its study design may require different psychometric
properties of the outcome measure. Consequently, the measure must either have the
property of being able to detect differences between subjects at a single point in time
(discriminative instruments) i.e. the ability to differentiate between groups ‘who have
a better HRFS and those who have a worse HRFS ‘. 25,36,37 Other studies may require
the instrument’s ability to detect change over time within subjects (evaluative
instruments). 38-40 Consequently, in randomised clinical trials (RCT), health-related
functional status instruments should have both properties, namely: 1. the ability to
reliably estimate change between baseline and post-test within an experimental and
a control group, and 2. the ability to estimate the difference in change over time by
comparing the average change assessed in treated and in non-treated subjects in
order to determine treatment effect, since in general, subjects in the treatment group
are expected to change (on the average) more than those in the control group do.
1.3.2    Responsiveness and the instrument’s scope: generic verses. specific
An important criterion for choosing an instrument in order to detect change in
health-related functional status is its generic or disease-specific scope, which will
depend on the objectives of the specific study. Generic health status measures seek
a broad perspective that is not specifically related to the restricted scope of the
health-related functional status of the aspecific disease. Therefore, generic measures
allow investigators to compare health status across different diseases. 41 Generic
measures are health-related to the extent that disease, injury, treatment, or policy 42
influences them. Disease-specific measures focus on the disease being studied,
allowing greater sensitivity to treatment-related change compared to generic
measures. The responsiveness of a health status instrument is an important issue in
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the decision to use disease-specific or generic measures of health-related functional
state. For example, for those cases in which therapeutic effects are likely to be
modest and undramatic,18,43 a better sensitivity to change over time of an instrument
is a necessary condition. It would seem that ‘cardio specific’ measures (for example)
may be more appropriate to detect change in HRFS.44 Although the question of
whether instruments, that are tailored to the disease, are superior to measures of
general function in terms of sensitivity to change, has not been settled definitely, a
growing number of studies indicate that disease-specific measures seem to be more
responsive than generic measures.45-52 To evaluate a disease-specific instrument’s
concurrent responsiveness, the amount of change in scores of both instruments
(often generic versus disease-specific measures) is assessed in relative terms under
identical conditions. To standardise the comparison of alternative instruments,
Relative Efficiency (RE) statistics are sometimes used. RE statistics are emphasised
as a comparative measure of responsiveness. RE expresses the change score as the
squared ratio of either t-scores from paired t-tests or the z-scores from the Mann-
Whitney-Wilcoxon ranked pairs test that compares the assessed instrument to a
standard. 16,48,50,53-59 Another method of standardising comparisons between generic
and disease-specific measures is known as the Relative Validity (RV) coefficient. 29,60-
63 This statistic is calculated for each pair of measures in the comparison and is
defined as the ratio of their F-statistics (F-statistic for each measure is estimated by
comparing change scores across groups that improved, stayed the same, or
deteriorated). The RV coefficient indicates how much more or less valid each
outcome measure is relative to the best outcome measure.
1.3.3 Effect size as responsiveness measure
Mean differences in outcomes of a test can be standardised to quantify an
intervention’s effect in units of standard deviation (SD). Consequently, standardising
mean change over time with a standard deviation allows comparison of a particular
intervention’s different outcomes, independent of the measuring units. The resulting
statistical measure is known as effect size index.
The effect size tells us something very different from the p-value, which indicates the
obtained probability of a Type I error in a test of statistical significance. If a p-value
is annotated as statistically significant, rejecting the null-hypothesis does not imply
that the effect was important in any way nor does a non-significant p-value indicate
a clinically trivial result. 64-67 Criticism of statistical hypothesis testing has a long
history, 68 and even Jacob Cohen 14,69 played a prominent role in the anti-hypothesis-
testing charge.70 The adoption of a fixed level of significance may lead to the
situation in which two researchers obtain identical treatment effects but obtain
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different p-values (0.04 and 0.06) due to the effect of (slightly) different sample sizes
leading to different decisions. Thus, p-values are confounded by the joint influence
of sample size and the effect size 71 and make the rejection of the null-hypothesis not
very informative. Another criticism of null hypothesis testing is ‘that it is foolish to
ask: ‘Are the effects of A and B different?’ "They are always different- in some
decimal place- for any A and B". 72 Since then, quantitative investigators in medical
and social sciences have proposed a variety of supplementary effect size indices,
some of which we will clarify. Reporting effect sizes without appropriate statistical
tests and associated p values is misleading and potentially dangerous if the number
of observations that is required to detect a difference has not been estimated by
means of a power analysis. Effect size statistics should be provided to supplement
statistical testing (not as a substitute for it), and only when the outcome is sufficiently
extreme from what would have been expected on the basis of chance (p <α ).
It should be noted that during the debate on ‘significance testing’, several vocal
leaders in psychology and education research called for the universal reporting and
interpretation of empirically produced effect sizes. 73,74
There are myriad estimates of effect size out of which the researcher can make a
choice 75 and the question arises as to which of the effect size measures ‘that could
be summoned up for a given problem should a researcher report?’ 70,71 The most
elegant solution for this problem would seem to be for authors to include the
sufficient statistics so that every reader can compute whichever effect size index they
believe is best suited to the situation. Table 1.1 gives an overview of responsiveness
measures in repeated measurement study designs.
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1.3.4   Effect size: a problematic statistic
Among researchers, who are not conversant with this method of estimating the
amount of change over time, have made various critical comments about Cohen’s
work. 15 These include:
1. there is no consensus on the ‘theoretical’ meaning, or the conceptualisation of
the effect size as an outcome variable;
2. there is no consensus on the mathematical way to determine the magnitude of
the difference between scores gained on two different occasions: researchers
classify the extent of responsiveness and magnitude with effect sizes using
several standard deviations (SD), including the baseline SD, the SD of change
(Cohen’s effect size index d) and so on by using for each of them the thresholds
of Cohen’s effect size index d’, which refers to the pooled samples’ standard
deviation.
Sub 1. Regarding the use of the notion of effect size in HRFS research, several
researchers have claimed that without an external criterion, the estimated amount of
change measured by the effect size index can be denoted as clinically important
change. 19,20,29,30,76 Other researchers assume that an effect size, estimated within a
group of subjects, expresses the measure’s ability to detect change over time (due to
a therapeutic intervention) 16-21,29 without claiming that their effect size indicates that
the instrument is sensitive or responsive to clinically relevant changes in patients’
perceived health. When a HRFS instrument is used as an outcome measure, and the
amount of change estimated with change scores (or quantified by an effect size) is
defined as clinically relevant, the following question logically arises: ‘What is meant
by a clinically relevant change?’ 77,78 Because patients and clinicians differ in the
preferences or perceived relevance that they assign to particular aspects belonging
to domains of health-related functional status, several authors have incorporated
these perceptions or preferences into health status instruments 6,49,76,77,79-82 to give
more significance to the term ‘relevant’.
Sub 2. Many clinical studies have been conducted, that use different methods to
estimate magnitude of change over time. These have indicated that there is no
convincing evidence that either method offers any apparent advantages. 7,48 Any
magnitude of change or responsiveness can be expressed by a ‘d-index’ estimate of
magnitude of change; in other words, it measures the difference between two means
in terms of their common standard deviation units. The literature shows that
numerous quantitative indices belonging to the family of effect sizes (ES) 75 have
been developed. However, there is no consensus on how to declare a difference in
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terms of standard deviation units. The interpretation of the effect size is determined
by the choice of the standard deviation used to standardise the mean change over
time and, related to that, by the ready adoption of the interpretation guideline as set
by Cohen. 15 Several effect size indices are used in quality of life research, which have
in common that 1 - 2 is divided by a standard deviation. The researcher’s decision
as to which SD he will take is either a well-considered choice or one which is copied
from well-reputed colleagues and has no further justification. However, in giving
meaning to standardised mean change in terms of ‘trivial’, ‘small’, ‘moderate’, or
‘large’ effects using the thresholds that Cohen 15 provided us with some thirty years
ago, it seems to have been forgotten that these cut-off points were calculated with
the pooled standard deviation. Consequently, applying these thresholds for mean change
scores standardised with the standard deviation of the change scores (t-1 - t-2
/SDX1-X2 ) may lead to over- or underestimates of effects.
For his effect size (mean baseline scores minus mean follow-up scores, divided by
the pooled standard deviation) Cohen came up with conventions for those values
that constitute a ‘trivial’ (ES < .20), ‘small’ (ES ≥ 20 < .50), ‘medium’ (ES ≥ .50 <
.80), and a ‘large’ effect (ES ≥ 80). However, for each of these effect size indices,
these thresholds are used indiscriminately, which may have contributed to the
confusion in this area. 33
1.4 ESTIMATES OF CLINICALLY RELEVANT CHANGE
Ideally, to assess clinically relevant change, an external definition of what constitutes
relevant is required. Clinicians, for instance, use reference values (reference range)
for physiological health status indicators such as blood sodium or erythrocyte
sedimentation rate as anchors for the degree of deviation from what can be valued
as ‘normal’. Reference values also provide us with the opportunity to rate changes
after treatment as being trivial, substantial, or clinically relevant in the expected
direction. For example, for a reference range of normal values ranging from 12 to 24
units of measurement, an observation of 36 found before treatment (48 units is the
maximum value this measure can acquire) would indicate the need for treatment. The
seriousness of the deviation is 12 units from the upper limit of the reference range.
When 18 units are measured after treatment, the amount of change in 18 units may
be valued as clinically relevant, since this outcome is covered by the reference range
(see Figure 1.1).
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Figure 1.1 Reference range
|12_________18_________24____________________36____________________48|
                      after       before
                      treatment       treatment
In contrast, when health-related functional status is relevant in the treatment
outcome evaluation, researchers do not have a ‘population-based’ reference range of
values or common sense anchors for measures of (for example) physical functioning
in order to be able to value the outcome after treatment in terms of clinical relevance.
In the absence of such a reference range or ‘golden standard’, an estimate of clinically
relevant change requires an external criterion to provide cut-off points or a reference
range to discriminate between relevant and irrelevant change. As stated above, one
common method of interpretation is to compare health status score with a global
subjective judgement of the direction and amount of change by clinician or patient,
often referred to as the external criterion. However, such an external criterion is not
a ‘golden standard’ of health related functional status against which measurements
could be calibrated. It is therefore not easy to place the magnitude of changes in
health-related functional status in a context that is meaningful for researchers,
clinicians, and other health professionals. Although the notion of clinically significant
change, relevant change, or important change has been used to refer to clinicians’
subjective judgements observed in patients undergoing treatment, it would appear
that such a notion lacks an objective definition. A common method of interpretation
of change magnitude in health status, and the one used in this thesis, is to compare
the change in health status score with a global subjective judgement of the direction
and amount of change by the patient. 30,39,83-94 This subjective judgement is obtained
by asking the patient at the post-test stage about the extent to which deterioration or
improvement has occurred since treatment. The measurement of retrospective
perception of treatment-related change is known as a ‘global question’ or a transition
question. Transition or global questions are used with verbal anchors varying from
a dichotomous scale (e.g. improved vs. not improved 59,79) to a 15-point scale ranging
from -7 = ‘a very great deal worse’ to +7 = ‘a very great deal better’. 91,92,95,96 In other
words, these verbal anchors can be used to estimate a relevant difference in an
instrument’s score over time. Thus, patients can be classified as having small but
meaningful serial change in health status score, if they state that they have changed
‘a little’ or ‘somewhat’ (sometimes defined as the minimal clinically important
difference). Change scores represent moderate change if patients felt they had
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changed ‘moderately’ or ‘a good deal’; scores represent large change if patients state
that they have changed ‘a great deal’ or a ‘very great deal’. 91,92,97
Numerous publications are devoted to the question of how the minimal clinically
important change in scores with a repeated administered health status measure can
be determined. 1,24,25,36,45,83,91,92,98-103 In the last decade, the concept of “minimal
important change” has been quantified ambiguously. Some of the studies determine
this minimal clinically important difference (MCID) from the perspective of
clinicians. 104 Some of the studies relate serial change scores to global scales of
perceived change after treatment to demonstrate that a change in score of 0.5 per
item is the minimal clinically important change, if patients say ‘I have improved
(worsened) a little, or improved (worsened) somewhat’. Other studies advocate that
any change of a patient’s disease status should be considered ‘minimally clinically
relevant’ if patients themselves think that they feel at least ‘a little better’. 89,105
Consequently, the mean change in repeatedly measured scores will increase with the
retrospective judgements of “I feel somewhat better”, ‘I feel a good deal better’ and
‘a very great deal better’. 32,84,91,92 Because of this, some studies use the mean
difference between adjacent groups of those who experience no change and those
who feel a little improved or a little worse as the best estimate of the minimal
relevant change. 33,105 A weakness in this approach (although these verbal anchors
can be used to estimate a relevant difference in an instrument’s score over time) is
that different distances between ordinal response categories will affect different
estimates of the change score per item that constitutes minimal, moderate, or large
change. 78 Varying distances on a global question or external criterion for what
constitutes relevant change from the patient’s perspective makes generalisability of
outcome problematic.
1.4.1   Researcher’s perspective versus patient perspective
In this thesis, the concordance between the patient’s perception of the magnitude of
change in domains of health-related functional status, the external criterion, and the
magnitude of change estimated in terms of standardised mean change in scores over
time is a major question (research question 3).
Change in scores on a health-related functioning scale is usually obtained by repeated
baseline measurement. In order to discriminate between relevant and irrelevant
change, so-called ‘transition’ or ‘global questions’ are used as the external criterion
or standard: the patients are retrospectively asked how much they feel better or worse
compared to the situation at baseline.
Consequently, we have two perspectives from which the direction and magnitude of
change can be assessed, namely:
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1. the researcher’s perspective .Subtracting scores from repeated measurements using
a health-related functional status instrument to determine change over time and
interpreting the results in terms of statistical significance (p-value) or relevance
(effect size);
2. the patient’s perspective. If one is interested in understanding the patient’s
perception of change, direct transition questions are used to compare patient
outcomes at one particular time (post-treatment) or over time. The patient gives
a retrospective indication of his or her state of health before treatment, he/she
compares it with the perceived present state of health after treatment and, by
making a ‘mental subtraction’ of both states, signifies the extent of change
(improved, unchanged, or deteriorated) on a global scale of transition.
These transition questions are put as retrospective questions after treatment and are
aimed at determining the direction and magnitude of perceived change in general 
state of health or in domains of physical, emotional, and social health related
functioning.
1.4.2  The patient’s perspective: single global question
In some studies, HRFS items are used as a serial global rating to examine incremental
perceived change between baseline and follow-up. 29,34-36,84,85,97,106-110
Several studies discuss the accuracy, precision, reliability, and validity of single global
ratings of health. 32,85,87,99,111-114 The main disadvantage of a single item of
retrospectively perceived change in overall health is that the answer on a global rating
scale indicated by “since the operation my state of health has worsened” does not
cover domain-specific change in health. We can imagine that improvement in the
domain of physical health is overshadowed by the perception of a worsening in
emotional functioning. Therefore, domain-specific single transition questions are
considered to be more valid indicators of perceived change in health status. 34,115,116
Additionally, another disadvantage of a single question used to capture perceived
change in specific domains of the patient’s life (physical, emotional or social
functioning) is that the internal consistency (reliability) cannot be estimated.
Therefore, we have good reason to presume that multiple-item transitional scales
tend to be more reliable than single-items 117. Moreover, when the items of
retrospective measures are conceptually identical with the repeatedly assessed items
from the baseline measure, they will also have a better validity. 116
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1.4.3   Multi-item transition scales
As mentioned before, a common method of interpretation is to compare health
status scores with a single, global transition judgement of the direction and amount
of change made by the clinician or patient: this is often referred to as the external
criterion. In clinical practice however, change after treatment is also assessed
retrospectively by asking the patient to give an appraisal of the magnitude and the
direction (improvement or deterioration) of change in health status or functioning.
Given this practice, why not measure change directly (retrospectively) in evaluation
studies of treatment efficacy?
In the interaction between clinician and patient, such a retrospective appraisal by the
patient and physician on several clinically relevant components of health status has
clinical relevance, as it determines the decisions made in the management of the
disease. There is an ongoing debate about methods for estimating clinically relevant
change. 34,112,118,119 In this debate, one of the assumptions is that changes inferred
from repeated measurements approximate the change captured by the patient’s
retrospective perceptions of change over a period of time. 12,35 Other researchers
have found that the retrospective recall of change in health status or symptoms is not
as accurate as change found in pre-post designs because of the complexity of the
question. When asked ‘ Have you got better or worse since your bypass operation?’
patients firstly have to make a judgement of their ‘present health state’, then make
a reconstruction of the situation before CABG, and then carry out a mental
subtraction and come with an estimate of the direction and amount of change over
time. This method has two weaknesses: the first is that when the time span is too
large, people simply do not remember how they were before treatment or at the
moment of their last visit at the clinic (the ‘recall bias’). The second weakness is the
correlation of the ‘present state’ with the retrospective estimate of change. 120 The
retrospective assessment of treatment-related change may be invalid if patients feel
prevented from living as they would like to by problems that are not related to the
disease for which they are being treated. However, patients, who experience no
limitation in their health-related functional status at follow-up, are likely to have been
limited before treatment, and consequently they are likely to perceive improvement.
Furthermore, if the time span is sufficiently large, we believe that retrospective recall
is a very useful measurement if the measurement goal is to assess what the subject
believes about the effect of treatment. Assessing change with single-transition
judgements is a time-honoured approach, but there is a good reason to avoid single
questions that are too global. With global transition items such as ‘ Have you got
better or worse since your bypass operation?’ the patient may refer only to a few
symptoms which are manifest at that particular point in time; symptoms such as
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‘shortness of breath’, ‘pain in the chest’, ‘fatigue’ etc.115,116,121,122 Additionally, due to
the relative coarseness of the single item compared with the multi-item scale, the
single item is less well suited to detect minor differences in health perception which
may still be clinically relevant. Multiple-item transition scales, on the other hand,
enable patients to rate the extent to which they have changed on a number of
disease-specific variables, thereby allowing for the possibility that not all aspects of
functioning and health status will be given the same response. With the summed
composite of transition items belonging to domains of HRFS, the constructed scale
will yield more information reflecting meaningful change in the dimension than
single items do. To the best of our knowledge, no studies have been detected in
which a set of transition items is used to measure change in domains of health such
as physical functioning, emotional functioning, and social functioning. The use of
such small sets of multiple-item transition scales to measure change in domains of
health provides an opportunity for an unequivocal representation of changes that are
relevant for the patient. This method may also be considered in study designs where
repeated measurement is not plausible, such as assessment of change after emergency
referral to a hospital of patients who have had an acute heart attack.
Chapter 1                                                                                                              27                                           
REFERENCES
1. Croft P. Measuring up to shoulder pain. Ann Rheum Dis 1998; 57:65-66.
2. Testa MA, Nackley JF. Methods for quality-of-life Studies. Annu.Rev.Public Health
1994; 15:535-559.
3. Hunt SM. The problem of quality of life. Qual.Life Res. 1997; 205-212.
4. Gill TM, Feinstein AR. A critical appraisal of the quality of quality of life
measurements. JAMA 1994; 619-626.
5. Spilker B. Quality of Life and Pharmacoeconomics in Clinical Trials. 2nd.Ed.
Philadelphia: Lippincott-Raven, 1996.
6. Browne JP, McGee HM, O’Boyle CA. Conceptual approaches to the assessment of
quality of life. Psychology and Health 1997; 12:737-751.
7. Bonomi AE, Patrick DL, Bushnell DM, Martin M. Quality of life measurement. Will
we ever be satisfied? J Clin Epidemiol 2000; 53:19-23.
8. Anderson KL, Burckhardt CS. Conceptualization and measurement of quality of life
as an outcome variable for health care intervention and research. Journal of Advanced
Nursing 1999; 29:298-306.
9. Fitzpatrick R. A pragmatic defence of health status measures. Health Care Analysis
1996; 4:265-272.
10. Kempen GIJM, Steverink N, Ormel J, Deeg DJH. The assessment of ADL among frail
elderly in an interview survey: Self-report versus performance-based tests and
determinants of discrepancies. Journal of Gerontology:Psychological Sciences 1996;
51B:254-260.
11. Van Heuvelen MJG. Physical activity, physical fitness and disability in older
persons.(Dissertation). Groningen: Rijksuniversiteit Groningen, 1999.
12. Emery CF, Blumenthal JA. Perceived change among participants in an exercise
program for older adults. The Gerontologist 1990; 30:516-521.
13. Rector TS, Kubo SH, Cohn JN. Patients’ self-assessment of their congestive heart
failure.Part 2: Content, reliability and validity of a new measure, The Minnesota Living
with Heart Failure Questionnaire. Heart Failure 1987; 3:198-209.
14. Cohen J. The earth is round (p < .05). American Psychologist 1994; 49:997-1003.
15. Cohen J. Statistical power analysis for the behavioural sciences. revised edition. New
York: Academic Press, 1977.
16. Stockler MR, Osoba D, Goodwin P, Corey P, Tannock IF. Responsiveness to change
in health-related quality of life in a randomized clinical trial: A comparison of the
Prostate Cancer Specific Quality Of Life Instrument (PROSQOLI) with analogous
scales from the EORTC QLQ-C30 and a Trial Specific Module. J Clin Epidemiol 1998;
51:137-145.
17. Murawski MM, Miederhoff PA. On the generalizability of statistical expressions of
health related quality of life instrument responsiveness: a data synthesis. Quality of Life
Research 1998; 7:11-22.
18. Taylor R, Kirby B, Burdon D, Caves R. The assessment of recovery in patients after
myocardial infarction using three generic quality-of-life measures. J Cardiopulmonary
Rehabil 1998; 18:139-144.
28                                                                              Assessment of change in clinical evaluation
19. Wiebe S, Rose K, Derry P, McLachlan R. Outcome assessment in epilepsy: comparative
responsiveness of quality of life and psychosocial instruments. Epilepsia 1997; 38:430-
438.
20. Russel MGVM, Pastoor CJ, Brandon S, Rijken J, Engels LGJB, Van der Heijde
DMFM, et al. Validation of the dutch translation of the Inflammatory Bowel Disease
Questionnaire (IBDQ): A health related quality of life questionnaire in inflammatory
bowel disease. Digestion 1997; 58:282-288.
21. Tuley MR, Mulrow CD, McMahan CA. Estimating and testing an index of
responsiveness and the relationship of the index to power. J.Clinical Epidemiology
1991; 44:417-421.
22. Parkerson GR, Willke RJ, Hays RD. An international comparison of the reliability and
responsiveness of the Duke Health Profile for measuring health-related quality of life
of patients treated with Alprostadil for erectile dysfunction. Medical Care 1999; 37:56-
67.
23. Wasserfallen JB, Gold K, Schulman KA, Baraniuk JN. Development and validation of
a rhinoconjunctivitis and asthma symptom score for use as an outcome measure in
clinical trials. J.Allergy Clin.Immunol. 1997; 100:16-22.
24. Guyatt GH, Walter S, Norman G. Measuring change over time: assessing the usefulness
of evaluative instruments. Journal Chron.Dis. 1987; 40:171-178.
25. Deyo RA, Diehr P, Patrick DL. Reproducibility and responsiveness of health status
measures. Statistics and strategies for evaluation. Control.Clin.Trials. 1991; 12:142S-
158S.
26. Katz JN, Gelberman RH, Wright EA, Lew RA, Liang MH. Responsiveness of Self-
Reported and Objective Measures of Disease Severity in Carpal Tunnel Syndrome.
Medical Care 1994; 32:1127-1133.
27. Middel B, Kuipers-Upmeijer H, Bouma J, Staal MJ, Oenema D, Postma Th, et al.
Effect of intrathecal baclofen delivered by an implanted programmable pump on health
related quality of life in patients with severe spasticity. J Neurol Neurosurg Psychiatry
1997; 63:204-209.
28. de Beurs E, van Balkom AJLM, Lange A, Koele P, van Dyck R. Treatment of Panic
Disorder With Agoraphobia: Comparison of Fluvoxamine, Placebo, and Psychological
Panic Management Combined With Exposure and of Exposure in Vivo Alone.
American Journal of Psychiatry 1995; 152:683-691.
29. Sneeuw KCA, Aaronson NK, Sprangers MAG, Detmar SB, Wever LDV, Schornagel
JH. Comparison of patient and proxy EORTC QLQ-C30 ratings in assessing the
quality of life of cancer patients. J Clin Epidemiol 1998; 51:617-631.
30. Van der Windt DAWM, Van der Heijden GJMG, De Winter AF, Koes BW, Deville
W, Bouter LM. The responsiveness of the Shoulder Disability Questionnaire. Ann
Rheum Dis 1998; 57:82-87.
31. Bain BA, Dollaghan CA. Clinical Forum: Treatment efficacy. The notion of clinically
significant change. Language, Speech, and Hearing in Schools 1991; 22:264-270.
32. Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes
in health-related quality-of-life scores. Journal of Clinical Oncology 1998; 16:139-144.
33. Husted JA, Cook RJ, Farewell VTGDD. Methods for assessing responsiveness: a
critical review and recommendations. J Clin Epidemiol 2000; 53:459-468.
Chapter 1                                                                                                              29                                           
34. Ziebland S. Measuring changes in health status. In: Jenkinson C, editor. Measuring
health and medical outcomes. London: UCL Press, 1999:
35. Ziebland S, Fitzpatrick R, Jenkinson C, Mowat A, Mowat A. Comparison of two
approaches to measuring change in health status in rheumatoid arthritis: the Health
Assessment Questionnaire (HAQ) and modified HAQ. Annals of the Rheumatic
Diseases 1992; 1202-1205.
36. Stucki G, Liang MH, Fossel AH, Katz JN. Relative responsiveness of condition-specific
and generic health status measures in degenerative lumbar spinal stenosis.
J.Clin.Epidemiol. 1995; 48:1369-1378.
37. Vliet-Vlieland ThPM, Zwinderman AH, Breedveld FC, Hazes JMW. Measurement of
morning stiffness in rheumatoid arthritis clinical trials. J Clin Epidemiol 1997; 50:757-
763.
38. Guyatt GH, Kirshner B, Jaeschke R. Measuring health status: what are the necessary
measurement properties? J.Clin.Epidemiology 1992; 45:1341-1345.
39. Norman G. Issues in the use of change scores in randomized trials. J.Clin.Epidemiology
1989; 42:1097-1105.
40. Guyatt GH, Feeny DH, Patrick DL. Measuring health-related quality of life. Annals of
Internal Medicine 1993; 118:622-629.
41. Stewart AL, Greenfield S, Hays RD, Wells K, Rogers WH, Berry SD, et al. Functional
status and well-being of patients with chronic conditions: results from the medical
outcome study. JAMA 1989; 262:907-913.
42. Patrick DL, Deyo RA. Generic and disease-specific measures in assessing health status
and quality of life. Medical Care 1989; 27S:S217-S232
43. Middel B, Bouma J, Crijns HJGM, De Jongste MJL, Van Sonderen FLP, Niemeijer
MG, et al. The psychometric properties of the Minnesota Living with Heart Failure
Questionnaire (MLHF-Q). Clinical Rehabilitation 2000; accepted for publication:
44. Hillers ThK, Guyatt GH, Oldridge N, Crowe J, Willan A, Griffith L, et al. Quality of
life after myocardial infarction. Journal of Clinical Epidemiology 1994; 47:1287-1296.
45. Juniper EF. Measuring health-related quality of life in rhinitis. J.Allergy Clin.Immunol.
1997; 99:S742-9.
46. Hawker G, Melfi C, Paul J, Green R, Bombardier C. Comparison of a generic (SF-36)
and a disease-specific (WOMAC) instrument in the measurement of outcomes after
knee replacement surgery. J.Rheumatol. 1995; 22:1193-1196.
47. Gliklich RE, Hilinsky JM. Longitudinal sensitivity of generic and specific health
measures in chronic sinusitis. Quality of Life Research 1995; 4:27-32.
48. Wright JG, Young NL. A comparison of different indices of responsiveness. J Clin
Epidemiol 1997; 50:(3)239-246.
49. Bessette L, Sangha O, Kuntz KM, Keller RB, Lew RA, Fossel AH, et al. Comparative
responsiveness of generic versus disease-specific and weighted versus unweighted
health status measures in carpal tunnel syndrome. Medical Care 1998; 36:491-502.
50. Stadnyk K, Calder J, Rockwood K. Testing the measurement properties of the Short
Form-36 Health Survey in a frail elderly population. J Clin Epidemiol 1998; 51:827-835.
51. Vaile JH, Mathers M, Ramos-Remus C, Russel AS. Generic health instruments do not
comprehensively capture patient perceived improvements in patients with carpal tunnel
syndrome. The Journal of Rheumatology 1999; 26:1163-1166.
30                                                                              Assessment of change in clinical evaluation
52. Wells G, Boers M, Shea B, Tugwell P, Westhovens R, Saurez-Almazor M, et al.
Sensitivity to change of generic quality of life instruments in patients with rheumatoid
arthritis: preliminary findings in the generic health OMERACT Study. The Journal of
Rheumatology 1999; 26:217-221.
53. Doeglas D, Krol B, Guillemin F, Suurmeijer Th, Sanderman R, Smedstad LM, et al.
The Assessment of Functional Status in Rheumatoid Arthritis: A Cross Cultural,
Longitudinal Comparison of the Health Assessment Questionnaire and the Groningen
Activity Restriction Scale. The Journal of Rheumatology 1995; 22:1834-1843.
54. Gordon JE, Powell C, Rockwood K. Goal attainment scaling as a measure of clinically
important change in nursing-home patients. Age and Ageing 1999; 28:275-281.
55. Hurny C, Bernhard J, Coates A, Peterson HF, Castiglione-Gertsch M, Gelber RD, et
al. Responsiveness of a Single-Item Indicator Versus a Multi-Item Scale; Assessment
of Emotional Well-Being in an International Adjuvant Breast Cancer Trial. Medical
Care 1996; 34:234-248.
56. Liang MH, Larson MG, Cullen KE, Schwartz JA. Comparative measurement efficiency
and sensitivity of five health status instruments for arthritis research. Arthritis and
Rheumatism 1985; 28:542-547.
57. MacKnight C, Rockwood K. A Hierarchical Assessment of Balance and Mobility. Age
and Ageing 1995; 24:126-130.
58. Rockwood K, Joyce B, Stolee P. Use of goal attainment scaling in measuring clinically
important change in cognitive rehabilitation patients. J Clin Epidemiol 1997; 50:581-
588.
59. van Bennekom CAM, Jelles F, Lankhorst GJ, Bouter LM. Responsiveness of the
Rehabilitation Activities Profile and the Barthel Index. Journal of Cliical Epidemiology
1996; 49:39-44.
60. Roberts R, Hemingway H, Marmot M. Psychometric and clinical validity of the SF-36
General Health Survey in the Whitehall II study. British J of Health Psychology 1997;
285-300.
61. Vickrey BG, Hays RD, Genovese BJ, Myers LW, Ellison GW. Comparson of a generic
to disease-targeted health-related quality of life measures for multiple sclerosis. J Clin
Epidemiol 1997; 50:557-569.
62. Ware JE, Kemp JP, Buchner DA, Singer AE, Norman G. The responsiveness of
disease-specific and generic health measures to changes in the severity of asthma
among adults. Qual.Life Res. 1997; 7:235-244.
63. Ware JE, Kosinski M, Bayliss MS, McHorney CA, Rogers WH, Raczek AE.
Comparison of methods for the scoring and statistical analysis of SF-36 health profiles
and summary measures: summary of results from the Medical Outcome Study. Med
Care 1995; 33(Suppl. 4):AS264-AS279.
64. Rosnow RL, Rosenthal R. Statistical procedures and the justification of knowledge in
psychological science. American Psychologist 1989; 44:1276-1284.
65. Rosenthal R. Progress in clinical psychology: Is there any? Clinical Psychology: Science
and Practice 1995; 2:133-150.
66. Rosenthal R, Rubin DB. The counternull value of an effect size: a new statistic.
Psychological Science 1994; 5:329-334.
Chapter 1                                                                                                              31                                           
67. Bartko JJ, Pulver AE, Carpenter WT. The Power of Analysis: Statistical Perspectives.
Part 2. Psychiatry Research 1988; 23:301-309.
68. Rozeboom WW. The fallacy of the null-hypothesis significance test. Psychological
Bulletin 1960; 57:416-428.
69. Cohen J. Things I have learned (so far). American Psychogist 1992; 45:1304-1312.
70. Levin JR, Robinson DH. Further reflections on hypothesis testing and editorial policy
for primary research journals. Educational Psychology Review 1999; 11:143-155.
71. Thompson B. If statistical significance tests are broken/misused, what practices should
supplement or replace them? Theory & Psychology 1999; 9:165-181.
72. Tukey JW. The philosophy of multiple comparisons. Statistical Science 1991; 6:100-116.
73. Thompson B. Editorial policies regarding statistical significance tests: Futher
comments. Educ.Res. 1997; 26:29-32.
74. Murphy KR. Editorial. Journal of Applied Psychology 1997; 82:3-5.
75. Kirk RE. Practical significance: A concept whose time has come. Educational and
Psychological Measurement 1996; 56:746-759.
76. Naylor CD, Llewellyn-Thomas HA. Can there be a more patient-centered approach to
determining clinically important effect sizes for randomized treatment trials?
J.Clin.Epidemiology 1994; 47:787-795.
77. Lachs MS. The more things change... Journal of Clinical Epidemiology 1993; 46:1091-
1092.
78. Wright JG. The minimal important difference: Who’s to say what is important? J Clin
Epidemiol 1996; 49:1221-1222.
79. Tugwell P, Bombardier C, Buchanan WW, Goldsmith CH, Grace E, Hanna B. The
MACTAR patient preference disability questionnaire- An individualized functional
priority approach for assessing improvement in physical disability in clinical trials in
rheumatoid arthritis. Journal of Rheumatology 1987; 14:446-451.
80. Mitchell PH. The significance of treatment effects: significance to whom? Medical Care
1995; 33:AS280-AS285
81. Wright JG, Rudicel S, Feinstein AR. Ask Patients what they want. Evaluation of
individual complaints before total hip replacement. J Bone Joint Surg 1994; 76-B:229-
234.
82. Rockwood K, Stolee P, Fox RA. Use of goal attainment scaling in measuring clinically
important change in the frail elderly [see comments]. J.Clin.Epidemiol. 1993; 46:1113-
1118.
83. Deyo RA, Patrick DL. The significance of treatment effects: The clinical perspective.
Medical Care 1995; 33:AS286-AS291
84. Beaton DE, Hogg-Johnson S, Bombardier C. Evaluating changes in health status:
Reliability and responsiveness of five generic health status measures in workers with
musculoskeletal disorders. J Clin Epidemiol 1996; 50:79-93.
85. Bindman AB, Keane D, Lurie N. Measuring health changes among severely ill patients;
The floor phenomenon. Medical Care 1990; 28:1142-1152.
86. Deyo RA, Centor RM. Assessing the responsiveness of functional scales to clinical
change: an anology to diagnostic test performance. J.Chronic Disease 1986; 39:897-906.
87. Fitzpatrick R, Ziebland S, Jenkinson C, Mowat A. Transition questions to assess
outcome in rheumatoid arthritis. British Journal of Rheumatology 1993; 32:807-811.
32                                                                              Assessment of change in clinical evaluation
88. Fitzpatrick R, Albrecht G. The plausibility of quality-of-life measures in different
domains of health care. In: Nordenfelt L, editor. Concepts and measurements of
quality of life in health care. Kluwer Academic Publishers, 1994:201-227.
89. Fortin PR, Stucki G, Katz JN. Measuring relevant change: an emerging challenge in
rheumatologic clinical trials. Arthritis Rheum. 1995; 38:1027-1030.
90. Guyatt GH, Deyo RA, Charlson M, Levine MN, Mitchell A. Responsiveness and
validity in health status measurement: a clarification. J.Clinical Epidemiology 1989;
42:403-408.
91. Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the
minimally clinically important difference. Controlled Clinical Trials 1989; 10:407-415.
92. Juniper EF, Gyuatt GH, Willan A, Griffith LE. Determining a minimal important
change in a disease-specific quality of life questionnaire. Journal of Clinical
Epidemiology 1994; 47:81-87.
93. Lydick E, Epstein RS. Interpretation of quality of life changes. Quality of Life Research
1993; 2:221-226.
94. Stucki G, Daltroy L, Katz JN, Johannesson M, Liang MH. Interpretation of Change
Scores in Ordinal Clinical Scales and Health Status Measures: The Whole May Not
Equal the Sum of the Parts. Journal of Clinical Epidemiology 1996; 49:711-717.
95. Wyrich KW, Nienaber NA, Tierney WM, Wolinsky FD. Linking clinical relevance and
statistical significance in evaluating intra-individual changes in health-related quality of
life. Medical Care 1999; 37:469-478.
96. Wyrich KW, Tierney WM, Wolinsky FD. Further evidence supporting an SEM-based
criterion for identifying meaningful intra-individual changes in health-related quality of
life. J.Clin.Epidemiol. 1999; 52:861-873.
97. Norman GR, Stratford P, Regehr G. Methodological problems in the retrospective
computation of responsiveness to change: the lesson of Cronbach. J Clin Epidemiol
1997; 50:869-879.
98. Guyatt GH, Townsend M., Pugsley SO, Keller JL, Short HD, Taylor DW, et al.
Bronchodilators in chronic airflow limitation: Effects on airway function, exercise
capacity and quality of life. American Rev Respir Disease 1987; 1069-1074.
99. Baker DW, Hays RD, Brook RH. Understanding changes in health status;Is the floor
phenomenon merely the last step of the staircase? Medical Care 1997; 35:1-15.
100. Wells GA, Tugwell P, Kraag GR, Baker PRA, Groh J, Redelmeier DA. Minimum
important difference between patients with rheumatoid arthritis: The patient’s
perspective. The Journal of Rheumatology 1993; 20:557-560.
101. Goldsmith CH, Boers M, Bombardier C, Tugwell P. Criteria for Clinically Important
Changes in Outcomes: Development, Scoring and Evaluation of Rheumatoid Arthritis
Patient and Trial Profiles. The Journal of Rheumatology 1993; 20:561-565.
102. Mahajan P, Pearlman D, Okamoto L. The effect of fluticasone on functional status and
sleep in children with asthma and on the quality of life of their parents. J Allergy Clin
Immunol 1998; 102:19-23.
103. Juniper EF. Quality of life questionnaires: Does statistically significant = clinically
important? J Allergy Clin Immunol 1998; 102:16-17.
104. Burback D, Molnar FJ, St-John P, Man-Son HM. Key methodological features of
randomized controlled trials of Alzheimer’s disease therapy. Minimal clinically
Chapter 1                                                                                                              33                                           
important difference, sample size and trial duration. Dement.Geriatr.Cogn.Disord.
1999; 10:534-540.
105. Eberle E, Ottillinger B. Clinically relevant change and clinically relevant diference in
knee osteoarthritis. Osteoarthritis and Cartilage 1999; 7:502-503.
106. Guyatt GH, Eagle DJ, Sackett B, Willan A, Griffith L, McIlroy W, et al. Measuring
quality of life in the frail elderly. J.Clin.Epidemiol. 1993; 46:1433-1444.
107. Redelmeier DA, Guyatt GH, Goldstein RS. Assessing the Minimal Important
Difference in Symptoms: A Comparison of Two Techniques. Journal of Clinical
Epidemiology 1996; 49:1215-1219.
108. Garratt AM, Ruta DA, Abdalla MI, Russell T. Responsiveness of the SF-36 and a
condition-specific measure of health for patients with varicose veins. Quality of Life
Research 1996; 223-234.
109. Deyo RA, Inui TS. Toward Clinical Applications of Health Status Measures: Sensitivity
of Scales to Clinically Important Changes. Health Services Research 1984; 19:275-289.
110. MacKenzie RC, Charlson ME, DiGioia D, Kelley K. A patient-specific measure of
change in maximal function. Arch Intern Med 1986; 146:1325-1329.
111. MacKenzie RC, Charlson ME, DiGioia D, Kelley K. Can the Sickness Impact Profile
measure change? An example of scale assessment. J Chron Dis 1986; 39:429-438.
112. Fischer D, Stewart AL, Bloch DA, Lorig K, Laurent D, Holman H. Capturing the
patient’s view of change as a clinical outcome measure. JAMA 1999; 282:1157-1163.
113. Manusco CA, Charlson ME. Does recollection error threaten the validity of cross-
sectional studies of effectiveness? Medical Care 1995; 33:AS77-AS88
114. Doll HA, Black NA, Flood AB, McPherson K. Criterion validation of the Nottingham
Health Profile: Patient views of surgery for benign prostatic hypertrophy. Soc.Sci.Med.
1993; 37:115-122.
115. Kempen GIJM. The MOS Short-Form General Health Survey: single item vs. multiple
measures of health-related quality of life; some nuances. Psychol Rep 1992; 70:608-610.
116. Kempen GIJM, Miedema I, van den Bos GAM, Ormel J. Relationship of domain-
specific measures of health to perceived overall health among older subjects. J Clin
Epidemiol 1998; 51:11-18.
117. Cunny KA, Perri M. Single-item vs. multiple-item measures of health-related quality
of life. Psychol Rep 1991; 69:127-130.
118. Mahler DA, Weinberg DH, Wells CK, Feinstein AR. The measurement of Dyspnea.
Contents,Interobserver agreement, and physiologic correlates of two new clinical
indexes. Chest 1984; 85:751-758.
119. Osoba D. Interpreting the meaningfulness of change in health-related quality of life
scores: lessons from studies in adults. Int.J.Cancer 1999; 12:132-137.
120. Streiner DL, Norman GR. Health measurement scales. A practical guide to their
development and use. Second edition. Oxford: Oxford University Press, 1995.
121. Read JL, Quin RJ, Hoefer MA. Measuring overall health: an evaluation of three
important approaches. J Chron Dis 1987; 40:7S-19S.
122. Leavey R, Wilkin D. A comparison of two health survey measures of health
 status. Soc.Sci.Med. 1988; 27:269-275.
2Effect of intrathecal baclofen delivered by an
implanted programmable pump on health related
quality of life in patients with severe spasticity
Berrie Middel*, Hanna Kuipers-Upmeijer**, Jelte Bouma*, Michiel
Staal***, Dettie Oenema**; Theo Postma****, Sijmon Terpstra*****; Roy
Stewart*
*Northern Centre for Health Care Research, Faculty of Medical Sciences, University of
Groningen, **Departments of Neurology, ***Neurosurgery and *****Long-range Planning,
University Hospital Groningen, **** Faculty of Economics, University of Groningen, the
Netherlands.
Journal of Neurology, Neurosurgery and Psychiatry




To compare clinical effectiveness and health related quality of life in patients with
severe spasticity who received intrathecal baclofen or a placebo.
Methods
In a double-blind, randomised, multicentre trial 22 patients were followed up during
13 weeks and subsequently included in a 52 week observational longitudinal study.
Patients were those with chronic, disabling spasticity who did not respond to
maximum doses of oral baclofen, dantrolene, and tizanidine. After implantation of
a programmable pump patients were randomly assigned to placebo or baclofen
infusion for 13 weeks. After 13 weeks all patients received baclofen. Clinical efficacy
was assessed by the Ashworth scale, spasm score, and self reported pain, and health
related quality of life by the sickness impact profile (SIP) and the Hopkins symptom
checklist (HSCL).
Results
At three months the scores of the placebo and baclofen group differed slightly for
the spasm score (effect size = 0.20) and substantially for the Ashworth scale (effect
size = 1.40) and pain score (effect size = 0.94); health related quality of life showed
no significant differences. Three months after implantation the baclofen group
showed a significant, substantial improvement on the SIP ‘physical health’, ‘mental
health’, ‘mobility’ and ‘sleep and rest’ subscales and on the HSCL mental health scale;
patients receiving placebo showed no change. After one year of baclofen treatment
significant (P < 0.05) improvement was found on the SIP dimensions ‘mobility’ and
‘body care and movement’ with moderate effect sizes. Improvement on the SIP
subscale ‘physical health’ (P = < 0.05; effect size 0.86), the SIP overall score (without
‘ambulation’), and the ‘physical health’ and overall scale of the HSCL was also
significant, with effect sizes > 0.80. Changes in health related behaviour were noted
for ‘sleep and rest’ and ‘recreation and pastimes’ (P = < 0.01, P = < 0.05; effect size
0.95 and 0.63, respectively). Psychosocial behaviour showed no improvement.
Conclusions
Intrathecal baclofen delivered by an implanted, programmable pump resulted in
improved self reported quality of life as assessed by the SIP, and HSCL physical
health dimensions also suggest improvement.
Keywords: baclofen, health related quality of life, clinical outcomes
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2.1 INTRODUCTION
Continuous intrathecal baclofen infusion via a subcutaneously implanted
programmable pump has been used in the treatment of severe spasticity since 1984.
Studies have evaluated neurological (Ashworth scale and spasm score),
neurophysiological (EMG), urological (bladder function), and other clinically relevant
outcomes, such as functional status activities of daily living.1-12 Little attention has
been paid, however, to health related quality of life, health status measures, and costs.
This study addresses health related dimensions of quality of life as well as
conventional outcome measures, including muscle tone (Ashworth scale) and
frequency of spasms. Treatment outcomes were evaluated during one year after
pump implantation to assess the long term effects of baclofen treatment, which is
aimed at relieving symptoms and improving function. Because of the multiple causes
of severe spasticity, no disease specific instruments were available and health related
quality of life was assessed by generic measures covering a wide range of health status
domains.
To our knowledge, this is the first time validated health status measures have been
used in a randomised, controlled, clinical trial to evaluate the results of baclofen
treatment. This paper presents the results of a first wave of 22 patients who were
enrolled in a double blind, placebo controlled, clinical trial and randomly assigned to
a placebo condition or effective drug (baclofen) treatment. Data collection of a
second wave of patients, who received baclofen infusion immediately after
implantation of the programmable pump, is in progress.
2.2 METHODS
2.2.1    Selection of Patients
Patients with severe spasticity caused by multiple sclerosis or spinal cord injury who
had been referred by their general practitioner or specialist, were recruited from
neurology, rehabilitation and neurosurgery departments of nine Dutch hospitals.
Patients were included in the study when they met the following criteria: (1) aged 18
years or over, with chronic disabling spasticity of spinal origin inhibiting personal
care, sitting, lying, and transfers, accompanied by pain and stiffness, or disturbed
sleeping; (2) insufficient response to treatment with maximum doses of oral baclofen,
dantrolene and tizanidine; (3) sufficient understanding of the consequences of the
treatment. Patients were excluded when they were pregnant, had no neurological
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symptoms of supraspinal origin, or were allergic to baclofen.
After written consent was obtained, patients who fulfilled the inclusion criteria
participated in a test phase to assess their responsiveness to baclofen. The maximum
duration of the test phase was eight days. Every other day either baclofen or placebo
was randomly administered by intrathecal bolus injections through a spinal catheter.
Both doctor and patient were blinded during the test. Depending on the observed
clinical effect consisting of improvement of at least 1 point on the Ashworth and
spasm scales for eight hours, the test was repeated with an increased dose. All
patients responded to one of the doses of baclofen (50, 75, 100, and 150 µg). At the
start of the placebo controlled phase, patients were informed of the 50% chance of
receiving a placebo for 13 weeks and of the possible risks and side effects of the
treatment. Patients were aware that they could end their participation in the study
and that this would not affect their care and treatment. All patients gave their
consent in writing.
Using the Kolmogorov-Smirnov’s test of normality, 13 we found that the normal 
distribution hypothesis had to be rejected for most of the variables used in the
analysis. Therefore, we used the Wilcoxon matched pairs signed ranks test to
estimate change scores between baseline and three months post-test. The difference
in outcomes between the baclofen and placebo group at three months was analysed
using the Wilcoxon-Mann-Whitney test for ordinal data. Effect sizes were calculated
for the statistically significant results. According to Cohen, an effect size of 0.20
implies a small effect, 0.50 a medium effect, and > 0.80 a large effect. 14
Due to lack of information on (clinical) indices from previous evaluations of patients
with severe spasticity of spinal origin, we had no reliable figures to perform a power
analysis and estimate the proper sample size.
2.2.2    Study Design and Treatment Assignment
A multicentre, randomised, double blind clinical trial was conducted to compare two
groups of patients who were implanted with a programmable pump. During the first
13 weeks after implantation of a Synchro-Med programmable pump, the patients
were randomly assigned to either baclofen (n = 12) or a placebo (n = 10). A
balancing procedure was used to allocate the patients to the two conditions to
achieve an equal distribution of patient characteristics with a potential effect on
treatment outcomes over the two groups. 15 The balancing criteria were age, sex, and
aetiology of spasticity.
Both patient and doctor were blinded during the first 13 weeks after implantation.
In patients assigned to the baclofen condition the pump was telemetrically started
after implantation. The initial pump velocity was based on the patient’s response
38                                                                              Assessment of change in clinical evaluation
during the test phase. If a patient’s response had been satisfactory at 75 µg of
baclofen, the initial day dosage was twice that dose (150 µg = 6.25 µg/h (150/24 =
6.25)). If response proved unsatisfactory, the velocity of the pump was increased by
10%. A maximum of two increases was made during the placebo-controlled phase.
In patients assigned to the placebo condition, the same adjustment criteria were
applied, but oral medication was maintained and at the end of the 13-week period the
placebo was replaced by baclofen. Baclofen, placebo, and oral medication were
supplied by the hospital pharmacist in a standard set of blank packages. The figure
shows that the placebo-controlled phase was followed by a 52-week observational
longitudinal follow up phase, which started as soon as the patient was put on
continuous baclofen infusion. In patients receiving baclofen during the placebo
controlled phase, the first phase coincided with the first 13 weeks of the second
phase, that is, they were followed for a total of 52 weeks. In patients who were put
on baclofen after 13 weeks of placebo, the two phases covered a period of 65
(13+52) weeks.
Figure 1.1 Study design
The questionnaires were administered at the start of the study, at four and 13 weeks after
the start of the placebo-controlled phase, and at 26 and 52 weeks of the follow up phase.
T0 T13 T26 T52 weeks





T = Test phase
I = Pump Implantation
Ran = Randomisation
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The study received approval of the joint ethics committee of the Faculty of Medical Sciences,
University of Groningen and University Hospital Groningen.
2.2.3    Measures
Ashworth scale and spasm score and self reported pain
The Ashworth scale and spasm score are clinical assessment scales for spasticity. To
calculate the Ashworth score the grades for hip flexion/extension, hip abduction and
adduction, knee flexion/extension and ankle dorsal flexion/extension on each side
are summed and divided by eight. The modified Ashworth scale has 4 grades: grade
0 (no increase in tone), grade 1 (slight increase in tone, giving a “catch” when the
affected part is moved in flexion or extension), grade 2 (more pronounced increase
in tone, but affected part easily flexed), grade 3 (considerable increase in tone; passive
movement difficult), and grade 4 (affected part rigid in flexion or extension). 16 The
spasm score evaluates the frequency of spasms with scores: 0 (no spasm), 1 (mild
spasms induced by stimulation), 2 (infrequent spasms occurring less than once per
hour), 3 (spasms occurring more than once per hour), and 4 (spasms occurring more
than 10 times per hour).
Pain was measured on a 10 point self-assessment scale with a sum score ranging from
zero to 10, where 0 = having no pain and 10 = having unbearable pain.
The sickness impact profile
The sickness impact profile (SIP) is a behaviour based self report measure that is
used to quantify sickness related dysfunction. 17 Patients are asked to complete a
standardised questionnaire consisting of 136 items aggregated into 12 domains of
daily functioning. It has a physical dimension consisting of three domains by
aggregation of the item scores of the ambulation, mobility, and body care and
movement scales, and a psychosocial dimension including four scales, that is, social
interaction, alertness behaviour, emotional behaviour, and communication. The
remaining, independent categories are not aggregated: sleep and rest, eating, work,
home management, and recreation and pastimes. 18 Differential weights per item are
aggregated for each category and for both dimensions, and standardised to a
percentage of the maximum possible score ranging from 0 to 100 (0 = no functional
limitation for the category and 100 = maximally possible limitation). As the patients
in the study were unable to walk because of multiple sclerosis or spinal cord injury,
the domains ambulation and home management were not considered. Only two
patients had a part time paid job, so the category work was not included in the
analysis.
The Hopkins symptom check list
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The Hopkins symptom checklist (HSCL) was translated and validated in the Dutch
situation by Luteijn et al. 19 It consists of 57 items with two subscales and an overall
scale. The subscale physical health contains eight items with scores ranging from 0
to 24 (0 = no complaints at all) measuring the physical health experienced, for
example, headache, low back pain, and dizziness. The subscale mental health
measures psychoneurotic complaints and consists of 17 items with scores ranging
from zero to 51 (0 = no complaints at all). Some examples of items of this scale are:
‘I cannot get rid of nasty thoughts’, ‘I am feeling desperate about the future’. The
overall scale covers all 57 items, including the 32 items of the subscales measuring
psychoneurotic and somatic complaints, and ranges from zero to 171. According to
Luteyn et al this scale is very sensitive to change in the evaluation of treatments.
2.2.4     Statistical Methods
The changes in clinical and health related quality of life at three months were
analysed for the treatment and placebo group using the Wilcoxon matched pairs
signed ranks test. The same test was used to analyse the results after one year of
baclofen infusion. The differences at three months between the treatment and
placebo group were analysed using the Wilcoxon-Mann-Whitney test for ordinal data.
20 Effect sizes (d) were calculated according to Cohen. 21 As the variance of the post-
test measure is partly explained by the pretest scores, estimating the magnitude of the
change between baseline and post-test in the treatment and control group required
adjustment of the effect size d’ for the correlation (r) between the scores of paired
observations.
d’ = effect size = mean change/pooled SD baseline and post-test score;
d = effect size adjusted for r;
r = correlation coefficient
( )test -postbaseline
test-postbaseline









Of 96 consecutive implantation candidates screened for inclusion in this study, 53
failed to meet the eligibility criteria because of suboptimal dosage of oral medication
(n = 17), functional spasticity or effective oral medication (n = 13), no spasticity (n
= 3), or because they fulfilled one of the exclusion criteria (n = 20). Five of the 43
eligible subjects refused to participate. Of the remaining 38 patients, 22 were
randomly assigned to placebo or baclofen using a balancing procedure. After the first
wave of 22 patients had been assigned to the double blind controlled conditions, all
16 patients of the second wave received baclofen immediately after pump
implantation. The results of the evaluation of clinical efficacy and health related
quality of life in all 38 patients are not yet available, but will be published in due
course.
2.3.1    Demographics
Table 1 presents the overall characteristics. The mean (SD) age of the sample was
48.3 (12.7) years (range 19-70), 55% were women, and 59% and 41% had multiple
sclerosis or spinal cord injury, respectively. Seventeen patients (77%) were married
or divorced with an average number of 2 children. At the start of the study a
relatively high proportion of patients with multiple sclerosis was enrolled. This was
caused by a difference in consultancy function of the centres that first participated
in the study and has led to a lower proportion of patients with spinal injury during
the placebo controlled phase compared with the follow up phase.
Table 2.1 Patient characteristics of study groups and balancing criteria
Baclofen Placebo





Multiple Sclerosis 7 6
Spinal cord 3 6
Children (mean n) 1.8 1.9
1 Balancing criteria
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2.3.2    Differences between the groups after three months
Our initial hypothesis was that the baclofen and placebo group would show
differences in both clinical efficacy and physical and psychosocial functioning. To
test the hypothesis we analysed the differences in mean scores on all the instruments
during the first three months of the study (baseline to three months). At baseline,
before implantation, no significant differences between the groups were found for
the complete set of variables (Wilcoxon-Mann-Whitney test, α  = 0.05). For the
three clinical efficacy measures, the null hypothesis - that is, equal mean scores at
baseline and at three months post-test - could be rejected (table 2, columns 8 and 9).
The estimated magnitude of the difference in the spasm score was small (effect size
= 0.20); differences in the Ashworth scale (effect size = 1.40) and pain score (effect
size = 0.94) were large.
However, the physical and psychosocial dimensions of the health related quality of
life measures showed no significant differences between the placebo and treatment
group at baseline and after three months.
2.3.3   Differences within the baclofen treatment and placebo group
Separate analysis of the two groups (table 2, columns 6 and 7) showed no significant
changes for any of the outcomes in the placebo group after three months. However,
the baclofen group showed significant changes in the following outcome measures:
spasm score (P = 0.04); Ashworth scale (P = 0.04), the overall SIP score (P = 0.03);
the physical dimension of the SIP (P = 0.02); the SIP mobility scale (P = 0.005); the
SIP scale sleep and rest (P = 0.02); the SIP psychosocial behaviour scale (P = 0.04);
the overall score of the HSCL (P = 0.002) and the mental health scale of the HSCL
(P = 0.005). This trend is confirmed by the effect sizes which ranged from moderate
to large (with values between 0.70 and 1.35) suggesting that baclofen infusion
affected the domains of health related quality of life and clinical outcome in the
predicted direction. Of the clinical efficacy data, the self reported pain score did not
show a significant decrease during this period and the same applies for the HSCL
physical health scale. Although the scores of the sickness impact profile dimensions
eating, recreation and pastimes, body care and movement indicated an improvement
after three months; the changes were not significant and are therefore not shown.















































































































































































































1 Effect size for paired observations
2 * p < 0.05, ** p < 0.01, *** p < 0.001, ns: not significant
3 Effect size for independent samples
4 Sickness Impact Profile
5 Hopkins Symptoms Check List
Chapter 2 45
Table 2.3 Clinical outcome measures, Health-related functional status, Perceived physical
and mental health and depression at baseline, 1 year after baclofen infusion and changes
in (sub)scale scores, and effect sizes (ES)
Instrument subscale Baseline score 1 year baclofen
score












































































































1) The items of the SIP ambulation scale were not applicable for the patients in this study and
were removed.
2.3.4    Results after one year of baclofen administration
Table 2.3 summarises the results of the evaluation of health outcome measures at
baseline and one year after the start of intrathecal infusion of baclofen in the
complete sample of patients with severe spasticity in the first wave of the study.
Patients who were assigned to the 13 week placebo condition followed by baclofen
treatment, were merged with the group who received baclofen from the start of the
study. This observational longitudinal phase includes the entire initial sample of 22
patients, who were followed up during one year of intrathecal baclofen infusion. At
one year patients showed substantial, significant improvement on clinical efficacy
outcomes (self reported pain P < 0.01; effect size = 1.07, Ashworth scale and spasm
score P < 0.01; effect size 6.23 and 3.05, respectively). Improvement was also found
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for the physical dimensions mobility and body care and movement of the SIP,
indicating a statistically significant (P < 0.05) change between baseline and post-test.
The corresponding effect sizes suggest moderate changes in health related behaviour
in these domains. Change was also significant and substantial for the physical health
subscale of the SIP (P < 0.05; effect size 0.86). The SIP overall score (calculated
without the ambulation items) and the physical health and overall scale of the HSCL
showed a significant and substantial decrease (improvement) after 1 year, with large
effect sizes > 0.80. Changes in health related behaviour was observed for the
categories sleep and rest and recreation and pastimes (P < 0.01, P < 0.05; effect size
0.95 and 0.63 respectively). In striking contrast to the physical dimensions, the
psychosocial dimensions of the SIP (social interaction, alertness behaviour, emotional
behaviour and communication) and mental health of the HSCL did not show any
significant improvement.
2.4 DISCUSSION
As expected, the mean scores of the clinical efficacy scales (muscle tone, spasm
score, and self reported pain) before and after treatment (table 3) showed a clear
change in the predicted direction after one year of intrathecal baclofen infusion.[22-
24] These changes, which can be interpreted as an improvement in relevant clinical
outcomes, are significant with large effect sizes.
We can conclude that intrathecal baclofen delivered by a subcutaneously implanted
programmable pump resulted in a significant improvement in self reported health
related quality of life regarding recreation and pastimes, rest and sleep, mobility, body
care and movement as assessed with the sickness impact profile. The changes
between the initial and final scores on the physical health dimension and the overall
scores of the sickness impact profile and the Hopkins symptom checklist also point
to improvement. No change was found for the SIP and HSCL psychosocial
dimensions. Significant improvements are associated with effect sizes > 0.63. For
non-significant changes the effect sizes ranged from 0.40 to 0.57.
Contrary to our expectations, three months after implantation the baclofen group
and the placebo group did not differ significantly in the mean scores on the physical
and psychosocial dimensions of health related quality of life instruments.
It was hypothesised that no significant changes would be found in the placebo group
but a significant change was expected to have occurred in the baclofen group at three
months. The group receiving baclofen immediately after implantation improved
significantly on the clinical outcome measures, demonstrating the clinical efficacy of
the treatment. This group showed significant changes in relevant physical and
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psychosocial dimensions of self reported health status except for the HSCL physical
health scale.
2.5 CONCLUSION
In interpreting the results of this study, one should bear in mind that the research
design may have caused some underestimation of the results. The following
considerations are important in this respect:
In the placebo phase of the study the pump could not be optimally programmed
because the doctor who was responsible for the treatment was blinded. In patients
assigned to the placebo condition this would have led to countless increases in the
concentration of the contents or the velocity of the pump. Therefore, we decided to
restrict the number of changes in velocity and/or concentration to two. This may
have resulted in suboptimal doses for some of the patients in the baclofen group,
which in turn may have affected treatment outcome. Thus the observed differences
between the baclofen and placebo group may not be representative of optimal
treatment results.
Three months is probably too short a period to find evidence of differences in
dimensions of health- related quality of life between the treatment and baclofen
group. Despite the significant and substantial observed change in clinical efficacy in
the baclofen group, these patients continue to have other invalidating consequences
of their underlying disease. This might explain the lack of significant differences in
health related quality of life between patients receiving baclofen and placebo.
The necessity of blinding, even if the outcome seems too obvious, was shown by
changes in spasticity and health related behaviour in one of the patients in the
placebo group. For several weeks both patient and research team erroneously
assumed that these changes were attributable to baclofen.
In cases where the optimum dosage was achieved after two corrections there is the
probability of habituation causing a reduction in the effects after the first four weeks.
Aspects of physical health and daily functioning are probably associated with the
degree of spasticity. Therefore, a reduction in severe spasticity is likely to induce a
substantial change in the dimensions of physical health. The psychosocial
dimensions, however, are probably more strongly associated with the unchangeable,
underlying disease, which may explain the absence of a treatment effect in this
respect even after one year.
The improvement on the psychosocial dimensions of quality of life during the first
three months is probably associated with patients receiving increased attention from
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medical professionals and their social network combined with (too) high expectations
of the treatment. This effect is likely to disappear after one year of treatment.
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ABSTRACT
Objective
The purpose of this study was to evaluate the psychometric properties of the
Minnesota Living with Heart Failure Questionnaire (MLHF-Q) in patients with atrial
fibrillation.
Design
This was a prospective study of the patients who underwent DC electrical
cardioversion.
Setting
Clinics of Cardiology and Thoracic surgery of the University Hospital in Groningen,
the Netherlands.
Main Outcome measures
The disease specific MLHF-Q and generic measures of quality of life were
administered. The sensitivity to change over time was tested with effect sizes (ES).
Internal consistency of MLHF-Q scales was estimated with Cronbach’s alpha. To
evaluate the construct validity multitrait-multimethod analysis was applied. The
‘known group validity’ was evaluated by the comparison of mean scores and effect
sizes between two groups of the NYHA-classification (NYHA I versus II-III).
Stability of MLHFQ-scales was estimated in a subgroup of patients, which remained
stable. Perfect Congruence Analysis and factor analysis were applied to confirm the
a priori determined structure.
Results
Cronbach’s alpha was ≥ 0.80 of the MLHF-Q scales. Perfect Congruence Analysis
(PCA) showed that the results resemble quite well the a priori assumed factor
structure. Multitrait-multimethod analysis showed convergent validity coefficients
ranging from .59 to .73 (physical impairment dimension); from.39 to .69 (emotional
dimension). The magnitude of change can be interpreted as medium (ES = .50). The
results of a "test-retest” analysis in a stable group can be valued as satisfactory for the
MLHF-Q scales (Pearson’s r > .60). The physical dimension and the overall score of
MLHF-Q showed statistically significant differenc between  NYHA I and II-III
groups (p < .001) with large effect sizes (ES > 1.0).
Conclusions
The MLHF-Q has solid psychometric properties and the outcome of the current
study indicate that the MLHF-Q is an effective and efficient instrument.
Keywords: Quality of life, outcome assessment, heart failure, validity
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3.1 INTRODUCTION
In assessing health related quality of life and functional ability or health status, a
distinction is made between disease-specific outcome measures developed to measure
quality of life dimensions characteristic for patients having a particular disease, and
generic instruments measuring more broadly defined dimensions of quality of life.
Both types of instruments have their strengths and weaknesses.1 An advantage of
generic instruments is that they have a broad scope and can be used in many
populations on a wide variety of diseases. A disadvantage is that general aspects of
quality of life which are not significant for a specific disease will result in a less valid
assessment of the concept of health-related quality of life in e.g. groups of (chronic)
disease. Assessing only those aspects of quality of life, which are determined to be
due to a particular disease, will result in a short instrument that will be more sensitive
to detect change in disease-specific groups after (medical) interventions. A
disadvantage of a disease-specific instrument is that study results are difficult to
compare with those of other populations. In the current study health related quality
of life was assessed with the specific Minnesota Living with Heart Failure
Questionnaire (MLHF-Q), 2  the generic RAND-36 or SF-36 3, the Multidimensional
Fatigue Inventory (MFI-20) 4,5,6 and the Hospital Anxiety and Depression Scale
(HADS). 7,8  The data were appropriate to conduct a validation study to estimate the
sensitivity to change (responsiveness), the reliability and validity of the disease-
specific MLHF-Q to obtain data for its future use in (Dutch) clinical evaluation
studies.
The MLHF-Q consists of 21 items and addresses a wide range of health-related
quality of life aspects. 9 In this article, the psychometric properties of the Dutch
version of the MLHF-Q scales are evaluated and validated with conceptually similar
dimensions of generic instruments: the RAND-36, the HADS and the MFI-20.
All instruments are self-report measures of quality of life on the dimensions of
physical, mental or  social  well-being. The psychometric properties of the MLHF-Q
have been evaluated already in its English version and the instrument has been used
as outcome measure in clinical trials in the context of the American health care
system. 2,10,11,12,13,14,15 In other countries the number of studies on the evaluation of
the reliability and validity of the MLHF-Q is up till now not substantial .16,17 The
RAND-36 was chosen as the generic counterpart because it is a generally accepted
and well-validated instrument, it is a short questionnaire with known psychometric
properties, 18,19,20,21 it resembles closely the MLHF-Q dimensions, and is available in
a Dutch version. 22,23
The objectives of this study were:
- to compare the results from the MLHF-Q with the RAND-36, HADS and MFI-
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20 in terms of reliability and sensitivity to detect change over time. It was
hypothesised that the MLHF-Q would demonstrate a comparable magnitude of
change over time;
- to compare the results of the questionnaire’s clinical validity. It was hypothesised
that the MLHF-Q would demonstrate that the more severely angina was rated
by the NYHA-classification, the greater the deterioration in the patient’s quality
of life turned out to be. The change assessed in a group of patients who
remained clinically unchanged or stable was hypothesised to be due to chance
fluctuation;
- to find support for the factor structure originally found by Rector and Cohn 12
in our data;
- to provide empirical evidence that the MLHF-Q scale measures the underlying
constructs of physical and emotional impairments it is reputed to represent.
The purpose of the present study was to use data of a treatment-outcome study to
determine the performance of the MLHF-Q. The results of the clinical efficacy study
will be published elsewhere.
3.2 METHODS
Consecutive patients scheduled for DC electrical cardio version were included in this
study. Patients presented arterial fibrillation and arterial flutter and were treated at the
department of Cardiology and Thoracic surgery of the University Hospital in
Groningen.
Out of the 60 consecutive candidates for DC electrical cardio version screened for
inclusion, five patients died within twelve months after the completion of the first
questionnaire. One year after the first visit to the clinic, 44 patients out of 55 (80.0%)
returned the questionnaire used for analysis of reliability and validity of the MLHF-
Q.
All patients completed the questionnaires as a baseline assessment before the first
treatment (DC electrical cardio version) in the department of Cardiology and
Thoracic surgery of the University Hospital Groningen. The patients were invited to
participate in the study by the cardiologist and after informed consent the patients
completed the questionnaires, undisturbed, in a separate room. The cardiologist was
blinded to the information of the questionnaires. The second and third assessment
was at home, three and twelve months after the first electrical cardio version
respectively. The questionnaires were returned in a pre-paid envelope to the
Northern Centre for Healthcare Research of the University of Groningen.
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3.2.1    Measurements
Both demographic characteristics of the patients and relevant medical background
variables were administered with standard or usual questions and items in the medical
examination procedure at the first visit to the outpatient clinic. To assess the impact
of the treatment on daily physical, emotional and social functioning, four instruments
were used. The RAND-36 is a generic instrument and consists of 36 items that
contribute to eight scales that measure the following aspects of health: “physical
functioning” (10 items), “social functioning” (2), “role limitations due to physical
problems” (4), “role limitations due to emotional problems” (3), “mental health” (5),
“energy/vitality” (4), “pain” (2), and “general health perception” (5). The one-item
scale on change in perceived health was not used in the transformation of scores into
a scale, because the MLHF-Q does not contain an item assessing change in perceived
health. The RAND-36 item scores are summed and transformed to eight scales, each
with scores between 0 and 100, where 0 represents the worst state of health and 100
 the best state of health possible. 3,23 The Minnesota Living with Heart Failure
Questionnaire is a disease-specific instrument and composed of 21 items and three
scales that measure: the physical dimension (8 items), the emotional dimension (5
items) and the overall score on health-related quality of life (21 items). Eight separate
items, which do not assess a single construct or dimension of health-related quality
of life, measure social and economical impairments patients relate to their heart
failure and are part of the overall score. The total score has a range between 0 and
105, the physical dimension (sub-scale) between 0 and 40, the emotional dimension
(sub-scale) between 0 and 25 and the separate items on the socio-economic
impairments between 0 and 40.
High scores on the MLHF-Q scales indicate a high negative impact of heart disease
on the assessed aspects of quality of life.
The Multidimensional Fatigue Inventory (MFI-20) consists of twenty items and five
sub-scales (General, Physical, Activity, Motivation, and Cognition). Each scale
consists of four items and has a range from 4 to 20 and its total score ranges from
20 to 100. High scores indicate high fatigue. The subscales Anxiety and Depression
of the Hospital Anxiety and Depression Scale (HADS) have a range between 0 and
21. A score of 7 or lower identifies ‘non-cases’, 8 to 10 ‘doubtful cases’ and a score
≥  11 ‘definite cases’.
3.2.2    Quantitative analysis
The features of the distribution of scores on the conceptually similar dimensions of
the MLHF-Q, MFI-20, HADS, and RAND-36 were computed. Mean scores,
standard deviations, and the percentage of patients with the maximal possible score
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(ceiling) and the minimal possible score (floor) are represented.
In the examination of the construct validity of the MLHF-Q, scales of all instruments
were used in the analysis. It was hypothesised that the scales, that are conceptually
associated, would show strong correlations and scales, that are conceptually weaker
associated, would demonstrate lower correlation coefficients.
In this study, the internal consistency of the MLHF-Q, RAND-36, HADS and MFI-
20 scales was tested with Cronbach’s α 24 to make comparisons between the
instruments’ mean alphas. An α-coefficient > 0.80 was considered as sufficient 32
irrespective of the number of items. Perfect Congruence Analysis and factor analysis
were applied to confirm the a priori determined structure on which Rector and Cohn
12 have selected the items.
Test- retest stability of the MLHF-Q scales was assessed with correlation coefficients
between baseline and 3 months after cardio version in a group in which the
treatment was not successful (that showed no sinus rhythm three months after the
first electrical cardio version), so their health status remained unchanged or stable.
Although the test-retest procedure was not carried out by sending the questionnaire
shortly after the first completion, we were interested in the variability of the MLHF-
Q scores between two points in time within a group whose condition remained
stable. However, high test-retest correlation coefficients as such do not give us
information about the changes in time between baseline and 3-months outcome
scores, and therefore we tested the hypothesis that the change over time in a stable
group is due to chance fluctuations. The Wilcoxon Matched-Pairs Signed-Rank test
was used due to the non-normal distribution of the outcome assessments.
To estimate the responsiveness, the ability of an instrument to detect the magnitude
of change over time within one group, we used Cohen’s effect size statistic d for
paired observations.25 As the variance of the post-test measure is partly explained by
the pre-test scores, estimating the magnitude of the change between baseline and
post-test in the treated group requires adjustment of the effect size d’ for the
correlation (r) between the baseline and post-test scores. 26,27
d’ = effect size = mean change/pooled SD baseline and post-test score;
d = effect size adjusted for r;
r = correlation coefficient between repeated measurements.
( )test -postbaseline
test-postbaseline








An effect size of .20 has to be interpreted as a small effect, an effect size of .50 as a
medium effect, and an effect size of > .80 as a large effect. 25,28 To evaluate the ability
of the MLHF-Q to discriminate between subgroups of patients of which is known
that they differ on an accepted classification of the seriousness of the disease, the
‘known groups validity’ of the MLHF-Q scales was tested. 29 The Man-Whitney U
Wilcoxon rank sum test was used because of the non-normal distribution of the
variables in the analysis. The grouping condition was NYHA classification I vs. II
and III (due to the small number of observations class II and III were combined). 30
Cohen’s effect size d’ for unrelated samples, to estimate the magnitude of the
difference in mean scores between these groups, was calculated by dividing the mean
difference score by the pooled standard deviation for groups with unequal number
of observations. 31
3.3 RESULTS
In table 3.1 the descriptive statistics of the sample are shown. The mean (range) age
of the patients in the study was 61.5 (range 28 - 87) years. The minority of patients
was female (35%). The majority of patients had one or more heart diseases or other
relevant diseases in addition to arterial fibrillation (AF). Only six persons had AF
without any other disease. Almost half of the patients (46.7%) had two or more
diseases next to AF. A relatively large group (41.7%) was treated for the first time for
AF. The mean score on the NYHA classification (range 1-4) of 1.9 indicates a
moderate severity of the underlying disease.
( )III-II  NYHA  I  NYHA
III-II  NYHA   I  NYHA
XX SD
X-X'd =
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Mean age (y) 61.5 (SD 12.7)
Martial status:
Married/living with partner 39 (60.0)
Widowed/unmarried/divorced 16 (24.6)
Missing value 5 (15.4)
Disease:
Aortic Valve disease 12 (20.0)
Mitralic Valve disease 12 (20.0)
Hypertension 16 (26.7)
Congenital heart disease  7 (11.7)





No disease  6 (10.0)
1 disease 26 (43.3)
2 diseases 21 (35.0)
3 -4 diseases 7 (11.7)
Mean NYHA-classification 1.9 (SD 0.6)
3.3.1    Distribution of scores, internal consistency and responsiveness
Mean baseline and post-test (1 year) scores, standard deviations and the percentages
of patients with the maximum and minimum scores, are represented in table 3.2. A
study of the distribution of scores of the MLHF-Q scales showed a skew ness in the
direction of positive functioning or little or no impairment. The RAND-36 data
showed the same tendency for four scales (social functioning, emotional role
functioning, pain, and health perception). The RAND-36 scale ‘physical role
functioning’ showed a tendency towards the opposite direction. Three conceptually
related scales of the MFI (‘physical’, ‘activity’ and ‘general’ feelings of fatigue) were
skewed in the direction of little impact on health-related quality of life while the
cognition scale was skewed in the negative direction.
Table 3.2 Means, standard deviations, minimum and maximum scale-scores, Crohnbach’s alpha’s, Pearson’s correlations t1 – t12
and within groups effect size for paired observations (N = 44)
                             Pre-test                         Post-test














Physical dimension (0-40) 14.2 9.6 15.9 2.3 .88 10.4 10.3 15.9 2.3 .91 .65 .67
Emotional dimension (0-25) 5.9 5.7 20.5 2.3 .82 3.8 4.5 31.8 2.3 .81 .56 .51
Overall score (0-105) 28.5 19.6 11.4 2.3 .91 21.6 20.8 13.6 2.3 .94 .59 .67
Rand-36
Physical functioning (0-100) 56.6 28.7 2.3 6.8 .93
(.92).**
66.1 27.1 11.4 2.3 .93 .63 .71
Social functioning (0-100) 60.4 25.3 13.6 4.7 .79 (.71) 72.3 25.2 31.8 2.3 .78 .72 .56
Role-physical (0-100) 27.3 39.3 15.9 56.8 .91 (.90) 51.7 45.1 38.6 34.1 .91 .77 .46
Role-emotional (0-100) 54.8 44.7 31.8 40.9 .90 (.86) 62.6 44.3 54.5 25.0 .90 .25 .52
Pain (0-100) 80.9 23.6 47.7 2.4 .90 (.93) 82.6 21.9 52.3 2.3 .89 .13 .67
Mental health (0-100) 64.6 21.7 6.8 4.7 .83 (.85) 72.5 17.8 2.3 2.3 .84 .54 .47
Energy/vitality (0-100) 48.2 24.2 2.3 4.9 .86 (.82) 58.6 22.4 2.3 2.3 .84 .65 .53
Health perception (0-100) 56.0 21.2 6.8 2.3 .79 (.82) 55.0 20.0 2.3 4.5 .76 .07 .51
HADS
Anxiety 5.7 3.9 4.5 2.3 .83 4.2 3.3 15.9 2.3 .81 .61 .53
Depression 6.0 4.6 6.8 4.5 .84 5.3 4.5 11.4 2.3 .86 .26 .74
MFI-20
General 12.6 5.2 6.8 11.4 .87 10.8 5.3 11.4 9.1 .89 .58 .66
Physical 12.1 4.5 7.0 11.4 .85 10.9 5.1 9.1 4.5 .90 .37 .49
Activity 12.3 5.1 4.5 9.1 .88 10.9 5.3 13.6 6.8 .90 .41 .54
Motivation 10.7 4.7 4.5 4.5 .76 10.2 4.5 15.9 2.3 .80 .20 .67
Cognitive 7.4 3.5 34.1 2.3 .82 8.0 3.9 27.3 2.3 .86 .24 .52
Overall fatigue 54.1 18.3 2.4 2.4 .94 49.5 20.2 2.3 2.3 .95 .40 .65
* Effect size d for paired observation 26                    ** Reliabilities of a general Dutch municipality population 21,22                         
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The Cronbach’s alpha’s, the internal consistency coefficients, of the MLHF-Q,
RAND-36, HADS and MFI-20 scales are also shown in table 3.2. The internal
consistency of the MLHF -Q scales had a satisfactory level of reliability (α > .80). 32
Only the RAND-36 scales “social functioning” and “general health perception” and
the MFI-scale “cognition” were below this level (.79, .79 and .76 respectively). The
reliability coefficients of the MLHF-Q scales remained satisfactory one year after
enrolment.
The scales of the MLHF-Q at baseline assessment yielded internal consistency
estimates (mean α = .85; range = .82 to .88) equal to the RAND-36 (mean α = .86;
range = .79 to .93) and somewhat higher than those of the HADS (mean α = .83;
range = .83 to .84) and MFI-20 (mean α = .84; range = .76 to .88).
The ability to detect change over time within one group with paired observations was
estimated with the effect size proposed by Cohen. 25 An effect size of .20 has to be
interpreted as a small effect, an effect size of .50 as a medium effect and as an effect
size of >.80 as large effect. Large effect sizes were not found. The MLHF-Q scales
showed medium effect sizes. The RAND-36 scales ‘role limitations due to emotional
problems’ and ‘pain’ demonstrated small effect sizes and ‘general health perception’
showed no ability to detect change between baseline and one-year outcome
assessment. The HADS-anxiety scale and the MFI-20 ‘general fatigue’ scale showed
medium effect sizes. The physical and emotional dimensions of the RAND-36,
HADS, and MFI-20 demonstrate comparable indicators of change over time within
this particular group.
3.3.2   Item analysis
The MLHF-Q contains three dimensions or scales: a physical dimension, an
emotional dimension, and a global quality of life dimension. A comparison was made
with the results of the factor analysis of Rector and Cohn. 12 Their data provided us
with an a priori assumed four-factor structure that was forced in order to evaluate the
congruence of our data with the original structure. Therefore, a computer program
for Simultaneous Component Analysis (SCA) for variables measured in two or more
populations was applied. 33 The four a priori assumed factors based on the structure
in the data of Rector and Cohn explained 58% of the total variance as a result of the
SCA-Perfect Congruence Analysis (PECON). 34 A principal component analysis with
rotation according to the varimax criterion was performed without the constraints
of the structure elaborated by Rector and Cohn. In this analysis the four factors
explained 61 % of the total variance. This difference of 3% indicates an acceptable
discrepancy, but still indicates an insufficient recognition in our data. A fourth socio-
economic dimension of impairments, that patients relate to their heart failure, was
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suggested by Rector et al., 2 but in the current study the items did not load on a
socio-economic component. As is demonstrated in the matrix (table 3.3), 6 out of the
21 items had very high loadings (> .70) and 13 items had high loadings (> .50 - <
.70) on their respective factors. Only one item had a high loading on two factors
(impairment because of ankle oedema). On face value we may conclude that the
results closely resemble the findings of Rector and Cohn. 12 A closer inspection of
the four factor solution, however, shows some deviations from the original factor
structure: two items of the physical dimension identified by Rector and Cohn
(“making your sleeping well at night difficult” and “your relating to or doing things
with your friends or family difficult”) have a high loading on factor three and four
representing the impairments on a heterogeneous set of health-related aspects of
heart failure. Factor 2 demonstrates high loadings of the items on the physical
dimension. Although all the items of the emotional dimension had high loadings on
factor 1, the following items showed also high loadings: “going away from home”
(physical dimension), “ankle oedema”, “hospitalisation”, and “medical costs”(socio-
economic impairments) on this factor.
62                                                                            Assessment of change in clinical evaluation
Table 3.3   Principal-Components factor Analysis with Varimax rotation of the MLHF-Q
Factor
    I
Factor 






stay in a hospital r .69 .23 .10 -.13
feel you are a burden to your family e .62 .12 .36 -.34
feel depressed e .70 .06 .33 .26
Worry e .69 .16 -.05 .14
feel a loss of self control in your life e .64 .37 .17 .09
going away places away from home difficult  p .67 .35 .11 .21
making it difficult for you to concentrate or
remember things
e .65 .01 .01 .33
costing you money for medical care r .47 .18 .25 -.29
causing swelling your ankles, legs, etc. r .52 .52 -.01 -.02
walking about or climbing stairs difficult .26 p .83 .10 .02
working around the house or yard .31 p .79 .26 .19
sit or lie down to rest during the day .40 p .73 .11 -.01
tired, fatigued or low on energy .27 p .54 .31 .25
short of breath -.06 p .60 .31 .26
sexual activities difficult .02 .13 r .82 .16
eating less of the foods you like .06 - .07 r .76 .16
recreational pastimes, sports/hobbies difficult .13 .49 r .68 .17
your relating to or doing things with with your
friends or family difficult
.28 .26 p .47 .24
side effects from medications .22 .32 r .56 -.06
working to earn a living difficult .11 .10 .21 r .73
sleeping well at night difficult .10 .22 .39 p .60
e = emotional dimension
p = physical dimension
r = single items used in the construction of the overall score
3.3.3   Construct validity 
In this study we attempted to provide evidence that the Minnesota Living with Heart
Failure Questionnaire scales are measuring the underlying constructs of physical and
emotional impairments it is reputed to represent.
The multitrait-multimethod approach outlined by Campbell and Fiske 35 was used
to assess the convergent and discriminant validity of the MLHF-Q measures of
physical and emotional impairment.
Convergent validity (i.e. evidence that we are measuring what we purport to measure)
is provided by data that show that different measures of conceptually related
dimensions of health-related-quality of life are highly correlated. 36,37 In addition, we
expect that each of the measures of physical and emotional dimensions of quality of
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life measures a different construct (i.e. that the ‘physical fatigue’ scale does not
measure depression (discriminant validity).
In Table 3.4, multitrait-multimethod matrices were constructed for each of the
assessed dimensions of quality of life (physical and emotional). Evidence of
convergent validity is drawn from examination of the coefficients in the heterotrait-
heteromethod triangles, enclosed by solid lines in Table 3.4. We also expect some
association between the scales measuring dimensions of, for example, physical quality
of life, if the same questionnaire (method) was used and items were not presented in
a randomised order (correlated measurement error). These heterotrait-monomethod
coefficients are depicted in bold. In the area enclosed by broken lines, the
coefficients between variables that have no trait in common are shown.
The correlations between the three generic methods and the MLHF-Q scale
assessing physical impact on quality of life are, as expected, high and have, compared
to the heterotrait-monomethod coefficients, the same magnitude. The correlations
between the three generic methods and the MLHF-Q scale assessing emotional
impact, while statistically significant, are moderate (except the correlation between
the HADS-depression scale with the RAND-’role emotional’ scale).
To demonstrate divergent validity the multitrait-monomethod correlation coefficients
must be higher than correlation coefficients for variables that have neither trait nor
method in common. The values that represent relations between the components of
physical and emotionally impaired quality of life, which are represented in the area
enclosed by broken lines, are of interest. Most of the scales that are supposed to
measure different constructs are weakly correlated, regardless the method used. In
accordance with our expectation, some correlations were of moderate magnitude
simply due to shared method variance (printed in bold).
This analysis provides reassurance that with the MLHF-Q we are measuring physical
impairment and that there is convergence among methods. The emotional
impairment component, however, is moderately associated with the other methods.
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Table 3.4  Multitrait-Multimethod Matrix for the emotional and mental dimensions of health
related quality of life (N=60)
Constructs     1      2        3    4      5      6      7     8     9   10
1. MLHF physical dimension
2. Rand-36 physical functioning-.65
3. Rand-36 role-physical   -.60  .64
4. Rand-36 energy/vitality   -.73  .66 . 61
5. MFI-20 physical    .63 -.72 -.59 -.70
6. MLHF-emotional dimension  .44 -.28 -.35 -.34  .37
7. Rand-36 mental health    .32  .35  .31  .53 -.35    -.46
8. Rand-36 role-emotional    .33  .27  .49  .43 -.27    -.47  .50
9. HADS anxiety  . .30 -.24 -.30 -.25  .42     .43 -.60 -.59
10. HADS depression    .44 -.46 -.37 -.46  .35     .44 -.59 -.39 .55
all correlations p < .01; corresponding dimensions are printed bold
The areas surrounded by solid lines are the hetero-trait-heteromethod triangles.
The area surrounded by broken lines comprises the coefficients for variables that have no
trait in common.
(the hetereo-trait monomethod coefficients are depicted bold in both areas)
3.3.4    Test-retest
If a quality of life instrument like the MLHF-Q is developed to be used as an
evaluative instrument in clinical trials, one of the conditions, which should be
fulfilled is that it has the ability to demonstrate stability over time in subjects whose
health status does not change ( test-retest reliability ). 34 Table 3.5 shows the test-
retest correlation coefficients after a period of three months of stability in health
status without serious cardiac events. The results can be valued as satisfactory for all
MLHF-Q scales. However, although we can interpret the test-retest correlation
coefficients as satisfactory, these estimates of linear relationships do not provide
information about the existence of significant change in a selected group of stable
patients. To test the statistical significance of the change between baseline and three-
month outcome the Wilcoxon Matched-Pairs Signed-Rank test was used, because of
the non-normal distribution of the MLHF-Q scales. None of the MLHF-Q scales
demonstrated significant change.
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Table 3.5  Means, standard deviations (sd) test-retest correlations (r) and difference in
scores between baseline and 3-months outcome in a group of patients that did not show
improvement in sinus rhythm.
t1 T2
mean sd Mean Sd r Z-score P
MHLF-Q
Physical dimension 14.39 9.59 15.91 12.91 .70 -0.23 .82
Emotional
dimension
6.05 5.77 4.63 4.69 .63 -1.47 .14
Overall score 29.79 18.65 26.00 20.34 .73 -1.28 .20
3.3.5    Known group validity
In order to evaluate the ability of the MLHF-Q dimensions to discriminate between
so-called ‘known groups’, which should show differences based on the cardiologists
(blinded) classification of the severity of the disease, the study sample was divided
into two subgroups: NYHA classification I vs. II-III. The results of the analysis of
the ability of the MLHF-Q scales to discriminate between ‘known groups’ are
presented in table 3.6. The physical dimension and the overall score of the MLHF-Q
discriminated sharply between the NYHA II-III and I groups (p < .001) with large
effect sizes. The MLHF-emotional dimension discriminated also clearly between
these groups (p = .01) but with a moderate effect size.







mean sd Mean sd z-value p-value es2
1 2 3 4 5 6 7
MHLF-Q
Physical dimension 5.5 7.1 16.7 9.0 -3.8 .0001 1.31
Emotional
dimension
3.5 6.4 6.5 5.3 -2.5 .01 0.53
Overall score 11.7 16.5 33.9 18.1 -3.6 .0003 1.25
                                                
1 Mann-Whitney U, one-sided
2 Estimation of the effect size used Cohen’s d for independent samples when n1 # n2, which
is defined as the difference in mean scores divided by the pooled standard deviation:
est. σ  = (N1 - 1)s12 + (N2 - 1)s22 / (N1 -1) + (N2 -1)
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3.4 DISCUSSION
To what extent does the Dutch version of the MLHF-Q measure the desired
underlying concept or reflect what it is supposed to measure? In this study, the
MLHF-Q construct validity was determined by higher and significant correlation
coefficients between the MLHF-Q scales and corresponding dimensions of the MFI-
20, HADS, and the RAND-36 and by lower correlations with non-corresponding
dimensions of health related quality of life of these instruments. The MLHF-Q
‘physical’ dimension showed higher correlations with the RAND-36 scales ‘social
functioning’, ‘energy-vitality’, ‘health perception’, and ‘pain’ indicating that these
domains of quality of life, which are not tagged by the MLHF-Q, are more likely to
be associated with physical limitations in this study group.
One of the great advantages in clinical trials is that the MLHF-Q is short; but its
disadvantage is that it does not cover other relevant domains of quality of life
impairment, such as impairment of social functioning or vitality. In the detection of
change over time (pre- and post-test) the MLHF-Q performs equally well compared
with the RAND-36 estimating the same standardised mean change-score expressed
in effect sizes that are interpreted as medium effect for both instruments on physical
and emotional functioning. We hypothesised a greater responsiveness, because the
MLHF-Q should have greater precision due to the disease specific operationalized
items of the domains’ physical and emotional impairment. An alternative explanation
for not detecting greater changes may be related to the selected group of patients:
firstly, the questionnaire is developed to assess health-related quality of life associated
with heart failure, which is not existent in every subject within this group; secondly,
disappearance of the arterial fibrillation (AF) probably hasn’t a strong impact on
health related quality of life because of the fact that in ninety percent of the subjects
the underlying diseases in addition to AF still exists. However, it is to be expected
that in ‘before - after’ intervention studies, the MLHF-Q will show the ability to
detect the appropriate magnitude of change over time. This expectation is based on
the result of our study, namely that the MLHF-Q showed to be sensitive to detect
change within and between groups, even if the differences are small.
In the ability to discriminate between ‘known groups’ the magnitude of the difference
on the physical dimension of the MLHF-Q was large (Effect size >1) and statistically
significant (p < .001). The emotional impact on quality of life showed a statistically
significant difference (accompanied with a moderate effect size) between NYHA-I
and II-III classified subjects. The substantial difference between both estimates of
the magnitude of the difference between NYHA-I and II-III may be determined by
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the dominant physical component of the NYHA classification. The correlations with
conceptually related emotional dimensions (scales) were, while significant, of
moderate magnitude. The cultural differences between the American and Dutch
society, in combination with semantic differences in the translation of the items, are
probably the explanatory factors. In the Dutch translation, ‘making your going places
away from home difficult’ and ‘making your stay in a hospital’ are probably more
associated with the emotional impact of disturbing the relationship with significant
others, than with physical inhibition. The results of the current study indicate that the
application of the MLHF-Q will enable Dutch researchers to assess health-related
quality of life in clinical trials in which clinically relevant change will occur.
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Clinical message:
Patients, considered for cardio version of arterial fibrillation, were studied to validate
the Dutch version of the Minnesota Living with Heart Failure Questionnaire
(MLHF-Q), by investigating responsiveness, reliability, validity, and effect size.
Outcomes showed that the MLHF-Q is an effective and efficient instrument to
assess clinically important change in health-related quality of life.
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ABSTRACT
This paper aims to identify problems in the evaluation of the magnitude of
treatment-related change, or responsiveness of health status or health-related quality
of life instruments, which are induced by standardizing change over time with the
standard deviation of the difference score. This effect size is widely used and is
represented as the Standardised Response Mean (SRM), and interpretation is
problematic when it is used to estimate the magnitude of change over time with
Cohen’s rule of thumb for effect size (ES) which is based on standardisation with the
pooled standard deviation. In the case of standardizing mean change with the SD of
that change, application of the well-known cut-off points for pooled standard
deviation units (‘trivial’ (ES < .20), ‘small’ (ES ≥ .20 <. 50), ‘moderate’ (ES ≥ .50 <
.80), or large (ES ≥. .80) may lead to over- or underestimation of the magnitude of
change over time due to the correlation between assessments.
.
Keywords: Responsiveness, Health Status, Sensitivity to change, Methodology, Effect
size, Standardised Response Mean
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4.1 INTRODUCTION
In the practice of health-related quality of life research, most researchers remain
primarily interested in the statistical significance of the change in health-related
functional status or quality of life in pre post designs. In combination with, e.g., the
T-test approach, substantial effects can be detected 1-3 with an estimate of effect size.
If a p-value is annotated as statistically significant, rejecting the null hypothesis does
not imply an effect of important magnitude; likewise, a non-significant p-value does
not indicate a trivial result, 4-7 although some researchers implicitly deem more
important those results with smaller p-values.
In the last decade, however, a growing number of longitudinal intervention studies
are focussed on questions like “If the change between baseline and outcome is
statistically significant, what can we say about the magnitude (or amount) of change
over time that has been detected? Can we interpret this difference in terms of an
important difference or as a relevant (substantial) change?” To answer these
questions, the responsiveness, i.e. the ability of quality of life outcome measures to
detect change over time, has become crucial in the past decade. However, the
responsiveness estimation is neglected in many clinical studies in which it could give
information on the importance of change due to treatment effects supplementary to
the statistical significance of change over time (e.g. before and after intervention) 8,9
Reporting effect sizes without appropriate statistical tests and associated p-values is
misleading and potentially dangerous when the number of observations that is
required to detect a difference has not been estimated with a power analysis. Effect
size statistic should be provided to supplement (not as a substitute for) statistical
testing, and only then, when the outcome is sufficiently extreme from what would
have been expected on the basis of chance (p < α ).
Noteworthy in this respect is that in the field of psychological research, editorial
policy indicates that “until there is a real impediment to doing so, authors should
routinely present an effect size estimate along with the outcome of a significance
test”. 10,11
Several quantitative indices have been developed 10-20 that belong to this family of
effect sizes or standardized differences, each calculated with a different denominator
in the
 (1 - 2 /SD) formula, namely the SD of stable subjects, the SD of the baseline
assessment, the SD of the observed difference score and the pooled standard
deviation (SDp). Obviously, there is no consensus on how to declare a difference in
terms of standard deviation units. Only in a small number of publications is this lack
of consensus on the most appropriate effect size indicator signalled. 21-25 Despite the
fact that different opinions exist on the method to estimate magnitude of difference
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between groups or the magnitude of change within groups, researchers use the
straitjacket of thresholds Cohen provided us with some 30 years ago. 26 However,
these thresholds are taken for granted by many researchers for every version of effect
size index. With regard to the correct use and interpretation of effect size indices as
estimates of treatment related magnitude of change, we must revisit some basic
assumptions:
1. the ES is developed and elaborated by Cohen to estimate power or the necessary
sample size to detect relevant change with the basic principle of independent,
equal size samples with common within-population standard deviation σ  ;
2. in the case that this ES is used in paired samples or in a repeated measurement-
design it  must be adjusted for correct use of power tables and sample size
tables;
4.1.1.   Independent samples
Cohen represented the effect size (ES) on some dependent or outcome measure used
in an experiment in terms of the difference (using the symbol d’ to denote this ES)
between the treatment and control group expressed in units of common within-
population standard deviation (in samples this standard deviation is estimated with
the pooled standard deviation) as follows: 
[A]
With this estimate of effect size, after analysing a wide sampling of behavioural
research, Cohen developed his rules of thumb and reported that effect of .8σ being
on the large end of the range, .5 σ  was the medium, and .2 σ  was at the small end
of the range. 27
4.1.2.  Dependent samples or paired observations
The difference or change in matched observations within subjects is standardized by
the common within-population σ , according to Cohen’s 1977,p.13, but due to the
removal of the variation in many extraneous characteristics of the subjects, the index
must be adjusted (see appendix), dividing d’ by √ (1-r ). Cohen used the symbol d to
denote this adjusted ES. 1
                                                
1 As we will demonstrate, the effect size d is equivalent to the Stadardised Response Mean (SRM), i.e.
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[B]
d’ = effect size for independent samples
d = adjusted effect size
r =correlation between baseline and outcome
This √(1-r) – correction of the denominator of formula A is necessary for a proper
use of power and sample size tables since these assume 2(n-1) degrees of freedom
where, in the case of paired observations, only n-1 are actually available. 26 This
consequence for power and sample size estimation is something different from the
use of the effect size d in evaluating efficacy of a new treatment in terms of amount
of change in health status, which was not the aim of Cohen’s work. Therefore, we
did not abstract data from effect size estimates of health-related quality of life scales
when they were used for the sole purpose of power analysis to draw conclusions
from the results of the statistical analysis, or to answer the question whether the
investigators had sufficient sample size to allow the detection of a relevant difference.
10,28,29
Effect Size as an evaluative indicator of magnitude of difference inhealth-
related functional status: Independent samples versus repeated measures
When effect sizes are calculated as the standardized difference in mean score to
evaluate the efficacy of a new treatment with the use of Cohen’s thresholds, for
example between a treatment group and a control group, formula [A] should be used.
The effect size can be calculated by pooling the estimates (pooled standard deviation)
derived from sample data. In contrast to this independent sample case, effect sizes
are also used in evaluation studies (pre- post study designs) as estimates of the
responsiveness of (for example) a new outcome measure. Effects are often used to
give meaning to change over time in terms of ‘trivial’ (ES < .20), ‘small’ (ES≥  .20 <
.50) ,’moderate’ (ES ≥  .50 < .80) or ‘large’ (ES ≥  .80) change. Cohen 26 introduced
this ‘matched pairs’ effect size (see appendix equation A2), which was later renamed
the standardised response mean (SRM) by Liang et al. 28 to avoid confusion
concerning other effect size indices. However, several researchers seem to have
adopted the idea that every standardized difference is subject to Cohen’s definitions
of trivial, small, moderate and large effect. Such a belief could lead to
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misinterpretations in studies focussing on treatment-related outcome in paired
samples since these cut-off points of the magnitude of the difference were not
established as a rule of thumb with the effect size d (dependent samples) but with the
index d’ (independent samples). Thus we argue that Cohen’s thresholds are based on
the assumption of common within-standard deviation (with matched pairs sample
data we use the raw within-group pooled SD), resulting in an effect size we annotate
as ESP. Consequently, in matched pairs studies these thresholds cannot be used
interchangeably for the SRM due to the role of the correlation between repeated
measures or paired samples. In this article the attention is focussed on the
standardized change in mean score between two points in time within a single group,
estimated with the within-group effect size. In relation to the use of Cohen’s rule of
thumb for effect size interpretation, we evaluate the consequences of the calibration
of the SRM with the ESP and the role of the correlation between pre and post test
scores.
To investigate how serious discrepancies can appear in effect size interpretation we
first elaborate a theoretical example and used a sample of studies to evaluate the
seriousness of these differences in practice. To evaluate the seriousness of the
discrepancies between SRM and ESP, the correlation of the subject’s repeated
measurements was needed. Empirical data were collected for the purpose of
secondary analysis to draw conclusions in terms of the relative size of the SRM to the
ESP in relation to the size of the correlation. Applying Cohen’s thresholds, which are
based on the pooled estimate of effect, to interpret the SRM on the one hand may
lead to similar results or subtle and trivial differences, but on the other hand also to
meaningful shifts in classification of the amount of estimated change. In this article
we analysed 148 SRMs interpreted using Cohen’s rule of thumb and compared these
SRMs with Cohen’s ESP from which these thresholds were derived. Furthermore, we
calculated for the range of the correlation coefficient 0.01 to 0.99 the SRM adjusted
for Cohen’s cut-off points 0.20, 0.50 and 0.80 of the pooled effect size.
4.2 MATERIALS AND METHODS
To study the consequences of the impact of the association or correlation between
repeated measures, we restrict the analysis to two effect size indices suitable for the
evaluation and interpretation of magnitude of change over time (or responsiveness)
within one group, namely the SRM and the ESP. In this study we use the pooled SD
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(SDP) as the standardizing unit (denominator) of mean change score over time
(nominator) to calculate the effect size (ESP)2.
[C]
The ESP introduced by Cohen was made comparable to the SRM where the SD(X-
change) is used as the denominator in which, as we will demonstrate below, the
correlation between baseline and outcome scores is involved.
The SRM is the ratio between the mean change score and the variability (the standard
deviation) of that change score within the same group.
[D]
The relationship between ESP (d’) and SRM (d) and the correlationbetween
baseline and outcome scores
One of our purposes was to get an indication of how the SRM varies in accordance
with the size of the correlation between pre and post test scores when the correct
pooled effect size estimate is used. An example may illustrate the role of r, the
correlation of a person’s health status measurements over time: In a study in which
the outcome of a medical intervention was evaluated with a health-related quality of
life measure, and in the case of improvement, a lower mean score after intervention
was hypothesized. The investigator finds at baseline a mean score of 11.12 with a
standard deviation of 4.43 and a mean score of 9.16 (SD: 4.88) at follow up. The
estimate of the common within-standard deviation, which is the square root of
(SDbaseline)2+ (SDoutcome)2 /2), thus 4.66, and the pooled effect size (ESP) is then 0.420
(11.12 – 9.16 /4.66). Before we compare the ESP and SRM in relation to the
correlation between repeated measurements, we must solve the problem of the
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equation of both formulas C and  D. According to Cohen, the difference between
means for dependent samples is standardised by a value “which is √2 (1-r) as large
as would be the case were they independent”. Cohen 1977, p.49
From equation A4 in the appendix, (d’/√2) / √(1-r) is equivalent to the SRM and
alternatively SRM * √ 2 * √(1-r) is equivalent to d’ and both indices will vary with the
size of r . In table 4.1 we have elaborated the hypothetical example in which the
effect size ESP (d’ ) = 0.42, is transformed into the SRM for a series of values of r.
Both effect sizes are equal in the case that r = 0.50): ESP = (0.42/√2) / √(1-0.50) =
SRM, and the SRM for r .50 is then (0.42/1.41) / 0.71 = 0.42. In table 7.1 it is shown
that the SRM gets larger for larger values of r. For example, an effect size of 0.42
indicating ‘ small effect’ corresponds with a ‘medium effect’ (SRM = 0.50) if the
correlation between the repeated measurements is approximately .64. This small
effect estimated with the ESP corresponds with a ‘large effect’ (SRM  ≥ .80) if this
correlation is approximately .86.
Table 4.1 The conversion of an effect size calculated with the pooled SD (ESP ) of 0.42 into
a SRM with correlation coefficients ranging from .00 - .90
corr. .00 0.10 .20 .30 .40 .50 .60 .65 .70 .80 .86 .90
(.42/√2)
  √(1-r)
.297 .313 .332 .355 .384 .420 .470 .502 .543 .664 .794 .940
4.2.2.  The sample of studies
In examining the role of the correlation in the estimation of a within-group effect
size index, we searched Medline and Psyclit for the years 1984-1999 and Current
Contents for 1996 and 2000. We searched for studies with key words 'quality of life',
'health status', and 'questionnaire' and articles were scanned for the terms
'responsiveness', or 'sensitivity to change'.
The primary selection consisted of 151 publications and showed the existence of
differing opinions about the appropriateness of the effect size as originally proposed
by Cohen, which has led to the introduction of new methods of estimating the
magnitude of change assessed over time. Due to the variation in the definition of the
mean change scores in the nominator and in the definition of the standard deviation
in the denominator of the effect size index formula, not all the studies were
appropriate for this study. Therefore, 29 studies suitable for our analysis were
selected using the following inclusion criteria:
1. the research should encompass repeated (self reported) health outcome
assessments evaluating change within one group (paired observations);
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2. a SRM must be represented accompanied with Cohen’s thresholds;
3. health outcome must be assessed by (self reported) questionnaires with a disease
specific or general mode.
Some other causes of the large reduction to 29 studies appropriate for the purpose
of this article are:
- standardised Response Means were used without referring to Cohen’s
thresholds;
- missing information inhibited us from calculating the effect sizes needed;
- the topics of responsiveness and sensitivity to change were discussed purely
from methodological or statistical perspective.
4.3 RESULTS
The original sample comprised 142 or scales belonging to scattered dimensions of
health-related quality of life or health status measures. The current selection of 29
papers was determined by the condition that, a SRM had to be represented with
referral to Cohen’s thresholds for interpretation of change magnitude. 1,21,22,28,30-35,35-53
These 29 publications comprised 411 Standardised Response Mean indices which
sizes were interpreted with referring to Cohen’s thresholds. From this sample of
SRM indices, 148 were published together with sufficient information to estimate the
ESP calculated with an estimated correlation coefficient (r) (see Appendix equation
A5). The correlation coefficient is needed to compare the SRM that was shown with
reference to Cohen’s thresholds, with the ESP as the correct yardstick for SRM
interpretation. Additionally, 263 Standardised Response Means were detected with
the investigator’s reference to Cohen’s rule of thumb (which is derived from pooled
estimates of standard deviation) but unfortunately, not sufficient information was
given to estimate the correlation between assessments.
4.3.1.   The classification of treatment effect with the SRM with Cohen’s     
            thresholds for ESP
In the interpretation of these two effect size indices, the thresholds proposed by
Cohen 26-54 as operational definitions of magnitude of change cannot be used
interchangeably as is generally assumed. Table 4.2 summarizes the results of the
SRM’s substituted into ESP ‘s (using equation A4 in the appendix). It shows clearly
that mistakes can be made in the classification of the magnitude of detected change
in health-related quality of life if Cohen’s rule of thumb of the ESP is assumed in the
interpretation of the SRM. In 148 SRM’s that were adjusted, the magnitude of the
80                                                                            Assessment of change in clinical evaluation
correlation coefficient caused no change in classification in 77%. Approximately, 34
of the 148 estimated effect sizes (23 percent) did not fall in the category indicating
the same magnitude of change. Underestimation of effect size according to Cohen’s
thresholds occurred in 5 SRM’s (3.4%), whereas 29 SRM’s (19.6%) were
overestimates of effect size.
Table 4.2 Similarities and differences between the Standardised Response Mean (SRM)
and pooled effect size (ESP) interpreted using Cohen’s thresholds (N=411: 148 + 263)
Calculated by equation A41 Equation
A42 not
applicable







< .20 43 2 45 33
 >.20 <. 50  6 35 2 43 92
 >50 <. 80 11 13 1 25 69
 ≥ .80 12 23 35 69
total 49 48 27 24 148 263
1 See appendix.
2 SRM used with interpretation according to Cohen’s thresholds for ESpooled
To get a better understanding of the role of the calculated correlation between
baseline and follow-up score in the relationship between these two effect size indices,
we have, for these 148 estimates, expressed the SRM as the percentage of the value
of the ESP . In figure 4.1 it is shown that the SRM covers the ESP 100% at the x-axis
with the calculated r = .50 at the y-axis for each of the instrument scales of which the
pre-post test correlation r was recalculated. The depicted curve shows, irrespective
of the values of the effect sizes estimated in our sample of health-related quality of
life scales, that the relative distance from the SRM to the ESP varies with the size of
the baseline-follow-up correlation.
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Figure 4.1 The relationship between the correlation and the relative ratio of the SRM and
ESP (N=148)
(SRM / ESP * 100)
To avoid invalid interpretations in the evaluation of responsiveness with SRM index
we have, for every value of the correlation between baseline and follow-up score,
calculated the corresponding ESP ‘s for Cohen’s thresholds of .20 = small, .50 =
medium, and .80 = large. Indices that lie within the interval that corresponds with
these thresholds are not depicted. To classify the magnitude of change estimated with
the SRM more precisely, this effect size index is adjusted for every value of the
correlation coefficient (r) between baseline and follow-up assessments and brought
into line with Cohen’s thresholds for effect size. Figure 4.2 shows that SRM’ s of
0.20, 0.50 and 0.80, don’t deviate after calibration with Cohen’s ESP taken as the
original standard, when r =.50. A SRM of 0.20 must be tagged as trivial effect as long
as the correlation coefficient ranges from r=.01 to r=.49. With large corresponding
correlation coefficients a small SRM of 0.20 must be tagged as moderate (.20/√2 /
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effect’ range of effect (not depicted) has to be classified as moderate or large effect
with correlation coefficients of 0.76 (.35/√2 / √1-.76 = .50) and 0.91 (.35/√2 / √1-
.91 = .80) respectively.
SRM’s of 0.80 has to be tagged as ‘moderate’ effect if the correlation ranges from r
= 0.01 to 0.49. The SRM ≥ 0.80 cannot drop below the cut-off points of small and
trivial due to the correlation magnitude between baseline and outcome
measurements. ‘Moderate’ effect (SRM = 0.50) must be tagged as ‘small’ if the
correlation between repeated measures is below 0.49 and has to be classified as ‘large’
in case of r = .81. The class midpoint 0.65 (not depicted) of the ‘moderate effect’
range of effect must be valued as ‘small’ with a r = 0.14 (.65/√2/√1-.14 = .49).
In contrast with the fixed threshold values .20, .50 and .80 in figure 4.2, in the
analysis of 148 effect size estimates from which the correlation of a person’s health
status measurements over time was calculated, we found SRM values ranging from
0.04 to 2.42. Correlation coefficients ranged from .08 to 0.89 and 70% of the 148
coefficients were larger than 0.50. Overestimates of effect size (see table 4.2) are not
depicted in figure 2, but are easily estimated. For example A SRM of 0.85 interpreted
by the researcher as large effect, changed into a moderate effect according to Cohen’s
thresholds, due to a correlation of 0.12 between repeated measurements
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4.4 DISCUSSION
The values used in effect size classification for difference between means as small,
medium, and large was arbitrary but seemed reasonable, Cohen stated some 30 years
ago. In the debate over which standardizing unit of the difference one should take
in a within- group situation, we propose that estimating the magnitude of change by
using either the SD of the change score or the pooled SD is preferable to the use of
the SD at baseline as proposed by Kazis et al., 12 although the SRM must be adjusted
to make correct use of Cohen’s thresholds when magnitude of change over time is
estimated in evaluation research. These thresholds of Cohen are now being cited
without distinguishing between the units by which the assessed change over time is
standardized. This is surprising since there is unequivocally no doubt that his rule of
thumb was derived from the pooled SD as the estimate of the common within
variance. Moreover, routine action in calculating effect sizes may have led to a
reduced awareness of factors originally considered only in the calculation of power
and sample size. For instance, the calculation of power of the detected change or
difference without using the information of r can lead to the wrong inferences. Cohen,
p. 50
In evaluation research on treatment-related quality of life, researchers seem to
overlook the fact that, in assessing change over time within one subject, the
experimental technique of ‘self-matching’ reduces the proportion of the total
variance due to extraneous variables not related to the treatment or intervention per
se. 55
We may conclude that the rule of thumb proposed by Cohen can induce differences
in the interpretation of the size of estimated effects. At present it does not appear to
us that a single set of rules that are unequivocal or normative at some level is
available. We have begun to explore alternative methods in effect size estimation and
have assessed the interrelation between two effect sizes as estimates of magnitude of
change over time within groups. As we have demonstrated, errors can easily be made
and different interpretations of the magnitude of detected change may occur. In
analysing the data from our sample of published studies on change over time in
health-related quality of life, we saw meaningful shifts in magnitude of detected
change in relation to the size of the correlation between pre- and post-test scores. In
this article we have attempted to draw the attention to the problem of over- or
underestimation of effect sizes when the Standardized Response Mean is used.
Studies in which the mean change over time is standardized with the SDbaseline
according to Kazis et al. 12  should report the ESP to show that the results were not
dependent on the choice of deominator in the d-index formula.
Due to their increasing appearance, it is important that all aspects of estimating the
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magnitude of change be inspected. One of these aspects is the consequence of the
hidden role of the correlation coefficient between repeated measurements, which
increases the risk of incorrect conclusions. This initial effort may provide a moderate
step toward the development of a precise and useful index in quality of life
assessment in clinical trials.
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APPENDIX
Given Cohen’s formula 1 for the Effect Size index for means from matched samples:
where:
and assumed equal variance, i.e.:
(A2) gives:
and for the Effect Size index for means of independent samples the standardizing unit is:
where:
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Now from equation A2 and A3 we use the difference between the standardizing unit for
difference in means for matched samples (SRM) being σ √2(1-r)/σ = √2(1-r) as large as would
be in the case of independent samples (ESP) 26, p.48-52. Now we can subsitute SRM into ESP
by:
we note that r is estimated in cases in which the standard deviation at baseline, outcome, as
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SUMMARY
Some clinical trials perform repeated measurement over time and estimate clinically
relevant change in instrument’s score with global ratings of perceived change or so-
called transition questions.
The conceptual and methodological difficulties in estimating the magnitude of
clinically relevant change over time in health related functional status (HRFS) are
discussed. This paper investigates the concordance between the amount of serially
assessed change with effect size estimates (the researcher’s perspective) with global
ratings of perceived change (the patient’s perspective) is described. 
A total of 217 patients who were scheduled for diagnostic examination were
included, and the Minnesota Living with Heart Failure Questionnaire, extended with
MOS-20 items, was assessed before and after medical intervention (Percutaneous
Transluminal Coronary Angioplasty, Coronary Artery Bypass Grafting or pharmaco-
therapy) . Global questions were applied to assess perceived change over time in for
every item from domains of physical and emotional functioning and used as the
external criterion of relevant change in the analysis of items. Global questions
corresponding with overall change in these domains were used in the comparison of
change in physical and emotional functioning scales. Two effect size indices were
used: 1. ES (mean change/SDpooled) and 2. ES (mean change/SDchange). A
method is described to calculate a value indicating the extent of discordance between
the researcher’s interpretation of magnitude of change and the external criterion (the
patient’s perspective).
Findings suggest effect size ES (mean change/SDpooled) was in keeping with the
magnitude of change indicated by patient’s judgement, or their category of subjective
meaning, for all scales. Furthermore, in cases that the magnitude of change estimated
with the SRM (mean change/SDchange) was not confirmed empirically by the
external criterion ratings, the discordance could be interpreted as a trivial
discordance.
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5.1 INTRODUCTION
In publications on methods of assessment of change in health-related functional
status (HRFS), the concept of responsiveness is used as either a psychometric quality
of a measurement instrument or an indicator of the amount of change over time. The
use of the term responsiveness, however, confuses the reader because the concept of
responsiveness, used in papers addressing treatment-related health status change, can
refer to a varying composite of aspects:
1. the ability to detect change over time 1-7 or the extent to which a measure is
sensitive to real change in health-related functional status (HRFS) 8 ;
2. the sensitivity of a health status instrument by analogy with test performances
in clinical practice (the ability of an instrument to detect the smallest change),
or as a property of measures used to assess the effectiveness of medical
interventions 5,6,9-11;
3. the ability to detect a clinically relevant or important change over time, according
to an external criterion, to distinguish between improved and non-improved
subjects 7,12-15;
4. the relative strength of correlation between the change in instrument score and an
external criterion of perceived change or satisfaction with treatment 16,17.
There seems to be no unambiguous method to define and assess the concept of
responsiveness in terms of measuring clinically relevant change in HRFS. Clinicians,
for instance, use reference values (reference range) for clinical ‘laboratory’ health
status indicators, such as blood sodium or erythrocyte sedimentation rate, as anchors
for the degree of deviation from what can be valued as ‘normal’. Reference values
also give the opportunity to value changes after treatment as being trivial, or
substantial and clinically relevant in the expected direction. In contrast, when HRFS
is relevant in the treatment outcome evaluation, researchers do not have a
‘population-based’ reference range of values or common sense anchors for measures
of e.g. physical functioning to value the outcome after treatment in terms of clinical
relevance. In the absence of such a reference range or “golden standard”, an estimate
of clinically relevant change requires an external criterion to provide cut-off points
or a reference range to discriminate between relevant and irrelevant change. One
common method of interpretation is to compare health status score with a global
subjective judgement of the direction and amount of change by clinician or patient
12,18,19 , often referred to as the external criterion. This subjective judgement is
obtained by asking the extent to which deterioration or improvement has occurred
since treatment, using a global question with verbal anchors ranging from a
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dichotomous scale (e.g. improved vs. not improved) 20,21 to a 15-point scale ranging
from -7=’a very great deal worse’ to +7 = ‘a very great deal better’ 22-25. In other
words, these verbal anchors can be used to estimate a relevant difference in an
instrument’s score over time. Thus, patients can be classified as having small but
meaningful change in health status score if they state that they have changed ‘a little’
or ‘somewhat’ (sometimes defined as the minimal clinically important difference).
Change scores represent moderate change if patients felt they had changed
‘moderately’ or ‘a good deal’; scores represent large change if patients state that they
have changed ‘a great deal’ or a ‘very great deal’ 22,23,26. Mean differences can be
standardized to quantify an intervention’s effect in units of standard deviation, and
allow comparison of the different outcomes of one intervention, independent of the
measuring units. The resulting statistical measure is known as effect size index.
If we use an effect size index to assess the magnitude of treatment-related change
over time, regardless of its outcome parameter and range of standardized values, we
can give it meaning “with the ‘straitjacket’ provided by Cohen some thirty years ago”.
27 The values used to classify effect sizes for mean differences as ‘small’, ‘medium’,
and large’ and the widely used thresholds of Cohen for effect size interpretation are:
trivial effect (ES =  <.20) , small effect (ES =  ≥  .20  <.50) , medium effect (ES =
> .50 <.80) and large effect (ES = > .80). The point open to discussion is: how are
these effect size interpretations related to subjective ratings of magnitude of change
with global questions? Our study’s objective was to compare the classes of
responsiveness as defined by Cohen with the self-report perception of the magnitude
of change.
We used two perspectives from which the importance of a change over time in
health status can be determined and which we shall discuss further in the coming
paragraphs:
1. the researcher’s perspective, calculating the score difference between two points
in time and estimating the magnitude of change in multi-item dimensions of
health-related quality of life with an effect size index, and
2. the patient’s perspective, estimating change by single global or transition
questions at post-test, asking directly how much the patient has experienced
improvement or deterioration in HRFS since treatment.
5.1.1.   The researcher’s perspective
A within-group effect size index is generally the result of subtracting baseline scores
from post-test scores (or vice versa) and dividing the mean difference by a standard
deviation. There is, however, still no consensus on the most appropriate strategy for
interpreting the standardized change score in health-related quality of life as
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treatment outcome in medical intervention evaluation. Guyatt et al. 9 recommended
the Responsiveness Index (RI) as the ratio of the average, treatment-related, change
to the variability of scores in stable subjects as the most appropriate measure of
responsiveness. We believe that a measure of change is not a function of stable
patients and is inherently prone to overestimation or underestimation of the
magnitude of change, because the numerator and denominator are based on different
samples 13,18 Therefore, the within-group effect size was estimated using two
methods:
1. Cohen 27,28 who introduced the effect size, calculated as the mean change in
score divided by the pooled standard deviation of some repeatedly assessed
outcome measure used in an experiment as follows:
Xtreatment  - Xcontrol
ES = d’ ____________________________
 σ
With this estimate of effect size, after analysing a wide sampling of behavioural
research, Cohen developed his rules of thumb for effect size interpretation. 29
2. The Standardised Response mean (SRM), which is calculated by dividing the
mean change of a serially assessed measure by the standard deviation of the
change score (i.e. difference in score before and after medical intervention). In
contrast with what seems to be widely assumed, it was not Cohen, but Liang et
al. 30 who introduced this effect size to avoid confusion with the effect size
index proposed by Cohen for correct use of his power tables.
In this study both ES and SRM are conceived as an estimate of the magnitude of
treatment-related change in domains of HRFS. The values of effect size indices,
derived from mean change scores in health status measures, vary from approximately
–2 to +2 in similar study designs. With these two methods the mean change scores
are standardized on three scales, covering a disease-specific and a generic measure
of physical functioning and one disease-specific measure of emotional functioning.
5.1.2.   The patient’s perspective
As mentioned before, another method of estimating change is the clinician’s
judgement, or posing global questions to patients regarding how much they have
improved or deteriorated since treatment. We consider the self-determined direction
and magnitude of change as the best estimate of clinically relevant change. Therefore,
this study has used the patient’s perspective as the external criterion to estimate the
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magnitude of perceived improvement in the domains of physical and emotional
functioning.
5.2 PATIENTS AND METHODS
To ensure that change in health status occurred, we selected a group of patients
undergoing a treatment with known efficacy, and used a disease-specific instrument
with known sensitivity in detecting change over time. 31,32 The study sample was
composed of patients who, after a diagnostic Coronary Angio Graphy (CAG), were
scheduled for Percutaneous Transluminal Coronary Angioplasty (PTCA), for
Coronary Artery Bypass Grafting (CABG), or were treated with a pharmaco-therapy.
To assess change in physical and emotional functioningserially, we used items from
a disease-specific health-status instrument (namely, the Minnesota Living with Heart
Failure Questionnaire (MLHF-Q) 33,34 and from the MOS-20, a generic instrument.
35
To assess change directly in both health domains, we modified all items into direct
questions of perceived change (transitional questions), to be administered at post-
treatment. Three items of the MOS-20, valued as most appropriate for the study
sample, were used in the same format as a measure of physical functioning.
5.2.1.   Patient selection
Patients were recruited from January to December 1998 from Groningen University
Hospital, Martini Hospital Groningen, and Weezenlanden Hospital in Zwolle, in the
Netherlands. Patients with other incapacitating diseases or cognitive impairments,
aged 75 or older, or who did not speak Dutch were excluded. Ethical approval was
obtained from each participating hospital’s ethics committee. We prospectively
administered the questionnaire at baseline and 6 weeks after the decision for non-
invasive intervention, or 6 weeks after the day a PTCA /CABG-intervention was
executed. Patients returned questionnaires at baseline accompanied by written
informed consent. Returned questionnaires were routinely checked for completeness.
If many questions or pages were not filled in, either a copy was sent with a kind
request for completion or, in cases of only one question’s omission, patients were
interviewed by telephone. Because the questionnaire’s completeness was monitored
by a computer program both at baseline and follow-up, we effectively reduced the
non-response on questions, and consequently, on scales.
We presumed that at baseline, i.e. prior to CAG, neither patients nor cardiologists
had information about decisions concerning either intervention, and would thus not
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affect the assessment of subjective health, most likely reducing the risk of ‘floor and
ceiling’ effects. However, this control for potential bias resulted in logistic problems
and, six months after the study began, we were forced to select patients waiting for
outpatient treatment (PTCA) or hospital admission (CABG) as soon as they were
scheduled on the waiting list.
5.2.2.   Data Collection and measures
The Minnesota Living with Heart Failure Questionnaire (MLHF-Q) is a disease-
specific instrument composed of 21 items and three scales measuring the following:
the physical functioning dimension (8 items), the emotional functioning dimension
(5 items) and the overall score on HRFS (21 items). Eight separate items, not
assessing an underlying construct or dimension of HRFS, measure social and
economic impairments which patients relate to their heart failure, and are part of the
overall score. The original MLHF-Q items were phrased as follows: ”Did your heart
failure prevent you from living as you wanted during the last month by making your
sleeping well at night difficult?”
The response options range from ‘no’ (score 0), very little (score 1) to very much
(score 5). The total score ranges between 0 and 105, the physical dimension (sub-
scale) between 0 and 40, the emotional dimension (sub-scale) between 0 and 25. To
assess physical functioning, we extended the questionnaire with 3 items from the
MOS-20. 35 These three items were: “Did your heart failure prevent you from living
as you wanted during the last month by making it difficult for you to 1) bend, stoop
or lift light objects 2) lift heavy objects, like moving a table and 3) run at a fast pace?
“
Two methods of assessing change in health-related quality of life (HRQL) with multi-
item scales were applied with the study data: HRQL-domains were serially measured
with items from MLHF-Q and MOS-20, and consequently, the  patient’s perception
or subjective significance of change was captured at follow-up of each of the MLHF-
Q and MOS-20 items in terms of the extent of feeling improved, deteriorated or not
changed.
These transition items are designed to elicit information regarding perceived change
over time in specific aspects or in domains of the patient’s heath status. For each
item in the questionnaire (except the items on socio-economic impairments:
‘hospitalisation and  medical costs’), patients rated at post-test the degree to which
they perceived that change had occurred, on that particular item, since baseline
assessment.
Two global questions corresponded to the domains of physical functioning and
emotional functioning of the serially assessed questionnaire. These items were
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intended to capture change in the domains of HRFS as prospectively measured and
were phrased as follows: “Since the last time I filled out the questionnaire (or: since
my operation), my physical problems are ….. “, 2) “Since the last time I filled out the
questionnaire (or: since my operation), my emotional problems are …..”
For every transition item and global question the patient was asked to circle the
answer best describing his/her perception of the direction and magnitude of change
at post-test on a seven-point Likert scale: 1) a great deal worse; 2) moderately worse;
3) a little worse; 4) no change; 5) a little better; 6) moderately better and 7) a great
deal better.
5.3 DETERMINATION OF CONCORDANCE BETWEEN TWO INTERVALS
OF MAGNITUDE OF CHANGE
Given that we established this study to evaluate assessment methods in health status,
we selected patients undergoing treatment with known efficacy; there were only 20
patients indicating post-treatment deterioration. Therefore we excluded the
calculated effect sizes of patients who deteriorated. Consequently, we analysed the
concordance between magnitude of change according to Cohen and the external
criterion as follows:
Cohen’s thresholds External Criterion (global question): 
Standardized Change score
Since the last time you filled out the
 questionnaire (or since your operation),
has there been any change in your
 physical/emotional problems related with
 your heart failure?
Trivial effect =  <.20 no change
Small effect = ≥  .20  <.50 a little better
Medium effect = ≥  .50  <.80 moderately better
Large effect = ≥  .80 a great deal better
The effect sizes of the interval Cohen defined as ‘trivial effect’ vary between the
values ES=0 and ES = .20. We have presumed that, for example, the subjective
judgement ‘there has been no change’ matches the judgement of the researcher using
Cohen’s rules of thumb for effect size, in order to give meaning to the estimated
magnitude of change within this interval. If we use the verbal anchor of the external
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criterion to determine the interval in which the effect size index should lie, the
magnitude of change, according to the researcher’s effect size interpretation, will
deviate from the patient’s interpretation. The concordance between ES and global
question, used as external criterion, will never be perfect if we make rigid
comparisons. For example: in a sub-group considering themselves unchanged after
treatment, the estimated magnitude of change in score was reflected by an ES= 0.25
which, according to Cohen, was evaluated as a small improvement by the investigator
(small effect: ES = 0.20 – 0.50). This ES of 0.25 is presumed to be out of range with
the interval that, theoretically, should correspond with the retrospective ‘no change’
rating (ES = 0 – 0.20). If we want to validate the researcher’s interpretation of the
amount of prospective change using the external criterion as an anchor point, we
need an indication of the extent of discordance between two interpretations. Thus,
how serious is the ES=0.25 deviation from the ‘no change’ interval’s upper limit, in
this case ES=0.20? To find an answer we calculated a value by means of which every
effect size index can be evaluated within the intervals determined by the external
criterion anchor points. We considered the effect size of a treatment in three
situations in which the estimated magnitude of change (ES) is: 1. concordant with the
external criterion interval; 2. discordant with the external criterion in terms of
overestimation (the ES represents, according to Cohen’s thresholds, a larger
magnitude of change than indicated by the patient’s judgement), and 3. discordant
with the external criterion interval in terms of underestimation (the ES reflects a
smaller magnitude of change according to the assumed interval corresponding with
the patient’s judgement).
The value by which we express the concordance between the researcher’s
interpretation of the estimated magnitude of change, Cohen’s thresholds and the
magnitude of perceived change (according to the external criterion), has the
advantage of being easily interpreted, and its range is from 0 to 1. With the
interpretation of the values between this minimum and maximum we must take into
account in which of the three aforementioned situations has the comparison between
effect size and external criterion has been made.
In the event that an effect size lies within the interval concordant with the external
criterion, or represents a surplus of the effect size, the maximum value is +1, whereas
the maximum is –1 when the effect size reflects a lower magnitude of change than
determined by the external criterion. When the effect size is concordant with the
external criterion, a value of zero means that the ES coincides with the lower limit
of the interval, and the value 1.0 means that it coincides with the upper limit.
In addition, we used 0.50 as the range midpoint with its class boundaries of 0.40 and
0.60 and, in the case of discordance, we signified the calculated value as follows: 0
– 0.20 = ‘poor discordance’; > 0.20 – < 0.40 ‘small discordance’; 0.40 - < 0.60 ‘fairly
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large discordance’; 0.60 - < 0.80 ‘large discordance’; and 0.80 – 1.00 ‘very large
discordance’.
In the situation of overestimation or underestimation, the values receive a positive
or negative sign respectively, and can be interpreted as the extent of the surplus or
shortfall of effect size as determined by the external criterion.
5.3.1.   Effect size concordant, according to the external criterion
Change in a serially assessed physical functioning scale was interpreted as small (ES
= 0.26) in the group of patients considering themselves physically ‘a little better’ (see:
table 5.3-b). We presumed that the upper and lower limits of this retrospective
judgement of improvement in physical functioning corresponds with the effect size
interval of what is assumed by Cohen to be a ‘small effect’, ES = .20 - .50, (range
.30). We determined the value, expressing ‘the extent of concordance’ as follows: the
distance between the operative ES (0.26) and the interval’s lower limit was
determined (0.26 minus 0.20 = 0.06) and divided by the interval’s range
(0.06/0.30=0.20).
When the magnitude of change valued by the researcher, with Cohen’s rule of
thumb, is concordant with the amount of change valued by the patient’s judgement,
the indicator has a minimum value of 0 with a maximum of 1. The value is 0 when
identical with the interval’s lower limit, and 1 when identical with the interval’s upper
limit. In this example the value of 0.20 indicates that we can interpret it as the
proportion it occupies from the interval’s range in the direction of the lower limit.
5.3.2   Effect size discordant, overestimation according to the external
criterion
It will occasionally occur that the estimated magnitude of change does not
correspond with the external criterion. The interpretation of the magnitude of
change, according to Cohen, can indicate a larger effect than was expected to
correspond within the judgement of the patient. For example: an ES= 0.75 was
found with the group of patients that considered their improvement as ‘a little
better’. If we presume that this judgement corresponds with effect sizes ranging
between 0.20 – 0.50, we will conclude that an ES = 0.75 is an overestimation in
relation to the external criterion by crossing the threshold of ES = 0.50. To get an
estimate of the seriousness of this deviation we cannot calculate the indicator in the
open-ended interval for large effect (ES > 0.80 standard deviation units). A
maximum value (>.80) of the studied effect size is necessary to estimate the extent
of concordance with the external criterion. Therefore, we fixed the maximum of
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standardized change over time at the 1.26 SD we detected in our sample, and
calculated the range between this maximum and the upper limit of the interval as
determined by the external criterion (1.26 – 0.50 = 0.76). The difference between the
operative effect size and the upper limit of the interval corresponding with the
external criterion, 0.25 (0.75 – 0.50), is divided by the range of the interval, resulting
in a value of 0.33 (0.25/0.76). According to our rule of thumb we would value the
discordance with the external criterion as small.
5.3.3.   Effect size discordant, underestimation according to the external
criterion
Suppose an ES = 0.73 was found in relation to the external criterion ‘a great deal
better’ which, according to our assumption, is considered relating an underestimation
to the lower bound of the interval corresponding with the external criterion, in this
case ES=0.80.
We calculated the range between the maximum value of ES in our sample and the
interval’s lower limit as determined by the external criterion (-1.26 – 0.80 = -2.06).
The difference between the operative effect size and the lower limit of the interval
corresponding with the external criterion is 0.07 (0.80 – 0.73); divided by the
interval’s range, this gives a value of  – 0.03 (0.07/-2.06). We consider this a trivial
discordance with the interval determined by the external criterion.
5.4 RESULTS
Of the 398 candidates screened for inclusion in this study, 139 (34.9%) did not return
the first questionnaire. Questionnaires were received from the remaining 259
patients. We could not test the probability of systematic differences between non-
respondents and the study sample because information was inaccessible without
written informed consent from the patients not returning the first questionnaire.
Forty-two patients (16.2%) dropped out before the post-test assessment. The reasons
for not responding at post-test were because the patient died (n= 7), had no heart
failure (n=9), refused further participation (n=9), was too ill at post-test (n=3), had
moved (n=3) or did not react at all (n=11). To ensure that the patients who left at
post-test did not deviate systematically from the study group, their characteristics at
the time they returned the first questionnaire were compared with the baseline
characteristics of those who completed the post-test questionnaire. Except for
education level (the study sample had a statistically significant higher education), the
demographic characteristics of the two groups were similar. This comparison also
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showed no statistically significant differences in mean scores on baseline health-status
scales.
Analyses were based on 217 subjects (83.8%) who filled in the questionnaires at both
baseline and post-test.
The mean age of the patients was 60.6 (SD ±9.43) with a range of 25 to 75. Sixty-one
(28%) were female and 156 (72%) male. Men were more likely to have a partner, live
with someone, have a higher education, and be employed. Five percent, 44%, 21%
and 27%, respectively, had a self-reported NYHA-class I to IV at baseline. At follow-
up, 64 (29%) had undergone a CABG, 71 (33%) a PTCA, and 82 (38%) were being
treated with pharmaco-therapy.
Additional sample characteristics are presented in Table 5.1
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Table 5.1 Sociodemographic Characteristics
N (%)
Marital status Married 170 (78)
                              Cohabiting               15 ( 7)
Partner, not cohabiting         2 ( 1)
Unmarried          6 ( 3)
Divorced          7 ( 3)
Widow/Widower      16 ( 7)
Living situation Alone    28 (13)
With others  185 (85)
Education1 Grade 6       44 (20)
Technical School (grades 7-9)     61 (28)
Junior High School (grades 7-9)     34 (16)
Junior High School incl. vocational education     33 (15)
High School/A-levels        6 ( 3)
College  (4 yr.)     22 (10)
University  (5 yr.+)         7 ( 3)
 Employment status Employed             57 (26)
Unemployed         147 (68)
1. These categories are used by the Dutch National Institute for Statistics (CBS) to classify
education level
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5.5 ANALYSIS
5.5.1.   Item-analysis
Every questionnaire item was linked to a global question addressing the same health
status aspect, and for 23 items the change scores were standardized and broken down
by the item-related global question rating. Thus, regardless of an item’s domain we
calculated 4,798 response combinations out of a total of 4,991 (217 x 23),
representing missing data of less than 4%. In table 5.2 we show the relationship
between the researcher’s judgement of magnitude of change and that of the patient,
for every repeatedly measured item (except those such as ‘being restricted by costs
of healthcare’ which were not suitable to ask for improvement after treatment). The
stratified SRM (for every global question rating, the mean change score was divided
by the standard deviation of the observed change) does not differ significantly from
the ES (for every global question rating, the mean change score was divided by the
pooled standard deviation of baseline and post-test scores). The magnitude of change
estimated with both SRM and ES (interpreted according to Cohen) is not in
concordance with the interval determined by the rating ‘a great deal better’ but,
considering the calculated value, represents a trivial deviation. When the effect sizes
have values in concordance with the external criterion, the calculated value shows a
tendency towards the interval’s upper limit. Although it seems that Cohen’s
thresholds of magnitude of change over time appear to confirm the patient’s
judgement of the extent of improvement, this approach has a certain weakness since
we analysed item response combinations, while clinicians are concerned with
estimated magnitude of treatment effects in patients.
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Table 5.2: Estimation of magnitude of change on items with the Standardized Response Mean and Effect Size index, broken
down by corresponding values of item-related external criterion of perceived magnitude of change.
Global question/ Corresponding
External criterion           Effect size










No change                     0 – 0.20    3314   0.15          yes 0.75 0.14  yes 0.70
A little better                 0.20 – 0.50    513   0.47        yes    0.90 0.41  yes 0.70
Moderately better          0.50 – 0.80    521   0.72        yes    0.73 0.63  yes 0.43
A great deal better         0.80 – max.    450   0.77        no    0.01 0.79   no 0.01
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5.5.2.   Scale analysis
To evaluate the concordance between the magnitude of change in domains of health-
related functional status and an external criterion, we used the standardized change
scores of scales and a single global question intended to correspond with the
repeated measures of physical and emotional functioning. Tables’ 5.3a to 5.3c present
mean scores across global ratings of perceived change in functioning. Mean scores
increase as the rating of global perceived magnitude of change increases, confirming
the outcome of other studies 22,23,36,37. Similarly, within each of the four categories of
degree of improvement as perceived by the patient, the SRM reflect systematically
more change than the ES, whereas the differences between these indices are very
small with regard to the 3-item scale of physical functioning, and the domain of
emotional functioning. Both effect size indices, as estimates of the magnitude of
prospective change, indicate that the 3-item  scale was less responsive than the
MLHF-Q physical functioning scale, regardless of the perceived improvement rating
(tables 5.3a and 5.3b). Overall effect sizes in the sample (see: total in tables 5.3a and
5.3b) indicated the same difference between the 3-item scale from a generic
instrument (MOS-20)(‘small’: SRM = 0.44 en ES = 0.42) and disease-specific scales
(‘moderate’: SRM = 0.59 en ES =0.58), a consistent result in other studies 38-41.
Change in the emotional functioning domain seemed less relevant for this group of
patients, given that 79% declared no change after treatment. Furthermore, the overall
effect sizes of this scale are, according to Cohen, small.
The magnitude of change estimated with effect sizes ES (mean change/SDpooled)
was, according to our rule of thumb, in keeping with the magnitude of change
indicated by the patient’s judgement, or their category of subjective meaning, for all
scales. Furthermore, in cases that the magnitude of change estimated with the SRM
(mean change/SDchange) was not confirmed by the external criterion ratings (Tables
5.3a and 5.3c), the discordance was trivial.
Table 5.3 a Stratified effect sizes of change over time in the disease-specific physical functioning dimension (8 items)
                                                                                                                                                                                                         
Mean    Within Within
change    corresp. corresp.
N score SRM    interval Value ES interval Value
Global question/ Corresponding                                                                                                                                    
External criterion Effect size interval
                                                                                                                                                                                                         
No change 0 – 0.20 71  1.99 0.25    n 0.05 0.20    y  1.0
A little better 0.20 – 0.50 35  4.18 0.52    n 0.03 0.43    y   0.77
Moderately better 0.50 – 0.80 44  6.96 0.87    n 0.15 0.71    y   0.70
A great deal better 0.80 – max. (1.26) 45  7.11   0.89    y 0.20 0.72    n - 0.04
                                                                                                                                                                                                         
Total 195  4.60 0.59 0.58
Table 5.3 b Stratified effect sizes of change over time in the  physical functioning dimension (3 items)
                                                                                                                                                                                                         
Mean Within Within
change corresp. corresp. .
N score         SRM interval Value ES interval Value
Global question/ Corresponding                                                                                                                                    
External criterion Effect size interval
                                                                                                                                                                                                         
No change 0 – 0.20 70 0.53 0.11    y 0.55 0.11    y 0.55
A little better 0.20 – 0.50 34 1.17 0.26    y 0.20 0.25    y 0.17
Moderately better 0.50 – 0.80 42 3.00 0.67    y 0.57 0.64    y 0.47
A great deal better 0.80 – max.(1.26) 45 3.82 0.85    y 0.11 0.81    y 0.02
                                                                                                                                                                                                           
Total 191 1.80 0.44 0.42
Table 5.3 c  Stratified effect sizes of change over time in the disease-specific emotional functioning dimension (5 items)
                                                                                                                                                                                                         
Mean Within Within
change corresp. corresp.
N score         SRM interval Value ES interval Value
Global question/ Corresponding                                                                                                                                    
External criterion Effect size interval
                                                                                                                                                                                                         
No change 0 – 0.20 159 1.13 0.21    n 0.01 0.20    y 1.00
A little better 0.20 – 0.50   17 2.71 0.53    n 0.04 0.48    y 0.93
Moderately better 0.50 – 0.80   11 3.16 0.59    y 0.30 0.56    y 0.20
A great deal better 0.80 – max. (1.26) 15 6.80 1.26    y 1.00 1.21    y 1.00
                                                                                                                                                                                                          
total 202 1.68 0.35 0.32
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5.6 DISCUSSION
The values used to classify effect sizes for difference between means as small,
medium, or large “was arbitrary but seamed reasonable”, as Cohen 27 stated when he
stressed that investigators should render their own judgement on the matter. Many
researchers evaluating change in health-related quality of life measures, using effect
size as an indicator of an instrument’s responsiveness or to estimate magnitude of
change over time, seem to have adopted Cohen’s thresholds with the same rigidity
that ‘ α = .05’ has been adopted. 42,43 Some researchers pose that an effect size is
synonymous with the importance of change over time, without questioning who
determines what should be considered trivial or important whether modified by
terms such as ‘minimal’ or not 37 and the dependence of effect size interpretation on
the perspective of the interpreter. 12
To signify the importance of change in this study, we used an anchor-based
approach, 44 asking patients to judge treatment-related magnitude of change over
time by responding to global or ‘transition questions’ intended to be analogous with
the instruments’ domains of health.
The amount of change estimated with the ES in this study showed, in contrast to the
SRM, the highest concordance between the researcher’s interpretation according to
Cohen and the patient’s rating of perceived change, used as external criterion.
Additionally, neither of the two estimates of amount of change, i.e. ES and SRM,
deviated from the interval determined by the rating from the external criterion with
regard to the 3-item  physical functioning scale. Our data suggest that the difference
in the number of items in the disease specific (5 items) and generic (3 items) physical
functioning scale may be related to the extent to which the magnitude of change over
time judgements are consistent with the external criterion. Given this study’s design,
this could not be verified. Despite the fact that the SRM was less concordant with
the interval associated with perceptible change in the same domain, as rated by the
patient, in comparison with the ES, we can conclude that Cohen’s thresholds ‘small’,
‘medium’, and ‘large’ appear to be in keeping with the external criterion. It is possible
that the terminology used in the global rating of change in physical functioning
covered the content of the 3-item scale from a generic instrument more precisely
than the content of the disease-specific items in this study sample. 
In our approach we have, in order to achieve a conveniently arranged and
comprehensible questionnaire, abandoned external criteria with 15 anchor points.
Although it is known that raw change scores derived from repeated measurement of
health-related quality of life increase with the amount of change as perceived by the
patient, this phenomenon is no guarantee that effect sizes will fall in Cohen’s range
as determined by the external criterion. Osoba et al. 37 used ES (mean change/SD
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baseline) in comparison with the same rating scale method as this study does. They
concluded: “Cohen’s estimates appear to be confirmed empirically in our direct study
of the degree of change experienced by women who received chemotherapy for
breast cancer.” We applied our approach to their data and concluded that the
magnitude of change in the domains of emotional functioning, social functioning,
and global functioning were consistent with the external criterion. In contrast, two
underestimates of effect were found in physical functioning determined by the
ratings ‘moderately better’ and ‘a great deal better’.
In our attempt to confirm Cohen’s estimates empirically with data from studies with
a 15-point global rating scale, 23 the only replicated result relates to the phenomenon
that means of change scores consistently increase with the perceived magnitude of
change. However, this concordance between mean raw scores and the external
criterion was demonstrated only after merging seven global ratings into three. For
example: 1)’almost the same’, ‘hardly any better at all’, 2)’a little better’ and 3)
‘somewhat better’ represent small improvement; 4)”a good deal better”, 5)
“moderately better” represent moderate improvement and 6)”a great deal” and 7) “a
very great deal better” a large improvement. Reducing the original rating scale could
cause a fallacy in the comparison of effect size and external criterion. The distances
between the merged ratings probably differ from those between the anchor points
on a seven-point rating scale, which can lead to differences in the relation with
magnitude of standardized change assessed over time.
Myriad effect size indices have been developed, from which the researcher can
choose, and no universal criteria exist to interpret this statistic 45,46. In this study the
criterion validity of the interpretation by Cohen’s thresholds was evaluated, and
results were compared with other studies. Future research is needed to clarify effect
size interpretation, using other effect size indices or methods to assess functional
status, e.g. weighed or unweighed scores in patient specific health status measures.
41,47-49
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In the literature on the measurement of treatment-related change some authors
advocate the use of change scores as the best approach; others prefer the approach
to measure change by asking patients how much they have changed after treatment.
The aim of this study was to compare these two methods in measurement of changes
in identical domains of health –related functional status (HRFS).
Methods.
Analogous to the widely used single global or transition questions which assess the
patient’s retrospectively perceived change, we modified every item belonging to
domains of health of the Minnesota Living with Heart Failure-Questionnaire
(MLHF-Q), into transition questions. Subjects were 217 patients with heart failure,
who underwent a treatment with known efficacy, were selected. 
Results.
The reliability of the scale ‘physical functioning’ as the composite of change scores,
and of the concordant scale composed of identical transition items were estimated
and yielded a Cronbach’s alpha of 0.86 and 0.92, respectively, whereas the change in
‘emotional functioning’ and the concordant transition scale yielded identical alphas
of 0.76. Factor analysis yielded similar and clearly interpretable dimensions for both
methods. The canonical correlation (Rc ) between the composite of the change score
items and the composite of the concordant transition items that belong to the
domain of physical functioning was Rc=.63 (p < .001), whereas the combination of
the emotional functioning-items yielded a Rc=.48 (p< .001) with a percentage of
linearly explained variance  between the two dimensions ( 40% and 23%,
respectively).
Conclusions.
The patient’s retrospective assessment of change after intervention appears to
provide reliable and valid information compared to prospective change scores when
items are used beloning to validated measures health-status.
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6.1 INTRODUCTION
Clinicians and other health professionals have difficulty to find Health-Related
Functional Status (HRFS) measures clinical important change that is expected to
occur after treatment evaluated in cardiological trials. To evaluate clinically relevant
change reliable and valid, the patient’s perception or opinion of what constitutes
relevant change in health status domains must be captured in a multi-dimensional
mode. However, treatment-related change over time is usually based on change or
difference scores that are calculated simply by subtracting baseline scores from post-
treatment scores. The interpretation of the amount of change over time as clinically
relevant depends on a subjective judgement of either clinician or patients as a
substitute for a golden standard. Therefore, a widely accepted solution to
discriminate between relevant and irrelevant change is the use of so-called ‘transition’
or ‘global questions’ as external criterion or standard, by asking the patients
retrospectively how much they feel better or worse compared to the situation at
baseline.
These transition questions are used in several modes: 1) single, retrospective
questions at follow-up about the direction and magnitude of perceived change in
general or 2) after treatment in domains of health, e.g. physical, emotional and social
functioning, 3) about satisfaction with the change after treatment, 4) perceived degree
of change in difficulty to accomplish a specified task or 5) as a serially assessed
retrospective global rating to examine incremental perceived change between
baseline and follow-up 1-12. Another reason to use transition questions is to compare
the results of assessing change in health-related quality of life with both repeated
measurement and with the patient’s retrospective perception of change after
treatment.
In several studies, the accuracy, precision, reliability and validity of single global or
transition questions of health have been discussed 6,13-19. The main disadvantage of
a single item of retrospectively perceived change in overall health is that the answer
“since the operation my health state has worsened” does not cover domain-specific
change in health. We can imagine that the improvement in the domain of physical
health is overshadowed by the perception of a worsening in emotional functioning
and in such situations a global single transition question is not a valid indicator of
change in health status. Another disadvantage of a single question used to capture
perceived change in specific domains of the patient’s life (physical, emotional or
social functioning) is that the internal consistency or reliability cannot be estimated.
Therefore, we have good reasons to presume that multiple-item transitional scales
tend to be more reliable than single-items 20 and, when these retrospective measures
are conceptually identical with the longitudinally assessed change in health domains,
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they would also have a better validity 21. On the one hand, several studies have
provided evidence that change in health-status domains estimated with direct
transition questions were more accurate when compared with estimates derived from
change scores 6,11,16,17. On the other hand, the direction of prospective or serial
change does not always correspond with the content of the single transition
question(s) and therefore may miss some contrary changes 11,21,22. To solve this, it has
been suggested that patients should be asked a series of transition judgements about
functional limitations related to their disease or to areas of health status such as
physical, emotional and social function 10,17. However, we have not been able to find
studies in which retrospective change in domains of health was measured with multi-
transition items intended to contribute to the assessment of change in an underlying
dimension of health status. Two studies we have found used a set of multiple
transition items but without a relationship with an underlying dimension of health
11,23. No study was found in which an attempt was made to investigate the question
whether both methods measure the same dimensions of health status by means of
the summed composite of item scores (scales). Also no study was found in which the
concordance between the perceived change and change scores, calculated in a
before-after design, was evaluated simultaneously in a one-to one relationship with
items and with scales. Before we can reasonably claim that multiple item transition
scales measure change in health-related functional status (HRFS), we have to
demonstrate that this new operational procedure yields substantially the same results
as measuring change with the standard repeated measurement procedure. To this
end, his paper examines the reliability, the convergent validity and ‘known groups’
validity of the patient’s view of change in domains of health as outcome measures.
The following questions are addressed:
1. Do we measure change in the same domains of HRFS if we use multi-item
transition scales assessing (retrospective) perceived change compared with
(prospective) change assessed with repeated measures?
2. To what extent does concordance exist between health status scales composed
of prospective change scores and those composed of retrospective transition
scores?
3. How do both instruments compare in their ability to discriminate between
groups known to differ on a measure external to the questionnaire (i.e.
disappearance of angina pectoris)?
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6.2 METHODS
To ensure that change in health status occurred we selected a group of patients
undergoing a treatment with known efficacy and selected a disease-specific
instrument with known sensitivity to detect change over time 24-26. The study sample
was composed of two groups: 1. patients who, after a diagnostic Coronary Angio
Graphy (CAG), were scheduled for an invasive treatment Percutaneous Transluminal
Coronary Angioplasty (PTCA ) or Coronary Artery Bypass Grafting (CABG) and 2.
patients who needed no operative intervention after CAG and were treated with
pharmacotherapy.
The aim of the current study was to compare potentially similar strategies of
measuring treatment-related change in  two well-defined important domains of
HRFS: physical functioning, and emotional functioning. Consequently, items that are
not purported to measure either the domain of physical or emotional functioning are
not used in the comparison.  To assess serial change in the domain of physical
functioning we used the 8-item scale from a disease-sepcific HRFS instrument
(namely the Minnesota Living with Heart Failure Questionnaire (MLHF-Q) 27,28  and
3 items from the MOS-20. 29  To assess serial change in the domain of emotional
functioning the 5-item scale of the MLHF-Q was used.   To assess perceived change
in these domains of health with a direct method we modified the selected items of
the MLHF-Q physical functioning scale and MLHF-Q emotional functioning scale
and the MOS-20 items into direct questions (transition questions). These multi-item
transition scales were administered at post-treatment.
6.2.1.    Patient selection
Consecutive patients who, following a Coronary Angiography (CAG), were
scheduled for Percuteneous Transluminal Coronary Angioplasty (PTCA) or
Coronary Artery Bypass Grafting( CABG) or who needed no operative intervention
but were treated with a (modified) pharmaco-therapy, were recruited from January
to December 1998 from the Groningen University Hospital, the Martini Hospital,
Groningen, and the Weezenlanden Hospital in Zwolle in the Netherlands. Patients
with other incapacitating diseases, with cognitive impairments, aged 75 or older, or
who did not speak Dutch were excluded. Ethical approval was obtained from the
ethics committee at each participating hospital.
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After inclusion patients received a mailed questionnaire accompanied by a written
informed consent form. The questionnaire was serially administered at baseline and
6 weeks after the decision for non-invasive intervention or 6 weeks after the day a
PTCA /CABG-intervention was executed. After the questionnaires were received,
they were routinely checked on completeness at baseline as well as at follow-up. If
questions or pages had not been filled in, either a copy was sent with a kind request
to complete the questions or, in the cases of it being one question, patients were
interviewed by telephone. Because the completeness of the questionnaire was
monitored by a computer-programme both at baseline and follow up, we effectively
reduced the non-response on questions, and consequently, on scales.
To ascertain the assessment of substantial treatment-related change we approached
patients treated with interventions with known efficacy, i.e. invasive treatments
PTCA or CABG and non-invasive pharmacotherapy. We presumed that at baseline
i.e. prior to CAG, both patients and cardiologists had no information about decision
concerning either intervention and would not affect the assessment of subjective
health and should reduce the risk of floor and ceiling effects. However, this control
for potential bias resulted in logistic problems and, six months after the start of the
study, we were forced to select patients waiting for outpatient treatment (PTCA) or
waiting for hospital admission (CABG) somewhat later  after the decision was taken.
6.2.2.   Data Collection and measures
The Minnesota Living with Heart Failure Questionnaire (MLHF-Q) is a disease-
specific instrument which is composed of 21 items and three scales that measure the
following: the physical functioning dimension (8 items), the emotional functioning
dimension (5 items) and the overall score on health-related quality of life (21 items).
Eight separate items do not assess an underlying dimension of health-related quality
of life and therefore were not used for the current paper.  These eight items measure
several meaningful social and economic impairments that patients relate to their heart
failure, although these ‘socio-economic’ items are used as a part of the overall score
27,30-33. However, one item from the MLHF-Q had no correlation with the physical
functioning scale, as predefined by Rector et al 28 both in a previous Dutch sample
26 and in the current study. Therefore, the item “‘did your heart failure prevent you
from living as you wanted by making your relating to or doing things with your
friends or family difficult?’’ was skipped for scale construction and not used in
further analysis. Finally, both the items from the MLHF-Q and the MOS-20 (10
items) were used in the analysis of the concordance between two methods of
measuring change in the domain of physical functioning.
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 The response options range from “no” (score 0); very little (score 1) to very much
(score 5). The total score of, the physical dimension (sub-scale) ranges from  0 to 40,
the emotional dimension (sub-scale) ranges from 0 to 25. To investigate whether
differences between the MLHF-Q and a generic measure of physical functioning
would exist we have extended the questionnaire with 3 items from the MOS-20 29
but with the response options analogue to the questionnaire’s format. These three
items had the following format: “Did your heart failure prevent you from living as
you wanted during the last month by making it difficult for you 1) to bend, stoop
or lift light objects?, 2) lift heavy objects, like moving a table? And 3) run at a fast
pace? “
Two methods of assessing change in health-related quality of life (HRQL) with multi-
item scales were applied with the study data: The first method, repeated baseline
measurement of HRQL-domains with items from the MLHF-Q and MOS-20.  In
addition, the repeatedly measured battery of questions was transformed in a
retrospective ‘transition question’ mode. Consequently, the patient’s perception or
subjective significance of change was captured at follow-up of each of the MLHF-Q
and MOS-20 items in terms of the extent of feeling improved, deteriorated or not
changed. Hence, the degree to which they perceived that change had occurred, on
that particular item was rated on a 7-point Likert scale. Following Osoba et al. 15, we
have chosen to use the term “subjective significance” because it indicates whose
judgement was used to determine the direction and magnitude of change. These
transition items are designed to elicit information regarding perceived change over
time in specific aspects belonging to domains of HRFS.
Figure 6.1 shows, with the physical functioning items, these two strategies of
assessing change in HRFS:
1.   The original MLHF-Q items were phrased as follows: ”Did your heart failure
prevent you from living as you wanted during the last month by making your
sleeping well at night difficult?” Serial change scores on items (SCI-scores) were
calculated by subtracting the follow-up score from the baseline score to get
positive numerical change data indicating improvement and negative numerical
change data indicating deterioration. A change score of zero was considered to
indicate neither improvement nor deterioration. With the summed composite of
the SCI scores we constructed the serial change scale (SCS).
2. The Subjective Signified Items (SSI) questionnaire was used to classify patients
according to whether they had improved or deteriorated on each item of the
questionnaire belonging to the dimension of physical and emotional functioning.
The questions were phrased as follows: “Since the last time I filled out the
questionnaire (or: since my operation), my problems with walking about or
climbing stairs related to my heart failure have become.
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3. For every SSI item each patient was asked to circle the answer that best described
the perception of the direction and magnitude of change at follow-up on a 7-
point Likert scale: 1) a great deal worse; 2) moderately worse; 3) a little worse; 4)
no change; 5) a little better; 6) moderately better and 7) a great deal better. With
the summed composite of the SSI scores we constructed the Subjective Signified
Scale (SSS). Figure 6.1 shows a general representation of prospective and
retrospective methods with the physical functioning scale items.
     Figure 6.1 General representation of the prospective and retrospective method of
assessing change in physical functioning.
Func
the C
respSerial Change Items  (T1 minus T2)           Subjective Signified Items (T2) (Transition items)
Physical functioning Physical
functioning
SCI score SSI score
Change score scale item: transition score item:
Lift heavy objects (SCI - 1) Lift heavy objects (SSI - 1)
Bend, stoop lift light objects (SCI - 2) Bend, stoop lift light objects (SSI - 2)
Run at a fast pace (SCI - 3) Run at a fast pace (SSI - 3)
Short of breath (SCI - 4) Short of breath (SSI - 4)
Tired, fatigued or low on energy (SCI - 5) Tired, fatigued or low on energy (SSI - 5)
Sleeping (SCI - 6) Sleeping (SSI - 6)
Working around the house (SCI - 7) Working around the house (SSI - 7)
Going places away (SCI - 8) Going places away (SSI - 8)
Walking about or climbing stairs (SCI - 9) Walking about or climbing stairs (SSI - 9)
Sit or lie down to rest during the day (SCI -10) Sit or lie down to rest during the day (SSI - 10)
Serial Change Scale Σ  = SCS score             Subjective Signified Scale Σ = SSS score                                                                        Assessment of change in clinical evaluation
tional impairment due to angina was assessed using a set of questions corresponding to
anadian Cardiovascular Society (CCS), and to the New York Heart Association (NYHA)
ectively.
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6.2.3.    Statistical analysis
To investigate whether the prescribed underlying domains of health of the baseline
scale-items by Rector et al. 28 were measured with the same results with the change
score items and the transition items, LISREL analysis was used to test the equality
of factor structures (principal component analysis). Cronbach’s α was used to
examine the internal consistency of the transition scales that emerged from these
analyses. Canonical correlation analysis was applied as a general procedure for
investigating the relationships between two sets of variables. With canonical
correlation analysis we transformed the prospective change item scores (PCI scores)
from the set of, for example, physical functioning items into a linear combination,
which is called the canonical variable. The linear combination, or canonical variable,
was also constructed from the concordant set of subjective signified items (SSI
scores). These linear combinations were composed so that the correlation between
both composed canonical variables was maximised. This correlation is called the
canonical correlation (Rc). In other words, this investigated the research question to
what extent the set of PCI scores be predicted or ‘explained’ by the pendant SSI
scores. Transformation into z-scores was used to convert different raw scores of the
items and scales in both batteries to share the same measurement unit with a mean
of 0 and a standard deviation of 1 in order to make comparisons between sub-




The source population consisted of patients who were referred by their general
practitioner for a CAG  in three hospitals in the northern part of the Netherlands.
Of the 398 candidates screened for inclusion in this study, 139 (34.9%) did not return
the first questionnaire. A questionnaire was received from the remaining 259 patients.
We could not test the probability of systematic differences between non-responders
and the study sample because no information was accessible without written
informed consent from the patients who did not return the first questionnaire.
42 patients (16.2%) dropped out before the follow-up assessment. The reasons for
not responding at follow-up were because the patient died (n= 7), had no heart
failure (n=9), refused further participation (n=9), was too ill at follow-up (n=3), had
moved (n=3) or did not react at all (n=11). To ensure that the patients who dropped
out at follow-up did not deviate systematically from the study group, the
characteristics of these patients at the time they returned the first questionnaire were
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compared with the baseline characteristics of those who completed the questionnaire
at follow-up. Except for educational level (the study sample had a statistically
significant higher education), the demographic characteristics of the two groups were
similar. This comparison also showed no statistically significant differences in mean
scores on baseline health-status scales.
Analyses were based on 217 subjects (83.8%) who filled in the questionnaires at
baseline and at post- test.
Demographics
The mean age of the patients was 60.6 (SD 9.43) with a range of 25 to 75. Sixty-one
(28%) were female and 156 (72%) were male. Men were more likely to have a
partner, to live together with someone, to have a higher education, and to be in
employment. Five percent, 44%, 21% and 27%, respectively, had a self-reported
NYHA-class I to IV at baseline. At follow-up, sixty-four (29%) had undergone a
CABG, 71 (33%) a PTCA, and 82 (38%) were being treated with pharmacotherapy.
Additional sample characteristics are presented in Chapter 5, table 5.1
Internal consistency
The homogeneity or unidimensionality of prospective change items and their
corresponding transition items was estimated with the internal consistency coefficient
(Cronbach’s α). The multi-item transition scale ‘physical functioning’ yielded a
somewhat higher internal consistency estimate (Cronbach’s α = 0.92) than the same
scale composed of items’ change-score (Cronbach’s α = 0.86), whereas these
coefficients were identical for both versions of the scale ‘emotional functioning’
(Cronbach’s α = 0.76)
Convergent validity of prospective and retrospective measures of change
Two different operationalizations to capture the same concept of self-rated health
were used. First, the classical repeated measurement change scores, derived from
items from the MLHF-Q and the MOS-20. Second, a new set of operations to
measure change in HRFS- domain by the means of transition items. We will consider
measuring global self rated health with multi-item transition scales and hypothesized
that, compaired to the serial change method, the underlying dimensions of physical
and emotional functioning could be measured with the same results. One way to
answer this question is to look at the concurrent or convergent validity of
retrospective transition measures.
To investigate the convergent validity of the two domains assessed with repeated
measurement as well with transition questions, we performed a factor comparison
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by means of a principal component analysis with baseline items, item’s difference
scores and pendant transition items.
Table 6.2 presents the results of the principal component analysis (PCA) with items
from three item-sets: 1. Items tapping the dimensions  ‘physical functioning’ and
‘emotional functioning’ assessed at baseline, 2) the change score as the difference
between baseline and follow-up for both dimensions (Serial Change Items) and 3)
directly assessed change with the same items but modified to measure the perceived
direction and magnitude of change at follow-up (Subjective Signified Items). Table
6.2 shows that in each battery, the items that cover the underlying construct of
physical functioning have the expected factor loadings, 28,26 which were satisfactory
 >.50, except for the item with reference to the impact of heart failure on sleeping
well at night. In each set of variables, the items that cover the domain of emotional
functioning were, without exception, unambiguously related to the expected factor.
The factor loadings of the prospective change scores on items were systematically
lower than those estimated with the concordant baseline items and transition items,
and the factor loadings of both baseline items and concordant transition items were
of the same magnitude. Scales composed of multi-item change scores are usually
more unreliable than either the baseline or follow-up measures on which they are
based. The unreliability of the change score ‘typically reduces its correlation with
anything, including retrospective assessments’ 37,38. Notwithstanding these
differences, the analysis of the three sets of items yielded similar factor loadings
(Lambda in LISREL-notation) not only by this elaboration. The factor structure as
prescribed by Rector et al. was confirmed by the baseline measure and the similarity
between the factor structures of each mode of measurement series was shown by the
overlap of the 95% confidence intervals. 
                                                                       
Table 6.2. The loadings* of the scale components (item scale correlations) of baseline items, change scores of repeatedly
assessed baseline items (Serial Change Items)  and transition items (Subjective Signified Items) with
95% Confidence Intervals (C.I.) (* Lambda in LISREL notation)
                                                                                                                                                                                                    
Baseline Serial Subjective
Items Change Signified
                                                                                                                       Items (SCI)                             Items (SSI)              
Loading    95%   C. I. loading    95%      C.I. loading    95%    C.I.
                                                                                                                                                                                                    
Physical functioning
Sit or lie down to rest during the day 0.76 0,86 0,62 0,67 0,69 0,41 0,75 0,85 0,61
Walking about or climbing stairs 0.82 0,94 0,70 0,74 0,80 0,56 0,83 0,95 0,71
Working around the house or yard 0.86 0,98 0,74 0,71 0,76 0,52 0,79 0,89 0,69
Going places away from home 0.69 0,78 0,54 0.55 0,64 0,36 0,62 0,74 0,50
Sleeping well at night 0.54 0,63 0,35 0,39 0,47 0,19 0,49 0,56 0,28
Tired, fatigued or low on energy 0.74 0,83 0,59 0,71 0,76 0,52 0,68 0,80 0,56
Short of breath 0.80 0,92 0,68 0,70 0,82 0,58 0,81 0,93 0,69
Bend, stoop, or lift light objects 0.79 0,91 0,67 0,73 0,85 0,61 0,81 0,93 0,69
Lift heavy objects, like moving a table 0.79 0,91 0,67 0,75 0,84 0,60 0,78 0,90 0,66
Run at a fast pace 0.69 0,80 0,56 0,66 0,74 0,46 0,69 0,81 0,57
Emotional functioning MLHF-Q
Feel you are a burden to the family 0,66 0,74 0,42 0,51 0,67 0,39 0,61 0,73 0,37
Feel a loss of self-control 0,85 0,97 0,73 0,88 1,00 0,76 0,84 0,98 0,70
Worry 0,72 0,84 0,60 0,69 0,83 0,55 0,64 0,78 0,50
Making it difficult for you to concentrate 0,60 0,72 0,41 0,59 0,70 0,35 0,57 0,65 0,37
Feel depressed 0,71 0,83 0,59 0,61 0,75 0,47 0,64 0,78 0,50
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Canonical correlation between composites of change and transition items
Another way to answer the question ‘do both operationalizations capture the same
change in domains of health?’ we also investigated with canonical correlation
coefficients the magnitude of association between two concordant sets of items.
Given that the transition items were forced into line with the content of the items
used to assess prospective change we analysed both batteries of items with canonical
correlation analysis (see Figure 6.2). Canonical coefficients only reflect the extent to
which each item (given the other items) contributes to the composite of the items in
the set of variables to which the item belongs. Therefore, we prefer to present the
results with the canonical loadings as follows 39,40 : The correlation between the
canonical variable and the items that belong to the underlying dimension of health
status which were calculated with prospective change scores of scale items and
corresponding transition items.

Figure 6.2: Hypothetical model of canonical correlation analysis with serial and retrospective change-items of the physical
functioning dimension.
Serial Change Items Subjective Signified Items
Prospective change T2 – T1 Retrospective change T2
lift heavy objects lift heavy objects
bend, stoop, lift   bend, stoop lift
light objects light objects
run at a fast pace  run at a fast pace
short of breath short of breath
 
tired, fatigued or  tired, fatigued or 
low on energy    Canonical. var.   Rc         Canonical var. low on energy
sleeping  sleeping
 physical function.   physical function.
working around  working around
the house the house
going places away  going places away
walking about or     walking about or
climbing stairs climbing stairs
sit or lie to rest sit or lie to rest
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The canonical correlation (Rc ) between the composite of the change score items and
the composite of the concordant transition items that belong to the domain of
physical functioning was Rc=.63 (p < .001), whereas the association between the
canonical variables as the combination of the emotional functioning-items yielded
a Rc=.48 (p< .001). These canonical correlations in terms of the percentage of
linearly explained variance is fairly large between the two dimensions (40% and 23%,
respectively).
Table 6. 3 Correlations between the Serial Change-Items and the Subjective Signified
Items and their corresponding canonical variable.
     Serial Subjective
     Change Signified
Items (SCI) Items (SSI)
                                                                                                                                   
Physical functioning MLHF-Q
Sit or lie down to rest during the day
.55      .48
Walking about or climbing stairs .79      .90
Working around the house or yard .68      .73
Going places away from home .35      .34
Sleeping well at night .36      .35
Tired, fatigued or low on energy .55      .69
Short of breath .41      .40
Bending, stooping, or lifting light objects .55      .45
Lifting heavy objects, like moving a table .77      .56
Running at a fast pace .51      .44
Emotional functioning
Feel you are a burden to the family .48      .44
Feel a loss of self control .64      .65
Worry .61      .79
Making it difficult for you to concentrate or
remember things
.60      .40
Feel depressed .94      .94
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Table 6.3 shows the correlations between the canonical variables with the original
items: the canonical loadings. The prospective change items as well as the concordant
transition items showed canonical loadings which were satisfactory according to the
criterion > .30 of Levine 39 and, regardless the method of measuring change over
time, we could unambiguously identify the items assessing the underlying
dimensional configuration demonstrated with factor analysis. This result was
remarkable because in the canonical correlation analysis the criterion of the linear
combination is aimed at maximising the explained variance between two sets of
variables, whereas in Principal Components Analysis (PCA ), the linear combination
criterion is aimed at maximising the explained variance within a set of variables. In
spite of these divergent criteria underlying the method of data reduction, in the set
with the change score items (PCI) as well as in the concordant set with transition
items (SSI), identical items covered change in the expected domain of health. This
result justifies, additional to the results from lisrel-analysis, the comparability of the
summed composite of prospective change scales (PCS) with the summed composite
of the retrospectively perceived change items (SSS).
Known groups validity
Another question was ‘do both operationalizations of the measures have an equal
ability to discriminate between subgroups known to differ on a clinically relevant
variable?’. Therefore, improvement of angina pectoris (AP) was used as an external
criterion to distinguish patients who improved from patient whose AP class stayed
the same. Hence. the sample was divided into two groups who should differ based
on the improvement of angina pectoris according to the NYHA classification 41:
patients who improved and patients who showed no shift in their NYHA
classification. To test the hypothesis that both instruments of prospective change
scales and retrospective transition scales have an equal ability to discriminate between
these subgroups with known change in AP the Mann-Whitney U test was employed.
For this analysis we have, apart from the overall scale of 10 all items belonging to the
physical functioning dimension, used the MOS-20 items as an additional measure of
physical functioning.
The results of the evaluation of the ability of the prospective and retrospective scales
to discriminate between 'known groups' are reported in table 6.4 All p-values were
beyond < .01, and effect sizes indicated small or moderate differences on both scales
(small effect: ES < 0.20; moderate effect: ES > 0.20 < 0.50 and large effect: ES >
0.80). The difference in change in disease-specific physical functioning derived from
repeated measurement detected a small difference between the groups whereas the
generic scale estimated a moderate effect. Retrospective scales composed of the same
136                                                                             Assessment of change in clinical
evaluation                        
items showed effect size in reverse order. Change in the domain of the emotional
functioning showed small difference between improved and stable AP groups for
both methods.  
This finding makes it reasonable to suppose that both methods are similar in several
respects and that it is difficult to prove that one of them has superior qualities.
Table 6.4 Discriminative ability of Serial Change Scales and corresponding retrospective transition scales between groups
differing in change on the NYHA-classification (improved patients vs. patients who remained the same).
Improved stable
Mean (SD) N mean (SD) N z-value p-value effect size1
                                                                                                                                                                                     
Prospective
Physical functioning:
MLHF-Q scale 0.22 (1.01) 124 - 0.17 (0.97) 86 - 2.69 < 0.01 0.40
MOS-20 scale 0.27 (1.08) 119 - 0.24 (0.87) 86 - 3.42 < 0.01 0.53
Overall scale 0.25 (1.02) 124 - 0.20 (0.95) 86 - 2.93 < 0.01 0.46
Emotional functioning:
MLHF-Q scale 0.21 (0.84) 123 - 0.19 (1.05) 87 - 2.42 < 0.01 0.41
                                                                                                                                                                                     
Retrospective
Physical functioning:
MLHF-Q scale 0.39 (1.01) 123 - 0.27 (0.91) 86 - 4.74 < 0.01 0.71
MOS-20 scale 0.24 (1.11) 124 - 0.16 (0.88) 86 - 3.39 < 0.01 0.42
Overall scale 0.36 (1.03) 123 - 0.25 (0.91) 86 - 4.50 < 0.01 0.64
Emotional functioning:
MLHF-Q scale 0.22 (1.03) 124 - 0.17 (0.96) 86 -.3.37 < 0.01 0.39
________________________________________________________________________________________________________
    (S21 + S22)
1 Effect size for independent samples:  ( 1 - 1 / SDpooled) SD = √   -----------------
  (N1-1 + N2-1)
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6.4 DISCUSSION
In patients suffering acute and or traumatic events, the measurement of health
outcome due to clinical intervention is often hampered by the absence of a baseline
measure. Reliable and valid measures of retrospective change would provide a
solution to this problem. This study provides a method to assess perceived change
with multi-item transition scales and we suggest that, in contrast with the single-item
approach, it can provide a more valid determination of the change score that is
signified as relevant by patients.
In most of the studies, transition questions are used as a single item to assess
retrospective perceived change. One of the problems with the global assessment of
change with one item is that the reliability cannot be established since Cronbach’s
alpha cannot be computed for a single item. Following Norman et al. 1, we could not
locate studies that have examined the reliability of transition scales measuring a
hypothesised underlying dimensional configuration. In our study, in which we
applied multi-item measures of prospective and retrospective change in domains of
HRFS, the scales had a satisfactory level of reliability 42. The lower reliability of the
emotional functioning scales may be due to a smaller number of items as the primary
way to make scales more reliable is to make them longer 42.
Both the methods we applied in this study have several strengths and criticisms.
Working with repeated measures and directly derived change scores has the major
problem that they are ridden with a regression effect and prone to measurement
error 43-45. Change scores derived from repeated measurement may also be flawed by
floor and ceiling effects 6,13, carryover effects of learning if the retest intervals are too
short, specific events occurring between the first and second assessment, the ‘natural’
course of the disease, acquiescence and social desirability, and so on. 46. Another
threat to the validity of change scores is the assumption of researchers that subjects
have an internalised perception of their level of functioning with regard to, for
example, the domain of physical health status and that this internalised standard will
not change from baseline to follow-up. This confounding is associated with
response-shift bias 47. There are also several threats to the reliability and validity of
our findings based on the use of multi-transition items. First, retrospective
perception of change may not be accurate due to recall bias. Patients may equate
their present state with change in health status: if a respondent is doing poorly after
treatment he might be inclined to think that on the whole things are getting worse
even if his health state improved or did not change 1,48,49. However, in the study of
Fitzpatrick et al. 17, the transition questions were shown not to be determined by the
patients’ mood at follow-up or their present state. Additionally, patients who have
suffered a large decline in health may overestimate their perception of baseline health
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if they long for the time when their health was better 13,49. Second, respondents may
recalibrate their baseline situation due to the clinical intervention or may feel inclined
to give socially desirable answers or they may change the “anchors” for their ratings
over time, the so-called called ‘response shift’ 13,18. Inaccurate recall seems to be
determined by the time interval since exposure or intervention and by the degree of
detail required 50, but the significance, the vividness and meaningfulness of events
also contribute to recall. Some of the findings of Aseltine et al. 49 suggest that their
measures assessing more concrete aspects of patient’s condition provided greater
correspondence between prospective and retrospective assessment than the more
abstract measures of general health. Despite the limitations of transition questions,
there is a growing realization that patients can be more directly involved in judging
for themselves whether treatments have improved their health status or that relative
to the observed health status of other patients by directly asked transition questions
5,6,17,51-53. Moreover, transition questions were shown to be more sensitive to changes
over time in health-related quality of life than were change scores 10,11,16. The result
of the analysis of equal factor loadings indicated that the multi-item transition indices
(scales) measure phenomena similar to those measured by the serially assessed
dimensions to which they were paired. This could arouse criticism because some
items may not have contributed optimally to the assessment of underlying constructs.
This may have been caused by the translation of items into transition questions,
which may have changed their content, leading to the association of an item with the
domain to which it did not belong. For example, the modification of the impact of
heart failure on sleeping as an item belonging to the dimension of physical
functioning may have become associated with sleeping problems caused by worries
and anxiety.  In several studies, the agreement between retrospective assessments and
serial assessments were poor if single items were used. Therefore, the results of this
study argue for multi-item batteries of transition items measuring (disease) specific
and relevant domains of HRFS, since one-item transition questions do not cover the
sum of aspects of health that belong to the underlying construct or dimension.
Further studies should address the psychometric aspects of transition scales used
repeatedly in longitudinal studies, such as test-retest reliability and so on.  
In conclusion, retrospectively assessed perception of change after intervention,
appears to provide reliable and valid information compared to prospective change
scores derived from repeated baseline measurement of health-status dimensions.
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7.1  INTRODUCTION
When clinicians are interested in patient-assessed health as a relevant outcome of
treatment, the choices that need to be made after consulting clinical epidemiologists
or social scientists, often put them in a state of indecision. Many choices can be made
on the basis of concepts belonging to the universe of ‘quality of life’ that is the most
appropriate one in the context of the disease and treatment. Subsequently, after
selection of the appropriate measures, it becomes apparent how complex and varied
the methods used to assess change are. Regardless of this, choices still have to be
made from the various methods to come to a valid interpretation of that change in
terms of clinical relevance or clinical importance.
In order to study the assessment of treatment-related change in health-related
functional status, we have used various methods to estimate the magnitude of change
over time and evaluated criteria for what constitutes relevance from the patient's
perspective. The first part of the discussion will focus on some problems of effect
size interpretation. The other part of the discussion is focussed on the reliability and
validity of the direct mode of assessing change in health-related functional status
using so-called global or transition questions.
7.2 MAIN RESULTS AND CONSEQUENCES FOR METHODOLOGY OF
ASSESSING CHANGE IN HRFS
In Chapter 3 we established that a Dutch version of a new HRFS instrument (the
“Minnesota Living with Heart Failure-Questionnaire”) measures what it purports to
measure and is reliable and able to detect change over time; we decided to use it in
the methodological part of the thesis. The MLHF-Q was used in a group of patients
undergoing treatments with known physiological efficacy, but no evidence was
available about improvement in HRFS. It was expected that change in HRFS would
occur, and that this would be moderate. We evaluated two ‘yardsticks’ for the
interpretation of change in scores for the researcher and the patient (Chapter 5). In
the first place, we discovered that Cohen's yardstick for the interpretation of change
magnitude is used inaccurately by researchers for a variety of effect size indices or so-
called responsiveness measures (Chapter 4). Many researchers do not know how to
interpret the magnitude of difference between mean scores in health-related
functional status. We demonstrated that overestimation and underestimation of
effect appeared in 20 to 50 percent of the estimated standardised response means
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(SRM’ s).  Several researchers who use (for example) the standard deviation of the
baseline score, or the standard deviation of the change in score as the denominator,
refer to Cohen who merely used the pooled standard deviation to express mean
differences in standard deviation units. Secondly, we showed that the patient
yardstick  (the external criterion), i.e. the judgement of what constitutes 'trivial',
'small', 'moderate' or 'large' change appeared to be in keeping with Cohen’s
thresholds for ‘trivial’, ‘small’, ‘moderate’ or ‘large’ change over time. To our
knowledge, no longitudinal studies have been performed in which the concurrent or
convergent validity of health state transition questionnaires was investigated.
Moreover, the responsiveness of multi-item transition scales has rarely been assessed.
In order to investigate the psychometric properties of the retrospective ‘transition
questionnaire’, we used the MLHF-Q in two modes: repeated measured HRFS
before and after treatment to assess change serially, and in a retrospective mode, with
MLHF-Q items modified in transition questions. We showed that direct assessment
of the amount of change measured by the instrument’s items belonging to a
dimension of HRFS is comparable with the corresponding dimension of serially
assessed change measured by the same items.
7.2.1 Statistically significant but how to interpret the magnitude of      
change?
The problem of testing change over time with null-hypothesis goes together with the
dilemma that with large samples, trivial change may be statistically significant. There
are many approaches towards estimating the relevance of change scores in health
status outcome measures, but even the apparent simplicity of standardising mean
differences, may bring inaccurate estimation of effect size according to Cohen’s
thresholds. The choice of standard deviations of baseline scores and change scores
(from stable subjects) etc. (Table 1.1, Chapter 1) in the denominator is in conflict
with the thresholds Cohen provided for the interpretation of this index. In this thesis,
the studies addressing the clinical efficacy of intrathecal baclofen infusion and the
psychometric properties of the MLHF-Q (Chapters 2 and 3) used the SD of change
scores in the denominator (following others uncritically in applying Cohen’s rule of
thumb for effect size interpretation). If we take Cohen’s original work (1) as being
valid, we will have to rectify interpretations of the meaning of the estimated
magnitude according to the results from these analyses.  In both studies, 40
Standardised Response Mean indices were interpreted according to Cohen’s
thresholds for pooled estimates of standard deviation (ESp) out of which 20 turned
out to be overestimation of treatment-related effect. (Table 7.1). In another study
Chapter 4) we analysed this problem using results from other researchers. This
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secondary analysis of data from other studies revealed that 20% of the estimated
effect sizes did not fall in the same magnitude of change category according to the
Cohen’s thresholds.
Table 7.1 Comparison of forty Standardised Response Means calibrated into Cohen’s
pooled effect size index (ESp) from Chapters 2 and 3 in this thesis.
Effect Size (ESp)
                                                                                                                               
Trivial Small Moderate Large
SRM 0 - <.20 ≥.20 - <.50 ≥.50 - <.80 ≥ .80
                                                                                                                               
Trivial    2
Small    3       4
Moderate       9     8
Large     8     6
                                                                                                   
Thus, the SRM interpretation of effect magnitude with the thresholds Cohen with
the ESp calculated on the same data (transformation of the same mean change over
time into units of pooled standard deviation may result in dramatic differences (50%
of the SRM indices are overestimated).  Unfortunately, we still have no algorithm for
effect size indices calculated with the standard deviation from baseline scores or from
change scores in stable subjects according to an external criterion. Furthermore, even
in a situation where we are able to reliably interpret effect size, we cannot
differentiate between a ‘large’ and ‘very large’ effect since the cut-off point for large
has a theoretical range from ES > .80 to infinite. However, Hopkins’ 2  Likert-scale
approach is able to give meaning to the extension of the scale to the level above large
for Cohen’s effect size statistic: ES = 0 - < .20 trivial effect; ES = ≥ .20 - < .60 small
effect; ES = ≥.60 < 1.20 moderate effect; ES ≥1.20 - < 2.0 large effect; ES ≥ 2.0 -
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< 4.0 very large and ES ≥ 4.0 - ∞ is considered to be ‘nearly perfect’. In addition to
thresholds for effect magnitudes, Hopkins elaborated Cohen’s thresholds for
correlation coefficients, relative risks and odds ratio. Despite this promising attempt
to proceed with a more complete scale of effect magnitude, further research will need
to provide empirical evidence for the external validity of this new rule of thumb for
effect size interpretation irrespective of health status measure and research designs.
Ever since Jacob Cohen wrote his well-known book 1, the effect size has been a
problematic parameter in clinical evaluation, and several promising alternatives (for
example, the “Reliable Change Index”), have been developed 3, improved and
criticised 4-8. In future studies statistical computer programmes may be able to give
the researcher additional information on some treatment effect indices
(notwithstanding the fact that no consensus exists on a method for signifying the
magnitude of change within and between experimental and control groups that is
meaningful in particular treatment contexts). Nevertheless, implementing effect sizes
standard in the representation of statistical results may require researchers to change
long-held patterns of behaviour.
7.2.2. Concordance between the researcher’s interpretation of effect size
            and the patient’s perception.
With global rating scales, respondents describe their state of health by answering just
one question. An example of this would be  ‘would you describe your health as very
good, good, fair, poor or very poor? Global, single-item measures of perceived
overall health have been shown to be reliable and valid 9-11 and able to predict both
change in functional status and mortality 12,13. Furthermore, some studies have shown
that the correlation between single global judgements of health with multiple-item
dimensions (scales) of health status is not perfect 9,14,15 while other results indicate
fair and good relationships 16-19. One of the research questions in this study was to
determine the concordance between the patient’s perceived magnitude of change in
a domain of health-related functional status (the external criterion), and the
magnitude of change as estimated by the researcher using effect size estimates. The
patient’s perception of magnitude of change was assessed at item level and at scale
or domain level. At item level, perceived magnitude was assessed with the
instrument’s items transformed into transition items. At scale level, for each domain
(physical and emotional function) a single global question was put that covered the
content of change in the corresponding domain. Change in these domains of HRFS
was assessed with a repeatedly measured multi-item scale. Assessing the
meaningfulness of changes in longitudinally assessed HRFS scores might have been
hampered by the weak reliability and validity of single global questions that measure
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the transitional state of health. However, we showed that at item level as well as at
scale level, the external criterion appeared to be in keeping with Cohen’s thresholds
for ‘trivial’, ‘small, ‘moderate’ and  ‘large’ effects. Furthermore we compared our
results with data from Osoba et al. 16 (Chapter 5) who used an identical transition
scale for the external criterion but a different effect size index (mean change scores
divided by the standard deviation of baseline scores). The concordance between
longitudinal effect magnitude and the transition ratings of “moderately better” and
“very much better” in the physical functioning domain was not perfect (see Table
7.2).
 Table 7.2   Stratified effect sizes (1 - 2/Sdbaseline) of  change over time in domains of health-related functional status
physical emotional social global
functioning functioning functioning functioning
                                                                                                                                                                                                                                                   
Corresponding within within within within
Effect size interval ES corresp. ES corresp. ES corresp. ES corresp.
Interval value interval value interval value interval value
                                                                                                                                                                                                                                                   
No change 0 – 0.20 0.09   y  0.45 0.35   n 0.16 0.07    y  0.35 0.06     y 0.30
A little better 0.20 – 0.50 0.09   n -0.08 0.43   y 0.77 0.22    y  0.07 0.51     n 0.02
Moderately better 0.50 – 0.80 0.16   n -0.21 0.84   n 0.13 0.26    n -0.15 0.73     y 0.77
A great deal better 0.80 – max (1.11)   0.38   n -0.22 1.11   y 1.00 0.81    y  0.03 0.86     y 0.19
                                                                                                                                                                                                                                                   
Source: Osoba et al. 16
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Different effect size indices may yield different outcomes. In addition, varying
numbers of global ratings of a transition question makes comparison with results
from other studies inconsistent and weak. The different distances between ratings
and the necessity of collapsing or merging an anchor point to allow comparison can
lead to differences in the relationship to the magnitude of standardised change over
time. Another threat of concordance between external criterion and amount of
change over time is that the composite of aspects belonging to (for example) the
instrument’s domain of physical functioning does not correspond with the set of
aspects in the patient’s mind by when he or she is asked “ has there been any change
in your physical problems”?
7.2.3    Reliability and convergent validity of transition scales
Eliciting the direction and magnitude of change in evaluative studies by directly
asking “how have you been feeling since the bypass operation?”, (as clinicians
frequently do when they see patients after treatment) has both been criticised as well
as considered to be a reliable and valid approach in evaluation of treatment. One
confounding factor that may affect the reliability and validity of direct transition
questions is known as ‘recall bias’. It is assumed that because of this recall bias effect,
patients are not considered able to make accurate and reliable estimates of their
health status, either before treatment or at another point in the history of their illness.
20
Acting on Coughlin’s conclusions, 21 we minimised the recall bias by taking the
shortest possible time span between the first questionnaire and follow up to reduce
errors in recollection. We also selected interventions such as PTCA or CABG for this
part of the thesis since the significance, vividness and meaningfulness of these events
contribute to the accuracy of recall. The second source of error that may occur is the
present health status influencing the patient’s perception of the direction and
magnitude of treatment-related change over time. 20,22,23 By choosing treatment with
a known efficacy in a study aimed at comparing repeated measurement of HRFS with
transition questions at follow-up, this ‘present state bias’ was assumed not to be a
significant confounding factor. Correlation between present state questions and
concordant transition questions seem ‘logical’ in a sample of patients who underwent
treatment with known efficacy. Consequently, it was expected that a perceived
improvement in, for example, ‘climbing stairs’ should correlate with no limitations
in climbing stairs after PTCA or CABG when these treatments are aimed at
improving the physical condition of climbing stairs at baseline.
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After applying the method of Asseltine et al, 23 it was concluded that there were no
differences in responsiveness (the Standardised Response Mean) between
longitudinal change scores and transition scores in the domains of emotional and
physical function. The SRM of the MLHF-Q physical function scale was 0.56 for
change scores and 0.53 for transition scale scores whereas the SRM s of the
emotional function scale were 0.31 and 0.30 respectively. It was hypothesised that if
a distinction between invasive and non-invasive treatment and between improvement
and stability in angina pectoris were made, differences in magnitude of effect would
be found. Invasive PTCA/CABG treatments were expected to produce more change
whereas non-invasive treatment was expected to produce very little change in HRFS
over time. Strikingly, the physical scale’s SRM s in the invasive treatment groups
ranged between .73 and .78 (improved group .82 and .89 respectively) and in the
non-invasive group, the SRM s ranged from. 29 to .12 (stable group .35 and .28).
Although smaller in magnitude, the SRM indices of the emotional functioning scale
showed similar results. These outcomes will be published after this thesis 24.
Table 7.3 Responsiveness (SRM) of the different measuring methods for
groups of patients
                                                                                                                               
Treatment Angina Pectoris a
Measure Invasive Non inv. Improved Stable Overall
(N=135) (N=82) (N=87) (N=121) (N=217)
Physical scale
SCSb . 73 (. 09)d . 29 (. 10) . 82 (.11) .  35 (. 09) . 56 (. 07)
URSc . 78 (. 09) . 12 (. 09) . 89 (.11) .  28 (. 08) . 53 (. 07)
Emotional scale
SCSb . 39 (. 09) . 17 (. 11) . 48 (. 09) . 14  (. 09) . 31 (. 07)
URSc . 36 (. 08) . 18 (. 12) . 51 (. 11) . 13  (. 09) . 30 (. 07)
                                                                                                                               
a NYHA classification; b Serial change scores; c Unweighted retrospective scores; d Values between
brackets are standard errors.
When improved and stable groups were broken down by type of treatment the
responsiveness indices (SRM s) of the improved CABG/PTCA and stable patients
ranged from .95 to 1,00 and from .48 to 54, respectively.  SRM s of improved and
stable patients treated with pharmaceuticals ranged from. 44 to. 50 and from. 04 to.
18, respectively.
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7.3  RECOMMENDATIONS FOR PRACTICE AND RESEARCH
So long as no consensus reached on standards for evaluating, using and interpreting
effect size estimates of treatment related change in clinical research, there is an
important need to develop uniform and widely accepted criteria to give meaning to
the size of an effect. This lack of precision is not only relevant when evaluating
treatment-related change within and between groups, but, even more important in
the estimation of power in the planning phase of a trial. Standardisation of effect size
interpretation needs reference ranges of health-related functional status assessed with
population surveys. Furthermore, longitudinal research is needed to discriminate
between changes in HRFS over time in a sample drawn from the general population,
with change in a sub-sample of chronically ill patients. In other words, with
knowledge about a reference range of an indicator of health-related functional status
in the general population, we can recognise that there are differences. Furthermore,
with a longitudinally assessed estimate of autonomous change in the same sample,
we will be able to better understand the meaningfulness of treatment-related effects.
In studies on the measurement of health-related quality of life and HRFS, effect sizes
(ES) have been used as surrogates for clinically relevant change when change over
time in outcome was substantial. However, ES do not provide a complete
understanding of the meaningfulness of the observed change. Patients have to
perceive a change in the performance of daily activities in order to rate the direction
and degree of change; moreover, even when this perceived change is small in
magnitude, it may still be perceived as a significant one by the patient.  According to
Osoba, 19 the significance of change as perceived by the subject ‘should be of
paramount consideration’ in future attempts to define the meaningfulness of change
in HRFS or health-related quality of life. The development of multi-item transition
measures may cover change in the relevant underlying domain more representatively.
Therefore, we suggest that measures that assess more concrete aspects of the
patient’s HRFS will provide greater accordance between serial and transition
measures of change.
 However, when a patient rates a reduction in (for example) difficulty in climbing
stairs, as ‘large’, it does not necessarily imply that a patient will view this subjectively
significant change as being important.  Future areas of research aimed at
quantification of meaningful change in HRFS should also include the importance
patients assign to that change, even if it is experienced as being small. One piece of
research has produced examples that seem promising extensions of transition
questions. In this approach, the respondent rates the direction and the degree of
perceived change by a assigning a value that has meaning to the respondent for the
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experienced change, as well as by rating the degree of importance the respondent
assigns to perceived change. In evaluation of treatment-related change in clinical
trials, the importance assigned to the small improvement in one item of a domain of
HRFS may outweigh a moderate deterioration in another item belonging to the same
domain.
Finally, the following are key issues in the debate on methods for estimating clinically
important change: Significance of treatment effects: significance to whom 25 who is
to say what is important? 26 and “ask patients what they want “27-29 have increasingly
become apparent. To give clinically relevant meaning to change scores gained on two
different points in time using HRFS instruments, several investigators suggest that
the current approaches could be improved by taking more explicit account of
patients’ perceptions and expectations. A new paradigm is incorporating individual
patient perspectives, expectations and preferences with respect to the effects of
(innovative) treatments in the outcome measures. With scoring systems based on
individualised measures such as the so-called Goal Attainment Scale (GAS) or Patient
Specific Index (PCI), each patient essentially receives his or her ‘own instrument’ and
these instruments seem to show an improved sensitivity to change in health-related
functional status when compared with conventional methods. 30,30-34,34-37
 This thesis is aimed at supporting clinicians, health professionals, investigators and
administrators in the understanding and critical evaluation of the psychometric
properties of health status measures and methods in estimating and interpreting
change in patient-assessed health outcomes. Health professionals increasingly stress
that in the realisation of effective care and expected outcome of planned change in
the process of care delivery, patients’ preferences are essential sources of
information. The operationalisation of the patient’s perception of the severity of
limitation in domains of health-related functioning, or operationalisation of
individual preference or weighted relevance of items of health-related functional
status measures is still in its infancy. However, for health administrators and decision-
makers, investigation into the validity of patient-specific HRFS instruments used to
evaluate the outcomes of innovative treatment and care, standardisation of methods
is required. HRFS instruments cannot be used in the evaluation of treatment and care
without a valid way of ascertaining what change in measured difference scores
means.
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In this thesis we used several methods that provide different perspectives on
estimation of the magnitude of change in health status and studied the criteria for
establishing the relevance or importance of that change.
Chapter 1 introduces the question of to what extent statistically significant changes
can be interpreted as relevant, or to what extent substantial changes can be related
to clinical interventions.
Trivial change assessed with a health status instrument is more likely to be statistically
significant in large samples than in small samples. To give meaning to differences in
scores, a widely used method to quantify the amount of change over time has
become known as the concept of ‘responsiveness’. There is no consensus about the
operationalisation of this concept. In studies validating new health status measures
are validated, the concept of responsiveness is often defined as the psychometric
property of the instrument’s sensitivity to measure change over time. In order to
demonstrate that the new instrument is more able to detect change compared to a
concurrent instrument (for example, generic vs. disease-specific measures), the
concept of ‘relative efficiency’ was introduced in health status measurement.
However, when the efficacy of medical interventions is evaluated in terms of change
in health status, the term ‘responsiveness’ is also used to indicate the magnitude of
treatment-related change. The relevance of the change between baseline and post-test
is estimated with effect size indices (ES). Large effects (ES > .80) are often
determined in terms of being clinically relevant or important. One might pose the
question whether this is a valid interpretation of an effect size. In order to interpret
change over time in terms of being clinically important, a golden standard or external
criterion for what constitutes importance is necessary. Therefore, in order to
interpret change scores as clinically relevant, the external criterion used in this thesis
is the patient’s perception of the relevance of change in corresponding domains of
health status. This external criterion is often called a global question or a transition
question, and its score represents a retrospective appraisal of change in terms of the
extent of improvement or deterioration or unchanged after treatment. In this thesis
health-related functional status was assessed longitudinally with the questionnaire
items and, after intervention, the perceived change was assessed with the same items
in retrospective mode, or with transition questions. Little is known about the
relationship between the longitudinal difference in scale scores, such as the
researcher’s indicator of the extent and direction of change, and the retrospective
transition scale scores assessing the patient’s appraisal of the extent and direction of
change in the same domains. Furthermore, even less is known about the
psychometric properties of measures assessing perception of change with transition
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questions. The aim of this thesis is to evaluate the concordance between scores
derived from repeated measurement and corresponding transition scores, the
overestimation and underestimation of effect size indices in dependent samples, and
the psychometric properties of transition scales.
In Chapter 2, the changes in health-related functional status are described in a
randomised, controlled, clinical trial among patients who responded insufficiently to
treatment with maximum doses of pharmaceuticals aimed at reducing severe
spasticity.  By means of continuous intrathecal baclofen infusion via a subcutaneously
implanted programmable pump, a substantial reduction in spasticity and an
improvement in health-related functional status was expected. In order to evaluate
change over time between baseline and outcome within groups, and the differences
in change between experimental and control group, non-parametric statistical tests
and effect size indices were used.
Intrathecal baclofen delivered by an implanted programmable pump resulted in
statistically significant and relevant improvement in both measures of clinical efficacy
(Ashworth scale, spasm score and pain) and self-reported health status (Sickness
Impact Profile and the Hopkins Symptoms Check List).
In Chapter 3, the psychometric properties of he Minnesota Living with Heart Failure
Questionnaire (MLHF-Q) are evaluated in a longitudinal study. The Dutch version
of the MLHF-Q was chosen to measure changes in health status among patients who
were treated with DC electrical cardioversion for atrial flutter. The one-year follow-
up included a self-administered disease-specific MLHF-Q and generic measures of
health-related functional status. Internal consistency of MLHF-Q scales was
estimated with Cronbach's alpha; the construct validity was evaluated with a
multitrait-multimethod analysis, using scales from the RAND-36, the Hospital
Anxiety and Depression Scale (HADS) and the Multidimensional Fatigue Inventory
(MFI-20). The 'known group validity' was evaluated by comparing mean scores and
effect sizes between two groups having low and higher severity of angina pectoris,
as assessed by the cardiologist (NYHA classification I versus II-III). Stability of
MLHF-Q scales was estimated in a subgroup of patients that remained stable three
months after baseline assessment. Perfect Congruence Analysis showed that the
results quite closely resemble the previously assumed factor structure from the
original American instrument. Cronbach’s alpha of the MLHF-Q scales were
satisfactory and the overall score of the MLHF-Q discriminated statistically
significant between the NYHA I and II-III groups.
Multitrait-multimethod analysis showed a good concordance between the MLHF-Q
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physical functioning scale and physical functioning scales from concurrent
instruments. The emotional functioning scale showed a weaker concordance with
concurrent scales. The MLHF-Q was sensitive to detecting change over time in a
group of patients undergoing treatment to improve sinus rhythm. The results of a
‘test-retest’ analysis in a stable group can be valued as satisfactory for the MLHF-Q
scales (Pearsons r > .60). The MLHF-Q has solid psychometric properties and the
outcome of the current study indicates that the MLHF-Q is a reliable, valid and
efficient health status
instrument.
In Chapter 4, we evaluated Cohen’s thresholds to interpret an effect size index,
namely in terms of ‘trivial effect’, ‘small effect’, ‘medium effect’ and ‘large effect’.
Cohen developed these thresholds with an effect size index based on standardisation
of differences between mean scores, using the pooled standard deviation (SDp). The
mean difference (d) between independent groups, expressed in units of pooled
standard deviation, was denoted as the effect size d’. The effect size d’ has to be
adjusted in cases of paired observations, as Cohen’s tables for power and sample size
estimation for independent samples assume 2(n-1) degrees of freedom, in contrast
with the case of paired observations, where only n-1 are available.  Consequently,
Cohen adjusted differences in mean scores in dependent samples or matched
observations by dividing d’ by √ 1-r (r = correlation coefficient T1 and T2). He used
the symbol d to denote this adjusted effect size index. This effect size is identical to
an effect size known as the Standardised Response Mean (SRM = the mean change
score divided by its standard deviation). This SRM belongs to a large family of
standardised mean differences used as effect size indices. In this chapter we
demonstrate that when Cohen’s rule of thumb for effect size interpretation based on
d’ are applied to SRM, there is a twenty percent risk of overestimation or
underestimation. We used publications which calculated SRM indices are calculated
for our analysis when the correlation coefficient from T1 and T2 could be calculated
in order to estimate d’ (148 of 411 SRM’s). Effect sizes estimated by using other
standard deviations in the denominator of the ratio could not be converted into d’.
Consequently, applying Cohen’s thresholds for effect size interpretation to every
standardised mean difference score may lead to over- or underestimation of the
magnitude of change over time.
Chapter 5 decribes the concordance between the researcher’s interpretation of the
direction and extent of change (using an effect size) and the patient’s appraisal of the
direction and extent of change in the same domains of health status. Patients from
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this study sample (N=217) underwent a treatment with known efficacy. After
treatment, twenty patients indicated deterioration. Due to the small number of
patients who deteriorated, the analyses are restricted to those who improved or
remained stable after treatment: Percutaneous Transluminal Coronary Angioplasty
(PTCA), Coronary Artery Bypass Grafting (CABG) or pharmacotherapy. In this
study, the Dutch version of the Minnesota Living with Heart Failure Questionnaire
was used, supplemented with three MOS-20 items from the physical function scale,
to assess change in health related functional status. Since we obtained from each item
both a change score and a score on the same corresponding transition question, the
concordance between both scores was analysed for 23 items. Every questionnaire
item was linked to a global question addressing the same health status aspect, and for
23 items the change scores were standardized and broken down according to the
item-related global question rating. Thus, irrespective of an item’s domain, we
calculated 4,798 response combinations out of a total of 4,991 (217 x 23),
representing missing data of less than 4%. To evaluate the concordance between the
magnitude of change in domains of health-related quality of life and an external
criterion, the standardized change scores of scales and a single global question
intended to correspond with the repeated measures of physical and emotional
functioning were used in the analysis. Global questions were phrased as follows:
“Since the last time I filled out this questionnaire (or: Since my operation), my
physical problems are …..1) a great deal worse; 2) moderately worse; 3) a little worse;
4) unchanged; 5) a little better; 6) moderately better and 7) a great deal better”. In this
chapter, an attempt has been made to develop a simple criterion to determine the
extent of concordance or discordance between the size of effect according to
Cohen’s thresholds (researchers appraisal of the amount of change) and the external
criterion (the patient’s appraisal) with a global question. The ratings of the global
question appeared to be in keeping with Cohen’s thresholds (< . 20 trivial; ≥ . 20 <
. 50 small effect; ≥ . 50 < . 80 moderate effect and  ≥ . 80 large effect at item level
(irrespective of domains) as well as at scale level.
In Chapter 6, we evaluated the relationships between the longitudinally assessed
change in scores from the physical and emotional functioning scales and the scales
of perceived change (transition scales) in the same domains. In this study, the
Minnesota Living with Heart Failure Questionnaire was used with 3 supplementary
items from the MOS-20, to assess change over time in health-related functional
status. Perceived change in physical and emotional functioning were assessed by
modified items added to the questionnaire’s scale items and were assessed at T2 after
treatment (Percutaneous Transluminal Coronary Angioplasty (PTCA), Coronary
Artery Bypass
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Grafting (CABG) or pharmacotherapy).  This modification was composed of the
retrospective mode of the items (denoted as transition items), by rating the extent
and direction of perceived change on that particular item (for example, ‘climbing
stairs’). Internal consistency estimated with Cronbach’s alpha yielded satisfactory
coefficients for both longitudinally assessed scales’ change scores as well as for scores
of transition scales in the same domains. Factor analysis of baseline items, change
scores of these items and their corresponding transition items demonstrated identical
factor loadings. To avoid unreliable eyeball interpretation, 95% confidence intervals
were calculated for the corresponding items in these data sets. The results indicate
that no differences between factor loadings exist, although the factor loadings for the
item change scores were, as expected, systematically lower, as compared to the
loadings of baseline and transition items. The canonical correlation between the
composite of the change score items and the composite of the concordant transition
items belonging to the domain of physical and emotional functioning were fairly
large and explained 40% and 23 % of the variance, respectively.
Chapter 7 summarises the main findings from the preceding chapter and critically
evaluates them based on insights gained afterwards. The main conclusions are that
wholehearted adoption of Cohen’s thresholds for interpretation of the Standardised
Response Mean (SRM) may lead to over- and underestimation of effect size.
Chapter 4 presents a simple method to adjust these thresholds for SRM estimates. A
secondary analysis on the data from Chapters 2 and 3 showed that - after applying
the adjustment rule from Chapter 4 on calculated SRM’ s - almost twice the number
of over- and underestimation of effect size, according to the thresholds belonging to
Cohen’s d’. The small number of observations in both samples may have determined
this deviation from the results of Chapter 4. Another main result regards the
concordant relation between the amount of longitudinally assessed change in health-
related functioning and the patient’s perception of the extent of change among
patients with heart failure. These results from Chapter 5 were confirmed by another
study 1  among cancer patients. Effect sizes estimated with transition scales and their
corresponding longitudinal change scales showed no differences between groups
who differed in treatment effect (improved vs. stable) nor in groups who differed in
the severity of treatment (invasive vs. pharmacotherapy). Administration of the
questionnaire’s items modified into transition items showed no differences
comparing longitudinally assessed items regarding internal consistency of scales,
effect size estimates with scales, and principal components factor structure. The
                                                
1 Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related
quality-of-life scores.  Journal of Clinical Oncology  1998;16(1):139-44.
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results regarding the assessment of perceived change in health status may have been
confounded by ‘recall bias’ (patients cannot remember exactly the extent of limitation
in, for example, climbing stairs before the intervention) and ‘present state bias’ (the
extent of limitation at the moment of assessment after the intervention). These two
confounding variables are part of this study and the outcome will be published after
publication of this thesis.
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Samenvatting 
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Dit proefschrift is het resultaat van een aantal artikelen waarin, met behulp van
verschillende ragenlijstmethoden, verandering in gezondheidstoestand is
gemeten. Het doel is na te gaan wat de betekenis van zo’n verandering in
gezondheidstoestand is. Hoofdstuk 1 is een inleiding op de wijze waarop
onderzoekers vat proberen te krijgen op de vraag:  in hoeverre zijn statistisch
significante verschillen ook relevante verschillen, d.w.z. ook substantiële
verschillen. Immers, in tegenstelling tot kleine steekproeven, hebben triviale
verschillen  in grote steekproeven een grotere kans om statistisch significant
zijn. Een veel gebruikte methode om de relevantie van verschillen te
kwantificeren en te interpreteren, wordt in de literatuur aangeduid met het
begrip ‘responsiveness’. Het concept responsiveness wordt niet eenduidig
gehanteerd. In studies waarin nieuwe instrumenten worden gevalideerd wordt
vaak met responsiveness ‘de gevoeligheid van een meetinstrument om
verandering te meten’ bedoeld als een psychometrische eigenschap van het
instrument. Om aan te tonen dat het ene meetinstrument meer gevoelig is
verandering te meten dan een soortgenoot (bijvoorbeeld een ziekte-specifiek
versus generiek) is het begrip ‘relatieve responsiveness’ geïntroduceerd. In
studies waarin (medische) interventies op werkzaamheid worden geëvalueerd,
wordt het begrip responsiveness ook gebruikt maar dan als indicator voor ook
de grootte van het aan de behandeling gerelateerde effect. Bij dit type
onderzoek is dus de relevantie van het gevonden verschil tussen voor- en
nameting bij klinische interventies bepaald door de hoogte van de effect size.
Een groot effect (effect size > .80) wordt dan als een klinisch relevant of
klinisch belangrijk verschil wordt geïnterpreteerd door onderzoekers. De vraag
is of dit terecht is. Om een verschil als klinisch belangrijk te kunnen
interpreteren is een extern criterium nodig voor die belangrijkheid of
relevantie. Om verschillen of veranderingen in gezondheidstoestand die
gemeten zijn met verschilscores verkregen door longitudinale meting met
vragenlijsten te kunnen interpreteren als klinisch relevant of belangrijk, is in dit
proefschrift het oordeel van de patiënt als extern criterium gebruikt. Een
dergelijk criterium wordt doorgaans gevormd door een score op retrospectieve
vraag aan de patiënt in welke mate hij of zij vindt onveranderd, verbeterd of
verslechterd te zijn na de behandeling.
In dit proefschrift is, met alle items van een vragenlijst verandering in de
gezondheidstoestand  longitudinaal gemeten en is, na de interventie met dezelfde
items in een retrospectieve vorm, de gepercipieerde verandering gemeten met
transitie-items. Er is nog veel onbekend over de relatie tussen de longitudinale
verschilscore die de onderzoeker gebruikt om te kunnen oordelen over de richting
en grootte van de verandering, en de retrospectieve transitie scores op schaal-items
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waarmee het oordeel van de patiënt over de richting en omvang van de verandering
wordt gemeten. Tevens is er zeer weinig bekend over de psychometrische
eigenschappen van meetinstrumenten die in retrospectieve vorm de gepercipieerde
verandering meten. Het tweede doel van dit proefschrift is om  na te gaan in welke
mate beide oordelen met elkaar overeenstemmen, welke over- en onderschattingen
van effectgrootte er gemaakt kunnen worden bij afhankelijke steekproeven en welke
psychometrische eigenschappen het meetinstrument in retrospectieve vorm heeft.
In hoofdstuk 2 is worden de veranderingen bestudeerd in een gerandomiseerde
studie bij een groep patiënten waarbij oraal toegediende medicatie in maximale doses
geen resultaat meer gaf in de verwachtte vermindering van ernstige vormen van
spasticiteit. Door de medicatie intrathecaal toe te dienen, door middel van een
subcutaan geïmplanteerde programmeerbare pomp, werd een substantiële
vermindering van spasticiteit en verbetering in gezondheidstoestand verwacht. Om
de verandering tussen baseline en post-test als ook de verschillen in verandering
tussen de groep intrathecaal toegediende placebo en de groep met werkzame stof
(Baclofen) te kunnen beoordelen, zijn non-parametrische toetsen en effect sizes
toegepast. In deze studie zijn effect sizes alleen gepresenteerd indien de verschillen
niet aan toevalsfluctuaties toe te schrijven zijn. De toedieningswijze van medicatie
voor ernstige spasticiteit resulteerde na een jaar in statistisch significante en relevante
verschillen in zowel klinische parameters als in scores op de lichamelijke dimensies
van gezondheidstoestand gemeten met de Sickness Impact Profile en de Hopkins
Symptoms Checklist. Deze studie illustreert het klassieke gebruik van statistische
toetsen en effect sizes om daarmee uitspraken te doen over de relevantie van het
gevonden effect.
In hoofdstuk 3 worden de psychometrische eigenschappen geëvalueerd van het
meetinstrument dat in deze studie gekozen is om verandering in gezondheidstoestand
te meten, de Nederlandse versie van de Minnesota Living with Heart Failure
Questionnaire (MLHF-Q). De steekproef voor dit onderzoek betrof een groep
patiënten die behandeld werd voor boezemfibrileren. De interne consistentie werd
geschat met behulp van Cronbach’s alpha; de construct validiteit werd beoordeeld
met behulp van multitrait-multimethod analyse met gebruikmaking van schalen uit
de Rand-36, uit de Hospital Anxiety and Depression Scale (HADS) en uit de
Multidimensional Fatigue Inventory (MFI-20). Known-Group validiteit werd
geëvalueerd door de verschillen te analyseren tussen de groep met de minst ernstige
vorm van angina pectoris met de groep met de meer ernstige vorm aan de hand van
het oordeel van een cardioloog (NYHA classificatie). De test-hertest
betrouwbaarheid is geschat met een sub-groep in de steekproef waarvan de
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gezondheidstoestand gedurende drie maanden na de baseline meting geen
verandering had ondergaan. Om na te gaan of de dimensies van de factoranalyse uit
deze steekproef, uit een Nederlandse populatie patiënten met een vorm van
hartfalen, overeenkomen met die uit de oorspronkelijke factor analyse in de
Amerikaanse studie, is gebruik gemaakt van Perfect Congruence Analysis (PCA). De
MLHF-Q schalen hadden een bevredigende Cronbach’s alpha  en discrimineerden
goed  tussen de groepen met ernstige en minder ernstige angina pectoris. Het
resultaat van de multitrait-multimethod analyse laat een goede overeenstemming zien
tussen de ‘fysiek functioneren’ schaal van de MLHF-Q en de fysieke dimensies van
de andere (concurrente) instrumenten. Voor de schaal ‘emotioneel functioneren’ is
deze overeenstemming zwakker. De factor ladingen in de oorspronkelijke schaal
constructie met een Amerikaanse steekproef kwamen goed overeen met de ladingen
in de Nederlandse steekproef. De MLHF-Q bleek gevoelig om verandering te meten
in een groep patiënten die een behandeling ondergaat die primair gericht is op
verbetering van sinusritme. De test-hertest van de  MLHF-Q resulteerde in
bevredigende correlaties groter dan .60. De MLHF-Q is dus een betrouwbaar en
valide instrument om veranderingen in gezondheidstoestand te meten bij patiënten
met hartfalen.
In hoofdstuk 4 wordt de toepassing van de grenzen van Cohen om een effect size
te interpreteren in termen van ‘triviaal’, ‘klein’, ‘medium’ of ‘groot’ nader
geanalyseerd. Deze grenzen zijn door Cohen ontwikkeld op basis van een index
gebaseerd op het verschil in gemiddelden tussen twee onafhankelijke steekproeven
gedeeld door de gepoolde standaarddeviatie (SDp) Dit in eenheden van de gepoolde
standaarddeviatie uitgedrukte verschil d (difference) is door Cohen geannoteerd als
d’. Omdat Cohen in zijn standaardwerk over poweranalyse en effect size de tabellen
waarmee de omvang van de steekproef te bepalen zijn heeft gebaseerd op twee
steekproeven, corrigeert hij d’ voor de situatie waarin er sprake is van bijvoorbeeld
een herhaalde meting binnen 1 steekproef. Hiertoe corrigeert hij d’ met √1-r waarbij
r de correlatie is tussen de meting op T1 en T2. Deze effect size is gelijk aan het
gemiddelde verschil tussen T1 en T2 gedeeld door de standaarddeviatie van dat
verschil. Deze effect size wordt veel gebruikt en staat bekend als de Standardised
Response Mean (SRM). Daarnaast is er een aantal effect sizes ontwikkeld waar het
gemiddelde verschil in eenheden van andere standaarddeviaties wordt uitgedrukt die
van deze SDp en SRM afwijken. In dit hoofdstuk wordt aangetoond dat, als men de
grenzen van Cohen, behorend bij de d’, toepast op de SRM, er een risico is van over-
en onderschatting van de geschatte effectgrootte in ongeveer één op de vijf  in de
gebruikte steekproef van effect sizes. Aangezien de SRM alleen te herleiden is tot d’
als de correlatiecoëfficient tussen T1 en T2 berekend kon worden op grond van de
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in de betreffende publicatie gerepresenteerd gegevens (148 van de 411 SRM’s) heeft
de analyse zich tot deze moeten beperken. Effect sizes indices geschat door het
gemiddelde verschil te standaardiseren met de standaarddeviatie (SD) van o.a. de
baseline scores (in subgroepen) of de SD van de veranderingsscores (in subgroepen)
zijn wiskundig niet te herleiden tot de effect size d’. Derhalve is het kritiekloos
toepassen van de grenzen van Cohen niet vrij van het risico van over- en
onderschatting van de grootte van het effect.
In hoofdstuk 5 is de overeenkomst tussen het oordeel van de onderzoeker over de
mate van verbetering (met behulp van effect size indices) en het oordeel van de
patiënt over de mate van verbetering beschreven. De patiënten in deze steekproef
(N=217) ondergingen een behandeling waarvan bekend is dat deze de
gezondheidstoestand verbeterd. Twintig patiënten gaven na de behandeling aan
verslechterd te zijn. De analyses zijn door dit kleine aantal beperkt tot patiënten die
van mening waren te zijn verbeterd of onveranderd te zijn gebleven en na de
interventie die zij ondergingen: Percutaneous Transluminal Coronary Angioplasty
(PTCA), Coronary Artery Bypass Grafting (CABG) of farmacotherapie). In deze
studie is de Nederlandse versie van de Minnesota Living with Heart Failure
Questionnaire (MLHF-Q), aangevuld met enkele MOS-20 items, gebruikt om
verandering in gezondheidstoestand te meten. Aangezien van elk item in de
vragenlijst zowel een verschilscore als een bij dit item behorend retrospectief oordeel
gemeten is, is in eerste instantie een vergelijking tussen onderzoekersoordeel
(verschilscore) en patiëntoordeel (retrospectief oordeel) op item niveau uitgevoerd
voor 23 items. Geen rekening houdend met de dimensies waartoe items behoren zijn
4798 response-combinaties berekend van een totaal van 4991 (217 x 23) als gevolg
van 4% missing data.
Voor de bepaling van de concordantie tussen de gestandaardiseerde verschillen
(effect grootte) van schalen of domeinen, is als extern criterium voor de relevantie
van de verbetering in de schaalscores gebruik gemaakt van zogenoemde ‘global
questions’ naar gepercipieerde verandering in deze domeinen. Een voorbeel van zo’n
global question is ‘Sinds de bypass operatie is mijn beperking in het trappenlopen:
1) sterk verbeterd, 2) nogal verbeterd, 3) weinig verbeterd, 4) onveranderd, 5) een
beetje slechter, 6) nogal slechter en 7) sterk verslechterd’.
 In dit hoofdstuk is geprobeerd een eenvoudig criterium te ontwikkelen om te
bepalen wanneer het oordeel van de onderzoeker over de grootte van de verandering
(effect size) in overeenstemming is met het externe criterium, of daarvan afwijkt in
termen van een over- of onderschatting. De vuistregel van Cohen (< .20 triviaal; ≥
.20 < .50 klein; ≥ .50 < .80 medium; en ≥ .80 groot effect) waarmee effect grootte
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doorgaans door onderzoekers worden geïnterpreteerd, lijken synchroon te lopen met
het de oordelen van de patiënt in termen van gepercipieerde verbetering
(respectievelijk: ‘geen verandering’; ‘een beetje verbeterd’; ‘nogal verbeterd’ en ‘veel
verbeterd’.
In hoofdstuk 6 is de relatie onderzocht tussen: 1) de gemeten verandering in de
schalen ‘lichamelijk’ en ‘emotioneel functioneren’ met longitudinale meting en 2) de
gepercipieerde verandering in deze domeinen. In deze studie is eveneens de
Nederlandse versie van de Minnesota Living with Heart Failure Questionnaire
(MLHF-Q), aangevuld met enkele MOS-20 items, gebruikt om verandering in
gezondheidstoestand te meten. De gepercipieerde verandering in lichamelijk en
emotioneel functioneren zijn gemeten met gemodificeerde schaal-items die
opgenomen zijn in de vragenlijst die na de behandeling (Percutaneous Transluminal
Coronary Angioplasty (PTCA), Coronary Artery Bypass Grafting (CABG) of
farmacotherapie) is ingevuld. Deze modificatie bestaat uit de retrospectieve vorm van
het betreffende item (transitie item genoemd) waarmee gevraagd werd naar de
richting en de mate van verandering na de behandeling. Analoog aan de interne
consistentie van de schaal van veranderingscores werd de interne consistentie van de
transitie schalen geschat. De interne consistentie uitgedrukt in Cronbach’s alpha van
de met herhaalde meting verkregen veranderscores en die van de corresponderende
transitieschaal ‘fysiek functioneren’ waren bevredigend. Factoranalyses van de
baseline items, de verschilscore van deze items en de hiermee corresponderende
transitie items resulteerden in dezelfde factorstructuur. Om onbetrouwbare ‘eyeball’
interpretatie te voorkomen zijn 95% betrouwbaarheidsintervallen rond de ladingen
 van de items binnen elke dataset berekend. De resultaten laten geen verschillen zien
ondanks de verwachtte systematisch lagere ladingen van de item verschilscores
vergeleken met die van de baseline items en transitie items. De canonische correlatie
tussen de lineaire combinatie van de verschilscores per item en de lineaire combinatie
van de transitie-items resulteerde voor beide schalen in 40% (verandering in fysiek
functioneren) respectievelijk 23% (verandering in emotioneel functioneren)
verklaarde variantie.  De conclusie is dat beide meetmethoden overlap vertonen maar
ook verschillende veranderingen registreren. In situaties waarin geen baselinemeting
mogelijk is, zou met de transitiemethode volstaan kunnen worden.
In hoofdstuk 7 worden de belangrijkste resultaten van de voorgaande hoofdstukken
samengevat en, op basis van de in een later stadium verkregen inzichten, kritisch
geëvalueerd. De belangrijkst conclusies zijn dat het kritiekloos toepassen van de
vuistregel van Cohen voor effect size op de Standardised Response Mean tot over
en onderschattingen leidt. In hoofdstuk 4 is daarvoor een eenvoudige correctie
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methode ontwikkeld. In een secundaire analyse van de gegevens uit de hoofdstukken
2 en 3 werden, in afwijking van het resultaat uit hoofdstuk 4, bijna twee maal zoveel
over- of onderschattingen gevonden ten opzichte van Cohen’s grenzen behorend bij
effect size d’. De veel kleinere steekproef kan hier een rol hebben gespeeld. Een
andere belangrijke conclusie is dat grootte van verschilscores verkregen uit herhaalde
meting, in grote mate concordant zijn met de door de  patiënt gepercipieerde grootte
van de verandering. De in hoofdstuk 5 gevonden overeenstemming tussen het
onderzoekers-oordeel over de effect grootte en de door de patiënt gepercipieerde
verandering werd door een andere studie 1  bevestigd. De effect size in domeinen van
de gepercipieerde verandering en die van de longitudinaal gemeten verandering
blijken niet van elkaar te verschillen, zijn even groot voor groepen waar een gotere
verandering verwacht wordt en waar deze niet verwacht wordt. Door de items uit een
vragenlijst na de operatie af te nemen in de vorm van transitie-items en deze op
schaalniveau te vergelijken met de veranderingscores, is aangetoond dat schalen die
gepercipieerde veranderingen meten vergelijkbare effect sizes, factorladingen en
interne consistentie hebben. De invloed van mogelijke confounders in de meting van
gepercipieerde verandering in domeinen van gezondheid, is object van analyse en een
publicatie na dit proefschrift. De beïnvloeding van het retrospectieve oordeel over
het effect van behandeling door ‘recall bias’ (men weet niet meer in welke mate men
voor de behandeling beperkt was in bijvoorbeeld trappenlopen) en de ‘present state
bias’ (de mate van (niet) beperkt zijn op het moment van herhaalde meting na de
behandeling) is onderwerp van lopend onderzoek.
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Dankwoord
In 1969 begon mijn eerste leermeester Jan Jessen een onderzoek naar Medische
Consumptie onder een representatieve steekproef uit de Nederlandse bevolking. In
1970 kwam ik als leerjongen en duvelstoejager voor het veldwerk, het uitbetalen van
student-interviewers, de dataverzameling, de codering en verwerking op ponskaarten.
Mijn tweede leermeester Ivan Gadourek nam de leiding van dit onderzoek over na
het overlijden van Jessen. Beide leermeesters hebben mij, voordat ik mijn
avondopleiding aan het Groninger Avond Atheneum had afgerond, gesocialiseerd
op de werkvloer van het medisch-sociologisch onderzoek. De mogelijkheden die ik
in deze periode onder leiding van Jan en Ivan heb gekregen en de persoonlijke
betrokkenheid die ik mocht ervaren zijn tot op de dag van vandaag voor mijn
professionele ontwikkeling van de grootste betekenis. Ik ben Herman Walta, student-
assistent van het allereerste uur nog altijd dankbaar dat hij op zijn rustige manier
heeft weten te voorkomen dat ik op die eerste schreden op het smalle pad der
sociologie reeds zou zijn verdwaald door de veelheid van nieuwe kennis en vooral
door het voor mij toen onbegrijpelijke jargon.
De groep studenten die, in 1973-74 in de fase van analyse en rapportage, de
belangrijkste peilers onder het Medische Consumptie project vormden bestond uit
Hans Knol, Hans Ormel, Johan Groothoff, Sineke Ten Horn, en Jelte Bouma die
allen hun weg vervolgden met het afronden van een dissertatie. Ik vind het leuk de
laatste van het “Medische Consumptie” team te zijn die de serie van proefschriften
compleet mag maken.
Het schrijven van een proefschrift is een avontuur waarvan het reisdoel bekend is,
de koers is uitgezet, maar het anticiperen op de gevaren die het slagen van een
dergelijke expeditie haalbaar maakt, lukt altijd maar ten dele. Zonder professionele
koersbewaking en zonder emotionele ondersteuning van mensen om je heen zou het
een barre tocht geworden zijn. In de eerste plaats wil ik Wim van den Heuvel op
deze plaats dank zeggen voor de samenwerking vanaf 1985 bij de oprichting van het
NCG. In het jaar daarop gaf al ik te kennen te willen promoveren, maar de opbouw
van het NCG in oprichting had prioriteit. "Als de NCG organisatie compleet en
operationeel is, dan kun je aan een proefschrift denken", was het standpunt van het
dagelijks bestuur destijds. Ik had toen geen enkele moeite met deze beslissing die jij
destijds met Wouter van Rossum in ons eerste functioneringsgesprek naar voren
bracht. Het was ook in de begintijd van zo’n klein onderzoekinstituut ‘in oprichting’
dat ik mij  wel eens liet ontvallen “een directeur van niks te zijn”.  Zonder de
ondersteuning van Liesbeth Massaut, in deze beginjaren uitgebreid met de komst van
Jacqueline Nannenberg, was het met het NCG niks geworden. Ondanks de
geweldige inzet van dit kleine team, bleven er elk jaar steeds te weinig vrijheidsgraden
                                                                                                            
over voor het schrijven van een proefschrift. Vijf jaar na dit eerste
functioneringsgesprek kon het predikaat ‘in oprichting’ weg worden gelaten op het
briefpapier en vijf jaar later werd de managementstructuur van het volwassen
geworden onderzoekinstituut gewijzigd waardoor er ruimte kwam om over dat plan
uit ’86 na te denken. En dank zij jou kon ik een jaar later beginnen. Eind 1997 was
het protocol gereed en konden we de dataverzameling eind 1998 afsluiten en in het
begin van 1999 met de analyses beginnen. In de hectische periode die daarop volgde
ben je voor mij het belangrijkste ijkpunt geweest voor de hypothesen en de analyse
technieken waarvoor ik meende te moeten kiezen. Op deze plaats wil ik zeggen het
als een voorrecht te beschouwen met je te hebben mogen samenwerken en je
bedanken voor het vertrouwen dat je in mij hebt gehouden in de afgelopen vier jaar.
Beste Mike. Toen we in ’97 met jou het idee bespraken om deze studie uit te voeren
en dat we daarvoor bij de afdeling Cardiologie en Thoraxchirurgie een
patiëntengroep zochten die op een wachtlijst stond voor een behandeling met
aangetoond effect, ben jij degene geweest die zijn nek durfde uitsteken en collega
cardiologen heeft weten te overtuigen. Ik  ben je zeer dankbaar voor kritische, maar
altijd relevante, commentaren op veel onderdelen van het manuscript die voor een
medicus niet tot de dagelijkse kost behoren.
Een stille kracht die altijd een oplossing wist creëren, en met lang doorvragen de
vraagsteling helder wist te krijgen was van doorslaggevende betekenis als ik weer eens
vastgelopen was. Beste Roy, je hebt me nooit in de kou laten staan en met jouw
inventiviteit is menig analyse tot stand gekomen.
In de beginfase van de eerste analyses op item-niveau,  met nog niet zo goed
doordachte veronderstellingen en hypothesen, was Willem Lok met zijn credo '
Berry, alles kan' voor mij een grote steun.
Mathieu de Greef en Jitse van Dijk, zijn collega’s waar je, als je het even niet meer
ziet zitten, altijd weer weggaat met een goed gevoel.
Eric van Sonderen en Jelte Bouma poogden het schip op koers te houden in 
werkbesprekingen met discussies die er soms niet om logen, maar waar ook altijd
plaats was voor relativering door humor met een hoog 'Bouma-gehalte'.
Prof. dr. D.Post, prof. dr. J.L. Peschar en prof. dr. H.J.G.M. Crijns wil ik bedanken
voor de snelle beoordeling van dit manuscript.
Zonder het ‘monitoring’ programma dat Danny Barnhoorn voor dit onderzoek
schreef, zouden we  nooit zo accuraat en efficiënt het veldwerk hebben kunnen
uitvoeren. Telkenmale als de pc werd aangezet wisten we wie de tweede vragenlijst
moest hebben, wie benaderd moest worden omdat de vragenlijst niet volledig was
ingevuld. Aan hem hebben we het vooral te danken dat we zo weinig missende
waarden in ons bestand hebben.
Wat is het een voorrecht samen te kunnen werken met studenten die geïnteresseerd
                                                                        
zijn in empirisch onderzoek, de handen uit de mouwen steken bij het veldwerk, hun
intellectuele talent inzetten om met de data scripties te schrijven en hun analyse
technieken toe te passen. Op deze plaats bedank ik in tijdsvolgorde waarop ze het
‘erf van Middel betraden: Marc Boerma, Egbert Hofhuis, Rutger Jansen, Marian
Klene en Ineke Koopmans en last but not least, Heike Goudriaan.
Ik ben grote dank verschuldigd aan de respondenten die mij het vertrouwen hebben
gegeven hun naam en adres te mogen gebruiken om ze twee keer lastig te mogen
vallen met een moeilijke vragenlijst.
Ziekenhuis de Weezenlanden te Zwolle en het Martini Ziekenhuis te Groningen
hebben aan de instroom van respondenten in belangrijke mate bijgedragen door
patiënten toestemming te vragen aan het onderzoek deel te nemen.
Wat een geweldige opluchting was het dat er collega’s zijn die een gevoel voor (en
plezier aan) vormgeving van de door mij niet erg professioneel opgemaakte tekst.
Wilma Warmelink de spil in de organisatie van de sectie Zorgwetenschap en Nettie
de Rade van de afdeling Bewegingswetenschap wil ik bedanken voor het fatsoeneren
van zoveel slordigheden.
Elke onderzoeker heeft een scientific community nodig om zijn onderzoek uit te
kunnen uitvoeren. Ik bewaar goede herinneringen aan de discussie in de beginfase
en aan het eind van dit promotietraject met collega’s die deelnemen aan het
onderzoeksprogramma ‘Public Health and Health Sevices Research’. Ik zie er dan
ook naar uit het  onderzoek van de sectie Zorgwetenschap in dit programma te
kunnen ontwikkelen en uitbouwen.
In de afgelopen 30 jaar hebben Heit en Mem met grote betrokkenheid en steun mijn
wel en wee aan deze universiteit gevolgd. Wat zou Heit het een gebeurtenis hebben
gevonden hierbij te zijn.  Ik mis hem zeer.
Lieve Kim. Dank je wel voor al je nauwgezette werk bij het bewerken en corrigeren
van de tekst.
Lieve Esther, lieve Mickey. Dank je wel voor jouw manier van vormgeven van dit
boekje.
Lieve Jan-Just. Wie had nog kunnen denken dat jij met mij deze dag zo zou kunnen
vervolmaken. Ik ben trots op je.
Lieve Aukje. In de jaren dat wij met ons gezin een hechte band vormden heb jij het
mij mogelijk gemaakt te studeren en ook in de moeilijke tijden in ons leven heb je mij
gesterkt in het idee dat het nooit te laat is om af te studeren.
Lieve Elke. Het is door mijn ‘late roeping’ dit werkstuk te willen voltooien voor jou
de laatste twee jaar niet gemakkelijk geweest je leven met mij te moeten delen.
Zonder jou had ik het echt niet kunnen voltooien.
                                                                                                            
Northern Centre for Healthcare Research (NCH) and previous dissertations
The Northern Centre for Healthcare Research (NCH) was founded in 1990 as a
research institute of the University of Groningen (RUG), The Netherlands.
Researchers from both the Medical and Social Faculty, with various professional
backgrounds, are members of the NCH. These include medical sociologists, medical
doctors, psychologists and human movement scientists. Research of the NCH is
aimed at optimising quality of life of patients and quality of healthcare, and focuses
on (a) determinants of health and illness, (b) consequences of illness, (c) the effects
of medical treatment and decision making, and (d) the evaluation of health services
and various types of interventions. At the time that this thesis is published, the NCH
comprises five research programmes.
Until 1998, the NCH covered two research programmes, i.e. Determinants of Health
and Medical Decision Making and Evaluation of Healthcare. The first programme
was reformulated in 1996 and was continued as Disorder, Disability and Quality of
Life (DDQ). Hence, previous dissertations in this area are listed as part of the present
DDQ-programme. The second programme was subdivided in 1998 into two new
programmes, i.e. Public Health and Public Health Services Research and Rational
Drug Use.
Dissertations published earlier within the second programme are listed
retrospectively under these new headings. In 1998, two new programmes, The
Outcome and Evaluation of Interventions in Patients with Motor Problems and
Process and Effects of Movement Programs, were formulated and officially
integrated in the NCH in January 1999. The accomplished dissertations since the
start of the programmes in 1998 are included in the list. In 2000 the Department of
General Practice joined the NCH and together with the Rational Drug Use group
initiated a new research programme, i.e. Implementation of Evidence Based
Medicine in the Medical Practice.
More information regarding the institute and its research can be obtained from our
internet site: http://www.med.rug.nl/nch
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